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IL-12 and IL-23 form a crucial link to adaptive immunity through their ability to 
influence the development of TH1 and TH17 cells respectively. Despite the importance 
of the TH1/IL-12 and TH17/IL-23 axis in protective immunity, excessive production of 
IL-12 and IL-23 can be a nuisance as it leads to immunopathology. This highlights the 
importance of regulating IL-12 and IL-23 production and we sought to investigate the 
ability of the mRNA-destabilizing protein, Tristetraprolin (TTP) in regulating IL-12 
and IL-23 production by bone-marrow derived dendritic cells (BMDCs). 
 
TTP involvement in the regulation of IL-12 and IL-23 production was suggested by 
the rapid kinetics of IL-23p19 mRNA induction and the sensitivity of IL-12p40,      
IL-12p35 and IL-23p19 mRNA stability to p38 MAPK inhibitor (SB202190). Using 
TTP
-/-
 BMDCs, there was enhanced production of IL-23 as compared to WT BMDCs. 
This enhancement was due to enhanced mRNA stability of IL-23p19 as the half-life of 
IL-23p19 mRNA was increased. The role of TTP in regulation of IL-23p19 was 
further confirmed with the overexpression of TTP in HEK293/Tet-off cells as a 
reduction of IL-23p19 mRNA half-life was observed. 
 
Besides IL-23, TTP also negatively regulates the production of IL-12p70 and IL-6. 
Coculture of naïve CD4 T cells with WT and TTP
-/-
 BMDCs revealed a role of TTP in 
negatively regulating TH1 responses as the proportion of IFN- producing cells was 
enhanced in cocultures with TTP
-/-
 BMDCs. This enhancement of TH1 responses 
results from increased IL-12p70 production by TTP
-/-
 BMDCs. Hence, our study has 
revealed the importance of TTP as a negative regulator of inflammatory dendritic cell 
function through the suppression of excessive IL-12, IL-23, TNF- and IL-6 
production and the inhibition of their TH1 polarizing potential. 
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1.1 Recognition of pathogen by innate immunity 
 
Innate immunity constitutes the first line of defence against infections. The ability of 
innate immune cells to recognize pathogen components is key in the initiation of 
defence mechanisms. Innate immune cells recognize pathogen components, also 
known as pathogen associated molecular patterns (PAMPs), via various families of 
evolutionary conserved pattern recognition receptors (PRRs).  The major classes of 
PRR include Toll-like receptors (TLRs), Nod-like receptors (NLRs), retinoic acid 
inducible gene-I (RIG-I)-like receptors (RLRs) and C-type lectin receptors (CLRs). 
Each family of receptors is specialized in the recognition of pathogen components, 
leading to the activation of diverse intracellular signalling pathways. 
 
1.1.1 Toll-like receptors (TLRs) 
 
Toll-like receptors are the most widely studied family of PRR and currently, 10 
members of TLRs have been identified in human, and 13 in mice. TLRs are type I 
integral membrane glycoprotein that contains leucine-rich repeat (LRR) motifs in the 
extracellular region (Bell et al., 2003). Despite sharing the conserved extracellular 
LRR domain, different TLRs can recognize structurally unrelated ligands. A series of 
genetic studies have identified the respective ligands for TLRs; TLR-4 recognizes 
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lipopolysaccharide component of Gram-negative bacteria. TLR-2, when dimerized 
with TLR1 and TLR-6, recognizes various bacterial components such as 
peptidoglycan, lipopeptide and lipoprotein. TLR-3 recognizes double-stranded RNA 
produced during viral replication. TLR-5 recognizes bacterial flagellin. TLR-7 and 
TLR-8 recognize ssRNA. TLR-9 recognizes bacterial and viral CpG DNA motifs 
(Akira and Takeda, 2004; Janeway and Medzhitov, 2002; Medzhitov, 2001). After 
recognition of pathogens, TLRs trigger intracellular signalling pathways via the 
Toll/IL-1R (TIR) domain in their cytoplasmic tails (Slack et al., 2000). This involves 
the recruitment of adaptor molecules such as myeloid differentiation primary response 
protein 88 (MyD88), IL-1R-associated kinases (IRAKs), transforming growth factor- 
(TGF-)-activated kinase (TAK1), TAK1-binding protein 1 (TAB1),  TAK1-binding 
protein 2 (TAB2) and tumour-necrosis factor (TNF)-receptor-associated factor 6 
(TRAF6) (Dunne and O'Neill, 2003; Takeda et al., 2003).  
 
Although each TLR differs in the engagement of adaptors, the resultant TLR 
signalling pathway can be broadly classified into the MyD88-dependent pathway or 
MyD88-independent/TRIF-dependent pathway. The MyD88-dependent pathway 
involves an early phase of nuclear factor-kB (NF-B) and MAP kinase/AP-1 
activation, leading to the production of proinflammatory cytokines (Hacker et al., 
2000; Hayashi et al., 2001; Hemmi et al., 2002; Kawai et al., 2001; Schnare et al., 
2000). While NF-B and AP-1 are also activated in the MyD88-independent pathway, 
the activation occurs at a later phase. This delayed activation of NF-B and AP-1 
coupled with the activation of IRF-3 are required for the induction of type I IFNs by 




1.1.2 Nod-like receptors (NLR) 
 
Another important class of PRR are the cytosolic nod-like receptors (NLR). Currently, 
there are 22 human NLRs identified and these intracellular proteins are characterized 
by their C-terminal leucine-rich repeat (LRR) domains and central NACHT 
nucleotide-binding domains (NBD) (Ting et al., 2008). The functions of most NLRs 
remained poorly defined but the two most well-studied NLRs are the NOD1 and 
NOD2 which function as sensors of the bacterial cell wall peptidoglycan (Kanneganti 
et al., 2007). More specifically, NOD2 responds to both Gram-positive and Gram-
negative peptidoglycan and the minimal fragment that can elicit a NOD2-dependent 
response is muramyl dipeptide (MDP), a monosaccharide with a dipeptide stem 
(Girardin et al., 2003b; Girardin et al., 2003c). In contrast, NOD1 responds to 
fragments of peptidoglycan containing meso-diaminopimielic acid (mesoDAP), an 
amino acid present in the stem peptide of peptidoglycan found widely in Gram-
negative bacteria (Girardin et al., 2003a; Girardin et al., 2003c). Following ligand 
binding, NOD1 and NOD2 recruit protein kinase, RIP2 via a homotypic interaction 
between the CARD domains present on both the NOD proteins and RIP2 (Hasegawa 
et al., 2008; Tanabe et al., 2004; Tigno-Aranjuez et al., 2010). This initiates the 
downstream transcription factors, NF-B and IRFs, to coordinate NOD-dependent 
inflammatory responses (Hasegawa et al., 2008; Watanabe et al., 2010). 
 
1.1.3 Retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs) 
 
Retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs) are a family of cytosolic 
receptors specialized in the recognition of non-self RNA species in the cells. RLRs 
include RIG-I and MDA5, all of which contain a conserved DExD/H box helicase 
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domain and tandem caspase recruitment and activation domains (CARD) (Kato et al., 
2011; Yoneyama et al., 2005; Yoneyama et al., 2004).  The helicase domain contains 
catalytic activity to unwind double stranded RNA (dsRNA) via an ATP-dependent 
mechanism (Takahasi et al., 2008), while the CARD is able to interact with another 
CARD containing molecule, interferon- promoter stimulator-1 (IPS-1) to trigger type 
I interferon induction (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et 
al., 2005). It has been hypothesized that the binding of viral RNA to RLRs induces 
conformational change to unmasked CARD, but there have not been any experiments 
demonstrating this so far.  
 
1.1.4 C-type lectin receptors (CLRs) 
 
C-type lectin receptors belong to a superfamily identified by their C-type lectin-like 
domain (CTLD) that confers their carbohydrate binding activity. Therefore, CTLD are 
also known as carbohydrate recognition domain (CRD). Four Ca
2+
 binding sites are 
found in the CRD and one of these sites contains two amino acids with long carbonyl 
side chains separated by a cis proline. The carbonyl side chains coordinate Ca
2+
, form 
hydrogen bonds with individual monosaccharide and hence is crucial for determine 
binding specificity of the CLRs. However, not all CTLDs bind carbohydrates and 
calcium, as many specifically recognize proteins, lipids and even inorganic ligands 
instead (Sancho and Reis e Sousa, 2012).  
 
Two members of CLR, Dectin-1 and Dectin-2, bind to microbial organisms and hence, 
functions as PRR.  Dectin-1 recognizes -1,3-linked glucans present in the cell wall of 
fungi, some bacteria and plants. The cytosolic domain of Dectin-1 contains an ITAM 
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domain which is a tandem repeat of YxxL/I sequences (where x represents any amino 
acids) where the single tyrosine residue is necessary to mediate signaling through Syk 
(Rogers et al., 2005). On the contrary, Dectin-2 has affinity for high-mannose 
structures and binds -mannans in fungal cell walls as well as mannose-bearing 
glycans in extracts of house dust mites (Barrett et al., 2009; McGreal et al., 2006; 
Saijo et al., 2010). Dectin-2 lacks an intracellular signaling motif but associates with 
the ITAM-bearing FcR chain (Sato et al., 2006). Following binding to agonistic 
ligands, Dectin-1 and Dectin-2 can both recruit Syk through phosphotyrosine in the 
ITAM motif. This leads to the activation of NF-, NFAT and MAPK pathways, 
resulting in the activation of inflammasome and the production cytokines and ROS 
(Sancho and Reis e Sousa, 2012). 
 
1.2 Subsets of dendritic cells and function 
 
 Dendritic cells are crucial players in the innate immunity with the ability to bridge the 
innate and adaptive immunity. Sparsely and yet widely distributed, dendritic cells are 
a heterogeneous population that differ in location, migratory pathways, immunological 
function and dependence on infection or inflammation that lead to their generation. In 
spite of this, the unifying role of dendritic cells is their ability to acquire, process and 
present antigens to naïve T cells. The characterization of dendritic cells has been 
difficult as dendritic cells are a heterogeneous population of cells and furthermore, 
there is no single cell-surface antigen that identifies all dendritic cells. However, the 
heterogeneity among dendritic cells is of interest because of the specialized functional 




Dendritic cells can be classified into steady state conventional dendritic cells (cDC) 
and inflammatory dendritic cells. Steady state cDCs are present under steady state 
conditions and they consists of, a) migratory dendritic cells that are present in the 
peripheral tissues of origin and migrate to lymph nodes in response to danger signals 
as well as b) lymphoid tissue resident dendritic cells where they acquire and present 
antigens from the lymphoid tissue. On the contrary, inflammatory dendritic cells are 
absent during steady state but are rapidly generated in presence of inflammation. 
 
1.2.1 Migratory dendritic cells and their origin 
 
Migratory dendritic cells serve as antigen sensing sentinels in the peripheral tissues 
and the migration to the lymph nodes is initiated upon encounter with pathogens or 
danger signals; although such migration to the lymph nodes also occurs, at a lower 
rate under steady state (Bell et al., 1999; Huang and MacPherson, 2001). Migratory 
dendritic cells consist of Langerhans cells (LCs) of the epidermis as well as dermal 
DCs and interstitial DCs (Romani et al., 2003; Schuler and Steinman, 1985). 
Epidermal LCs are readily distinguished from the dermally derived DCs by high 
levels of langerin expression (Henri et al., 2001; Kissenpfennig and Malissen, 2006; 
Valladeau et al., 2000). 
 
Langerhan cells (LC) migration to the lymph nodes occurs at a basal rate during 
steady state but is increased after microbial stimulation or inflammation (Hemmi et 
al., 2001; Henri et al., 2001; Jakob et al., 2001; Kissenpfennig and Malissen, 2006). 
Although LCs can turn over rapidly once they reach the lymph nodes, they have a 
long lifespan in skin, with the ability to persist up to 3 weeks without division 
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(Kamath et al., 2002). Accordingly, the entry of blood-borne precursors into the 
mouse LC pathway is an infrequent event (Merad et al., 2002). Mouse skin contains 
significant numbers of immediate LC precursors or immature LCs which are capable 
of local clonal expansion to produce LCs. These precursors can in turn be generated 
from blood monocytes after LCs or their precursors are depleted (Ginhoux et al., 
2006). 
 
A series of transfer experiments have investigated the origin of LCs. Transfer studies 
using recipients with UV-irradiated skin have shown that Ly6C
+
 inflammatory mouse 
monocytes are effective LC precursors. Tracking the progeny of these Ly6C
+
 
monocytes in the skin has revealed the ability of these monocytes to proliferate locally 
and upregulate the expression of MHC class II molecules and langerin, which are 
classical markers of LCs, by day 7 (Ginhoux et al., 2006). Regeneration of LCs is also 
dependent on FLT3 and M-CSFR as reconstitution of LC population can be achieved 
by transfer of FLT3
+
 bone marrow precursors but not if these precursors are derived 
from M-CSFR deficient mice (Mende et al., 2006). The requirement of CCR2 for LC 
regeneration further affirms the role of Ly6C
+
 monocytes in LC development as 
CCR2 is also crucial for the generation of Ly6C
+
 monocytes (Serbina and Pamer, 
2006). The ability to generate Langerhans cells from a monocyte origin is also 





monocytes are able to generate LCs (Schaerli et al., 2005). In addition, a number of 
studies have generated LCs from myeloid precursors under the influence of cytokines 
that include GM-CSF and TGF- (Caux et al., 1996a; Caux et al., 1996b; Schaerli et 




The development of interstitial migratory DCs has been less extensively studied than 
that of LCs. Using a culture system that models transendothelial migration by 
allowing human monocytes to pass through a human endothelial cell monolayer on a 
collagen matrix, most of the monocytes became macrophages. However, a small 
proportion of the CD16
+
 non-inflammatory monocytes that underwent ‘reverse 
transmigration’, mimicking movement from tissues to lymphatics, had the phenotype 
of dendritic cells than macrophages (Randolph et al., 1998; Randolph et al., 2002). 
The transendothelial model of monocyte-to-migratory DC transformation was 
reaffirmed with an in vivo model where fluorescent latex microspheres were injected 
intradermally into mice. These beads were taken up avidly by phagocytic monocytes 
but less avidly by tissue resident DCs. After 4 days, MHC II
+
 DCs containing a high 
level of fluorescent microspheres and derived from the infiltrating monocytes were 
found in the draining lymph nodes. These DCs were derived from the non-
inflammatory CCR2
-
 monocytes (Qu et al., 2004). Hence, in contrast to LCs, 
interstitial migratory DCs seem to be derived from the non-inflammatory monocytes. 
 
1.2.2 Lymphoid tissue resident dendritic cells and their function  
 
Lymphoid organ dendritic cells differ from periphery migratory dendritic cells as they 
do not migrate into the lymphoid organs from the lymphatics; rather they collect and 
present antigens in the lymphoid organ itself. Lymphoid organ dendritic cells include 
most of the DCs in the thymus (Ardavin, 1997), spleen (Vremec et al., 2000) and even 
in the lymph nodes. Around half of the DCs in the steady state seem to be resident 
DCs rather than migratory dendritic cells arriving from the lymphatics (Wilson et al., 
2003). However, different DC substypes can be detected within one lymphoid organ. 
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This reflects the specialization of these DC subtypes in aspects of antigen processing, 
presentation and interaction with T cells. 
 
Early studies characterizing DC subtypes from mouse lymphoid tissues revealed 
heterogeneity in expression of several surface markers, including CD8. However, CD8 
is not an appropriate marker for this DC subset. First, there has been no evidence that 
CD8 has any role in DC development or function (Kronin et al., 1997; Vremec et al., 
2000). Second, a proportion of normal plasmacytoid dendritic cells in the spleen also 
express CD8 (O'Keeffe et al., 2002). Third, CD8 appears late in DC development, so 
not all functional DCs of this sublineage express the CD8 surface marker (Bedoui et 
al., 2009; Vremec et al., 2007). Finally, CD8 only serves as a useful DC subset marker 
in mice as it is absent from DCs in many other species, including humans. In view of 




 DC lineages can be better defined 
with a combination of markers. The first account of CD8
+







 (Crowley et al., 1989). Subsequently, 
multiparameter fluorescent analysis confirmed the existence in mice of a 
































 (Caminschi et al., 2008; 
Henri et al., 2001; Huysamen et al., 2008; Lahoud et al., 2006; Leenen et al., 1998; 
McLellan et al., 2002; Sancho et al., 2008; Vremec et al., 2000)  
 
FLT3L (FMS-related tyrosine kinase 3 ligand) is crucial for steady-state lymphoid 
resident DC development as mice lacking FLT3L have low levels of DCs (McKenna 
et al., 2000). Furthermore, mice deficient in STAT-3, which is an important molecule 
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in FLT3L signaling cascade, have similar defect in the development of lymphoid 
tissue resident DC (Laouar et al., 2003). Conversely, the administration of FLT3L 




 lymphoid tissue resident 
DCs although a larger enhancement was observed on the CD8
+
 DC subset (Bedoui et 
al., 2009; O'Keeffe et al., 2002). Furthermore, the culture of bone marrow cells with 





 dendritic cells subsets (Naik et al., 2005). While FLT3L is critical for the 




 DCs, mice deficient in interferon-regulatory factor-
8 (IRF-8) and IRF-4 have marked selective deficiency of CD8
+
 DCs and CD8
- 
DCs 
respectively (Aliberti et al., 2003; Schiavoni et al., 2002; Suzuki et al., 2004; 
Tsujimura et al., 2003). The differential role of IRF-4 and IRF-8 also reaffirms the 










 DC subset have the ability to take up exogenous 
antigens and process these for presentation on MHC class II, CD8
+
 DCs are more 
efficient at cross-presenting cell-bound or soluble antigens on MHC class I than its 
CD8
-
 DCs counterpart (Pooley et al., 2001). The major role of CD8
+
 DCs in cross-
presentation has been demonstrated in Batf3-deficient mice, which lack CD8
+
 DCs, as 
the mice are also deficient in responses that require cross-presentation in vivo (Hildner 
et al., 2008).  Besides the enhanced cross-presentation ability, CD8
+
 DCs are more 
efficient in the phagocytic uptake of dead cells (Iyoda et al., 2002; Schnorrer et al., 
2006; Schulz and Reis e Sousa, 2002). Some distinguishing markers on CD8
+
 DCs 
such as CD36 and Clec9A are involved in this process. This ability of CD8
+
 DCs to 
efficiently process and present antigens associated with dead cells provides a 
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mechanism for prolonging antigen presentation beyond the lifespan of an individual 
DC (Inaba et al., 1998).  
 
The selective ability of CD8
+
 DCs to phagocytose dead cells was suggested as a main 
reason for the ability of this DC subset to cross-present cell bound antigens. However, 
CD8
+
 DCs are also more adept at cross-presenting soluble antigens in both in vitro 
and in vivo models (Lin et al., 2008b; Pooley et al., 2001), suggesting that their 
internal antigen processing machinery is specialized for cross presentation on MHC 
class I. Experiments comparing the ability to process and present exogenous antigens 




DCs subtypes. Dendritic cells were 
selected after internalization of the same number of fluorescent beads coated with a 
model antigen and CD8
+
 DCs were found to be significantly more efficient at cross-
presentation of antigen on MHC class I (Schnorrer et al., 2006). Interestingly, 
although both DC subsets presented antigen on MHC class II, CD8
+
 DCs were less 
efficient than its CD8
-
 counterpart. Hence, this finding suggests a role of CD8
+
 DC as 
more efficient activator of CD8
+
 T cells, whereas CD8
-
 DCs being more efficient at 
activating CD4
+
 T cells. Indeed, this trend has been observed in vivo (Dudziak et al., 
2007). 
 
Besides their differential ability to prime CD4 and CD8 T cells, CD8
+
 DCs produce a 
unique pattern of cytokines on activation. Of particular importance is the ability of 
CD8
+
 DCs to produce high levels of bioactive IL-12p70 (Hochrein et al., 2001; Reis e 
Sousa et al., 1997). This is also in line with the preferential ability of CD8
+
 DCs but 
not CD8
-
 DCs in directing the development of TH1-type helper T cell responses 
(Maldonado-Lopez et al., 1999; Pulendran et al., 1999). 
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1.2.3 Inflammatory dendritic cells, the protector and the destroyer 
 
Unlike the migratory and lymphoid tissue resident DCs that are present under steady 
state conditions, inflammatory dendritic cells are not found in the steady state but 
appear as a consequence of infection or inflammation. Various lines of evidence 
suggest that the inflammatory dendritic cells are derived from the inflammatory 
CCR2
+
 monocytes. Transfer of Ly6C
+
 inflammatory mouse monocytes produced no 
detectable DC progeny in lymphoid organs of naïve mice. However, when transferred 
into mice that were subjected to vigorous inflammation, these monocytes produced 
DCs in the peritoneum and entered the spleen to produce a distinctive DC subset 
(Geissmann et al., 2003; Naik et al., 2006; Sunderkotter et al., 2004). The ability to 
generate inflammatory DCs from monocytes is GM-CSF dependent as inflammatory 
monocytes derived from mice deficient in GM-CSF receptor failed to develop into 
MHC-II
+
 DCs. Hence, the generation of inflammatory DCs from inflammatory 
monocytes and the dependence on GM-CSF indicates that the developmental pathway 
of inflammatory DCs differs from that of the lymphoid tissue resident DCs. Indeed, 
these monocyte-derived inflammatory DCs can be distinguished from steady state 
splenic DCs by their intermediate rather than high level of CD11c expression and also 
by their high expression of CD11b and MAC3 (Naik et al., 2006).  
 
Inflammatory dendritic cells are first shown to be crucial in protective immunity as 
they are essential for the clearance of Listeria monocytogenes from infected spleen. In 







cells is recruited in a CCR2 dependent mechanism. This subset of dendritic cells has 
been termed TNF/iNOS-producing dendritic cells (Tip-DCs) due to the high levels of 
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TNF- and NO production upon stimulation by heat-killed Listeria monocytogenes. 
(Serbina et al., 2003).  
 
The study into the role of inflammatory dendritic cells has been greatly facilitated with 
the use of CCR2
-/-











 inflammatory monocytes and exudate 
macrophages, to the site of inflammation are selectively inhibited (Aldridge et al., 
2009; Bosschaerts et al., 2010; Lin et al., 2008a; Peters et al., 2004). In the absence of 
Tip-DCs, CCR2
-/-
 mice have impaired ability to clear Listeria monocytogenes from 
infected spleen (Serbina et al., 2003). This appears to result from the decreased levels 
of TNF- and NO produced as they have been shown to be crucial for control of 
infection by intracellular bacteria (Flynn et al., 1995; Pasparakis et al., 1996). 
Additionally, CCR2
-/-
 mice have increased susceptibility to Mycobacterium 
tuberculosis and Cryptococcus neoformans infection due to the impaired trafficking of 
leukocytes to lung and lymphoid tissue (Peters et al., 2004; Peters et al., 2001; Scott 
and Flynn, 2002; Traynor et al., 2002). The crucial role of Tip-DCs in the recruitment 
of T cells to the lungs during Mycobacterium tuberculosis is demonstrated via a model 
of mixed bone marrow transplantation. In mice transplanted with CCR2
-/-
 bone 
marrows, there is defective recruitment of both dendritic cells and T cells. However, 
under the conditions where only the T cells are CCR2 deficient, the recruitment of T 
cells to the lung is restored. This demonstrates the role of Tip-DCs in the downstream 
recruitment of T cells (Peters et al., 2004).      
 
While inflammatory dendritic cells are indispensable for the clearance of bacterial 
infections, this is not the case for influenza infection as inflammatory dendritic cells 
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and exudate macrophages appears to contribute to pulmonary immunopathology and 
mortality (Lin et al., 2008a). Despite this, Tip-DCs are still involved in virus specific 
CD8
+
 CTL responses (Aldridge et al., 2009).  
 
1.3 Interleukin-12 and interleukin-23: Linking innate and adaptive immunity 
 
In 1986, Mosmann, Coffman and colleagues identified the presence of two subsets of 
CD4 T helper (TH) cell clones that exhibit distinctive cytokine profiles. The TH1 cell 
subset produced IL-2, granulocyte/macrophage colony-stimulating factor (GM-CSF) 
and interferon- (IFN-), whereas the TH2 cell subset secreted soluble factors later 
identified to be IL-4, IL-5 and IL-13 (Mosmann et al., 1986). For a long period of 
time, it was widely believed that the CD4 T cells mediated immunity can be broadly 
classified into cell-mediated (TH1) and humoral (TH2) immunity during infection and 
vaccination. However, the events that govern the predominance of TH1 or TH2 
responses remained unclear. The identification of interleukin-12 (IL-12) as a soluble 
factor that could induce IFN- production in natural killer (NK) cells became the 
missing link that could account for the development of TH1 immune responses. This 
discovery paved the way for studies which demonstrated that macrophages and 
dendritic cells, by producing IL-12 in response to bacterial and parasitic infections, led 
to the polarization of naïve T cells to produce TH1 cell response.  
 
The identification of a fraction of effector T cells positive for IL-17A, GM-CSF and 
TNF- but negative for IFN- or IL-4 revealed a novel cytokine phenotype distinct 
from TH1 and TH2. Concurrently with this finding, Kastelein and colleagues reported 
the discovery of IL-23 during a database search for sequences homologous to IL-
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12p35. The novel protein identified (IL-23p19) could pair with IL-12p40 to form a 
distinct, heterodimeric cytokine that was named interleukin-23 (Oppmann et al., 
2000). Aggarwal et al (2003) later discovered a role of IL-23 but not IL-12 in the 
stimulation of memory CD4 T cells to produce IL-17A and IL-17F. This was the 
pivotal finding that first associated IL-23 with the production of IL-17. Subsequently, 
IL-23 was identified as a crucial factor required for the maintenance of TH17 lineage. 
 
1.3.1 Interleukin-12 and interleukin-23 and their receptors 
 
Despite their divergent roles in adaptive immunity, IL-12 and IL-23 belong to the 
same family of heterodimeric cytokines and share the same IL-12p40 subunit. 
Although IL-12 is identified as a unique heterodimeric cytokine, it was recognized 
that the IL-12p35 subunit of IL-12 is homologous to type I cytokines such as IL-6. 
Type I cytokines are a superfamily of immunomodulators that are defined on the basis 
of structural motifs such as the common four helix bundle and the haematopoietin 
receptor domains. The similarity of IL-6 and IL-12 extended to their receptors as IL-
12 receptor components (IL-12R1 and IL-12R2) and gp130 component of the IL-6 
receptor both belong to the gp130 (glycoprotein 130) family of receptors. On the other 
hand, IL-12p40 is structurally related to the soluble IL-6 receptor (IL-6R) (Hunter, 
2005). 
 
IL-12R is mainly expressed by activated T cells and NK cells (Presky et al., 1996) 
although expression of IL-12R has also been reported on other cell types such as DCs 
and B-cell lines (Airoldi et al., 2002; Grohmann et al., 1998). IL-12R is undetectable 
on most resting T cells and is expressed at low level by resting NK cells. Upon 
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activation through TCR, the transcription and expression of both chains of IL-12R is 
upregulated, and this upregulation is further enhanced in the presence of IFN-, IFN- 
TNF-, costimulation with CD28 and by IL-12 itself (Rogge and Sinigaglia, 1997; 
Szabo et al., 1997).  
 
Besides sharing the same IL-12p40 subunit, similarity between IL-12 and IL-23 is 
extended to their receptors as IL-23 receptor (IL-23R) comprises of the IL-23R 
subunit as well as the IL-12R1 subunit that is shared with IL-12R (Oppmann et al., 
2000; Parham et al., 2002).  
 
Similar to IL-12R, expression of IL-23R was absent in naïve T cells but is upregulated 
by TH17 cells as well as memory T cells. On top of that, NKT cells, macrophages and 
dendritic cells were also found to express IL-23R (Parham et al., 2002). With the 
generation of IL-23 receptor GFP mice, more insights were shed regarding the 
distribution of IL-23R. While IL-23R expression was absent on CD8 T cells, B cells 
and NK cells in the lymph nodes, a small percentage of CD4 T cells expressed IL-
23R. However,  T cells were the majority population of IL-23R+ T cells in the 
lymph nodes. Similar to earlier findings, CD11b

 macrophages and CD11c

 dendritic 
cells also expressed IL-23R. However, compared to the lymph nodes, the lamina 
propria expressed an enhanced frequency of IL-23R expressing immune cells with the 
majority of IL-23R
+
 T cells being  T cells (Awasthi et al., 2009). This finding was 
consistent with the key role of IL-23 in intestinal inflammation (Geremia et al., 2011; 




1.3.2 Interleukin-12 and the TH1 lineage 
 
Despite their structural similarities, IL-12 and IL-23 play a divergent role in adaptive 
immunity. IL-12 is crucial for the development of TH1 responses and is required for 
optimal TH1 responses during infection (Hsieh et al., 1993; Manetti et al., 1993; 
Trinchieri, 2003). The role of IL-12 in the induction of TH1 responses has been 
demonstrated by the addition of recombinant IL-12 in both in vitro and in vivo models. 
Furthermore, treatment of animals with neutralizing antibodies specific for IL-12 or 
using animals genetically deficient for IL-12p40, IL-12p35, IL-12R1, IL-12R2 and 
STAT4 resulted in a suppression of TH1 responses (Trinchieri, 2003).  
 
TH cell differentiation is determined early after infection by the balance of IL-12 and 
IL-4, which favours TH1 and TH2 development respectively. Indeed, IL-12 when 
present early during clonal expansion, primes both CD4 and CD8 T cells for the 
production of high levels of IFN- upon restimulation (Manetti et al., 1994; Seder et 
al., 1993). However, in experiments involving single cell cloning, IL-12 has minimal 
ability to reduce T-cell production of IL-4, whereas, unexpectedly, it primed most T-
cell clones for high level of IL-10 production (Gerosa et al., 1996). A requirement of 
IFN- for IL-12 induced TH1 cell generation has been shown in many mouse 
experimental systems (Gerosa et al., 1996; Macatonia et al., 1993; Manetti et al., 
1993). Hence, it has been hypothesized that IL-12 produced in vivo during 
inflammation phase induces NK cell and T cell production of IFN-. Subsequently, 
IL-12 in cooperation with IFN- induces T cell clones that are expanding in response 




Although there is no doubt that IL-12 is required for efficient TH1-type responses 
(Gerosa et al., 1996; Macatonia et al., 1993; Manetti et al., 1993), there has been 
various lines of evidence suggesting that IL-12 might not be an absolute requirement 
and raised the possibility that IL-12 might be more involved in expanding or final 
lineage commitment of TH1 cells than a direct role in polarization of naïve T cells to 
TH1 lineage. TCR signaling has been shown to induce early TH1 polarization of naïve 
T cells independently of IL-12. The balance between mitogen activated protein kinase 
and calcineurin signaling which favours TH1 cell polarization and protein kinase C 
signaling which favours TH2 cell polarization has been proposed to be responsible for 
TH cell commitment (Noble et al., 2001). Furthermore, in IL-12 deficient mice, 
repeated immunization with a soluble extract of the pathogen induced a low but 
substantial number of CD4 T cells producing IFN- (Jankovic et al., 2002). Although 
the minimal TH1 response induced in IL-12 deficient mice were unable to protect mice 
from T. gondii infection, mice with double deficiency of IL-12 and IL-10 survived. 
Hence, this indicates a role of IL-10 in limiting the induction of TH1 responses 
(Belkaid et al., 2001; Jankovic et al., 2002). Unlike IL-12 deficient mice, MYD88 
deficient mice that are unable to mount most TLR mediated responses, completely 
failed to induce a TH1 response but developed a full TH2 response (Jankovic et al., 
2002). Hence, TLR receptor signaling possibly induces the production of pro-
inflammatory factors other than IL-12 that could induce TH1 response.  
 
Following the identification of cytokines that induces TH1 differentiation, the key 
signaling pathways involved were identified. TH1 differentiation is initiated by the 
coordinate signaling through TCR and STAT1 associated cytokine receptors, which 
include type I and type II IFNs as well as IL-27 (Hibbert et al., 2003; Lucas et al., 
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2003; Pflanz et al., 2002). Activation of STAT1 results in the upregulation of 
transcription factor, T-bet, which is a master regulator of TH1 differentiation. T-bet 
potentiates expression of IFN- and IL-12R2, enabling IL-12 signaling through 
STAT4 (Mullen et al., 2001; Szabo et al., 2000). Signaling through IL-12 potentiates 
IFN- production, induces expression of IL-18R and these reinforce the commitment 
to TH1 development (Robinson et al., 1997; Yang et al., 1999).  
 
1.3.3 Role of interleukin-23 in the TH17 lineage 
 
The first evidence of IL-23 in the regulation of T cell effector function comes from the 
finding that IL-23, but not IL-12, induced the production of IL-17 by activated and 
memory T cells (Aggarwal et al., 2003). Subsequently, with an experimental 
autoimmune encephalomyelitis (EAE) model, IL-23 was unable to induce the 
development of IFN- producing TH1 cells but instead, promoted development of a T 
cell subset with an unique cytokine expression pattern (IL-17A, IL-17F, TNF- and 
IL-6) (Langrish et al., 2005). This unique population of CD4 T cell subset was termed 
TH17 cells due to their characteristic production of IL-17. Various lines of evidence 
suggested a TH1 independent pathway of TH17 differentiation. The inability of IL-23 to 
induce IL-17 production from TH1 polarized cells indicates that TH1 cells are not IL-23 
responsive, which is distinct from the IL-23R expressing TH17 cells. Furthermore, type 
I and type II IFNs that activate STAT1-induced expression of T-bet and TH1 
commitment strongly inhibited TH17 development in vitro (Harrington et al., 2005; 
Park et al., 2005). These findings indicated that TH1 pathway is non-permissive to TH17 
development and this result from the suppression of TH17 development by IFN-. 
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The role of IL-23 on TH17 cells was evident as neutralization of IL-23 severely 
impaired IL-17 responses (Aggarwal et al., 2003; Happel et al., 2003; Murphy et al., 





 mice in a model of collagen induced arthritis (Murphy et al., 2003). 
However, the role of IL-23 in TH17 polarization and function remains controversial. 
Although IL-23 is crucial for TH17 function, IL-23 appears to be dispensable for the 
polarization to TH17 subset as T cells from IL-23p19 deficient mice can still produce 
IL-17 when restimulated with IL-23 (Murphy et al., 2003). IL-23 deficient mice    
(p19
-/-
) mice also have normal IL-17 effector response to a TH17 dependent pathogen 
(Mangan et al., 2006). Furthermore, the addition of IL-23 to naïve CD4 T cells did not 
enhance the polarization towards a TH17 phenotype. On the contrary, TH17 
development is suppressed in TGF- deficient mice and thus it appears that TGF- 
together with IL-6, are the crucial mediators of TH17 polarization in mice (Bettelli et 
al., 2006; Veldhoen et al., 2006), although IL-1 and TNF-can also serve to enhance 
the development of TH17 subset (Veldhoen et al., 2006).  
 
The involvement of TGF- in TH17 commitment was surprising as TGF- was well 
known to be involved in the development of Foxp3-expressing Tregs. The presence of 
IL-6 during inflammation deviates the TGF--driven development of Foxp3-
expressing Treg toward TH17; through the suppression of Foxp3 expression while 
reciprocally promoting the generation of TH17 cells (Bettelli et al., 2006; Mangan et 
al., 2006). By enabling CD4 T cells to overcome the default expression of Foxp3 in 
the presence of TGF-, IL-6 functions as a critical switch factor that diverts antigen 




TH17 lineage are plastic and fail to maintain a stable phenotype when cultured in vitro 
or transferred in vivo to recipient mice (Murphy et al., 2010; O'Shea and Paul, 2010). 
Hence, rather than inducing the development of TH17 lineage, IL-23 is critical for 
maintaining the TH17 phenotype and the terminal differentiation of TH17 cells in vivo. 
The restimulation of polarized TH17 cells with IL-23 enhanced the proportion of IL-17 
producing cells while IL-2 converted TH17 cells into IFN- producing cells (Veldhoen 
et al., 2006). The role of IL-23 in the final lineage commitment of TH17 subset was 
further demonstrated in IL-23 deficient mice where TH17 development in an EAE 
model was stalled at an early stage with inability to downregulate IL-2 receptor, 
impaired upregulation of IL-7 receptor  chain and failure to maintain IL-17 
production (McGeachy et al., 2009). Hence, this evidence suggested a role of IL-23 in 
reinforcement of TH17 lineage and maintenance of TH17 effector functions. 
 
Recent studies have re-emphasized the importance of IL-23 in TH17 development. 
Although a combination of IL-1, IL-6 and IL-23 have lower capacity to promote TH17 
lineage as compared to IL-1, IL-6 and TGF, TH17 cells polarized in the presence of 
IL-23 are more pathogenic and induce a more severe EAE upon adoptive transfer. 
Furthermore, TH17 cells generated with IL-23 express T-bet and IL-18R, each of which 
are essential for EAE and expresses CXCR3 essential for trafficking to sites of 
inflammation (Ghoreschi et al., 2010). On the contrary, TH17 cells generated with 
TGF- have reduced expression of IL-23R, are poorly pathogenic and trafficked 
mainly to the spleen.  
 
While IL-12 and IL-23 are involved in TH1 and TH17 lineages respectively, IL-12 
appears to antagonize IL-23 induced IL-17 responses as TH17 frequencies were 
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elevated in IL-12p35 deficient mice (Murphy et al., 2003). Furthermore, TH1 effector 
cytokine, IFN- has also been shown to suppress development of TH17 lineage 
(Harrington et al., 2005; Park et al., 2005). The cross regulation of IL-12 on the TH17–















Figure 1.1 Model of divergent differentiation of TH1 and TH17 lineages and role of Treg cells. 
Differentiation of naïve CD4 T cells in the presence of dendritic cells, NK cells and T cells 
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1.3.4 IL-12 and IL-23 in resistance to infection 
 
The ability of IL-12 to stimulate innate resistance and generate a TH1 response is 
essential for resistance to pathogens. By inducing an effective TH1 immune response, 
resistance to bacteria burden is achieved through the release of proinflammatory 
cytokines, direct bacteria lysis and B-cell activation (Gazzinelli et al., 1993; Hsieh et 
al., 1993; Scharton-Kersten et al., 1995). In addition, IL-12 and IFN- can promote the 
bactericidal activities of the macrophages, including increased phagocytosis, oxygen 
radical (ROS) and nitric oxide (NO) production. Besides bacterial infection, IL-12 
also confers resistance to intracellular protozoa and fungal pathogens (Decken et al., 
1998; Park et al., 2000; Yap et al., 2000). Irrefutably, IL-12 mediates the development 
of TH1 response and early protection against pathogens. However, the long-term 
maintenance of IFN- dependent immunity against intracellular pathogens, such as 
Toxoplasma gondii, also requires IL-12 as the removal of IL-12 supplementation from 
IL-12p40 deficient mice reactivated the disease phenotype and resulted in increased 
brain cyst burden and development of toxoplasmic encephalitis. This reactivation was 
associated with a loss of T cell-dependent IFN- production (Yap et al., 2000). The 
requirement of IL-12 for continued TH1 immunity was similarly observed in 




 mice and IL-12R1-/- mice are more susceptible to bacterial 
challenge than p35
-/-
 or IL-12R2-/- mice. Although these studies highlight the 
importance of IL-12 in controlling microbial infection, they also point to a role of IL-
23. Dendritic cells treated with Gram-negative bacteria showed enhanced expression 
of IL-23 without elevation of IL-12 expression (Smits et al., 2004).  Furthermore, the 
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p40 subunit appears to have a protective role independently of IL-12p70 during the 
infection of mycobacterial (Holscher et al., 2001), Francisella tularensis (Elkins et al., 
2002) and Salmonella enteritidis (Lehmann et al., 2001; Schulz et al., 2008) 
infections. The administration of IL-23 to p40
-/-
 mice infected with Toxoplasma gondii 
resulted in a decreased parasite burden and prolonged survival but the increased 
resistance to infection did not correlate with enhanced IFN-production. p40-/- mice 
rapidly succumbed to toxoplasmosis, while p35
-/-
 mice displayed moderate resistance 
though they eventually succumbed to this infection. On the contrary, IL-23p19
-/-
 mice 
were able to control parasite replication similar to wildtype mice (Lieberman et al., 
2004). Similarly, the infection of p40
-/-
 mice with Cryptococcus neoformans exhibited 
higher fungal load and mortality as compared to p35
-/-
 mice (Decken et al., 1998). 
However, IL-23p19
-/-
 mice only showed a moderately reduced survival time as 
compared to the wildtype, while IL-12p35
-/-
 mice demonstrated higher mortality 
(Kleinschek et al., 2006). Hence, earlier studies suggested a critical role of IL-12 for 
clearance of many pathogens while IL-23 plays a complementary role by enhancing 
inflammatory cell response and inducing a distinct cytokine regulation.  
 
More recent reports have reported a protective role of IL-23 against bacterial 




 mice with Klebsiella 
pneumoniae showed similar susceptibility to infection, while p40
-/-
 mice were 
exquisitely sensitive to K. pneumonia challenge. Administration of IL-17A restored 
bacterial control in p19
-/-
 mice and to a lesser degree p40
-/-
 mice. Hence, in the case of 
Klebsiella pneumonia, both IL-12 and IL-23 mediate a role in pulmonary host defense 
whereby the former is required for IFN- expression and the latter is required for IL-
17A production (Happel et al., 2005). IL-23 has also been reported to mediate 
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immunity against Citrobacter rodentium via an IL-22 dependent production of Reg 
family of anti-microbial proteins (Zheng et al., 2008). Furthermore, IL-23 induced 
production of IL-17A and IL-17F from  T cells is critical for optimal liver 
neutrophil recruitment and resistance against Listeria monocytogenes (Meeks et al., 
2009). A role of IL-23 in fungal and virus immunity has also been demonstrated 
(Dejima et al., 2011; Kagami et al., 2010; Town et al., 2009; Werner et al., 2011).  
 
Despite a role of IL-23 in immunity against a variety of pathogens, IL-23 has been 
implicated in the immunopathology observed in various infections. Lung pathology 
observed during Pseudomonas aeruginosa infection is induced by IL-23 and occurs as 
a result of excessive airway inflammation with increased production of IL-17, KC, IL-
6, metalloproteinase-9 (MMP-9) and increased accumulation of neutrophils (Dubin 
and Kolls, 2007). Neutralization of IL-23 is able to protect mice from the endotoxin 
shock syndrome when mice are infected with Pseudomonas aeruginosa (Belladonna 
et al., 2006). A role of IL-23 in the immunopathology of Toxoplasma gondii infection 
has also been demonstrated (Sieve et al., 2010). Interestingly, IL-23-/TH17 mediated 
enhancement of neutrophils recruitment has also been shown to enhance the disease 
progression of cutaneous leishmaniasis (Lopez Kostka et al., 2009). Thus while IL-12 
and IL-23 serve as critical cytokines mediating immunity against pathogens, excessive 
inflammatory responses leading to immunopathology are undesirable. 
 
1.3.5 IL-12 and IL-23 in autoimmunity inflammation 
 
TH1 cells were initially thought to be the causative agent for autoimmune disease 
primarily through experimental models using p40
-/-
 mice and p40 neutralizing 
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antibodies. Indeed, treatment with IFN- led to exacerbation in human multiple 
sclerosis and transgenic mice overexpressing IFN- in the brain showed enhanced 
oligodendrocyte death resulting in demyelination (Panitch et al., 1987; Renno et al., 
1998; Vartanian et al., 1995). Despite the toxic effects of IFN- in the central nervous 
system, mice lacking the critical components of TH1/IFN- axis (IFN-
-/-
, IFN-R-/-, IL-
12R2-/- and IL-12p35-/- mice) are highly susceptible to experimental autoimmune 
encephalitis (EAE) (Becher et al., 2002; Ferber et al., 1996; Gran et al., 2002; 
Willenborg et al., 1996; Zhang et al., 2003). Furthermore, treatment of mice with 
neutralizing antibodies to IFN- showed exacerbation of EAE (Willenborg et al., 
1996; Langrish et al., 2005). Hence, this indicates that IL-12/IFN-/TH1 axis is not 
required for EAE but may provide protection against autoimmune diseases instead. 
 
A number of inflammatory or autoimmune diseases in humans have been associated 
with IL-23. Polymorphisms in IL-23R but not IL-12R1 or IL-12p40 have been 
associated with susceptibility to Crohn’s disease, ulcerative colitis, inflammatory 
bowel disease, psoriasis and ankylosing spondylistis (Capon et al., 2007; Cargill et al., 
2007; Duerr et al., 2006; Wellcome Trust Case Control et al., 2007).  In murine 
models, by using IL-23 deficient, p19
-/-





 mice, IL-23 has emerged as the key player in autoimmune 
inflammatory diseases. In an EAE model, IL-23 deficient, p19
-/-
 mice were resistant to 
development of CNS inflammation (Cua et al., 2003). Contradictory to the initial 
belief of TH1 cells being the etiology of autoimmunity, p19
-/-
 mice have normal TH1 
responses but are severely impaired in the capacity to develop IL-17 producing TH17 
cells. In addition, the transfer of pathogenic IL-23 dependent, MOG-specific TH17 cells 
to naïve recipient mice results in the development of chronic CNS inflammation 
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(Langrish et al., 2005). Besides chronic CNS inflammation, IL-23 but not IL-12 has 
also been implicated in the development of joint autoimmune inflammation. Mice 
deficient in IL-23 display resistance to collagen induced arthritis (CIA), a mouse 
model of autoimmune inflammatory arthritis (Murphy et al., 2003). Furthermore IL-12 
appears to protect mice from CIA as IL-12 deficient mice have exacerbated disease as 
compared to wildtype (Murphy et al., 2003). 
 
The generation of IL-23 receptor GFP reporter mice revealed distinct population of 
IL-23 responsive cells. Strikingly, highest proportion of IL-23R expressing immune 
cells occurs at the lamina propria with most of the IL-23R expressing cells being  T 
cells (Awasthi et al., 2009). Hence, it is unsurprising that IL-23 plays a crucial role in 
intestinal inflammation. In an experimental model of colitis by injecting anti-CD40 
antibodies, the neutralization of IL-23p19 reversed intestinal inflammation. Hence, IL-
23 is crucial for local mucosal immunopathology while IL-12 has been implicated in 
the systemic wasting disease and serum cytokine production (Uhlig et al., 2006). 
Similarly, IL-23, but not IL-12, is essential for intestinal inflammation in a model of 
Helicobacter hepaticus-induced colitis (Hue et al., 2006; Kullberg et al., 2006).  
 
The mechanism by which IL-23 caused autoimmune inflammation has been most 
studied in models of colitis. In colitis, IL-23 induces intestinal pathology through both 
innate and adaptive immunity. Using Rag
-/- 
mice, colitis was ameliorated with the 
treatment of anti-IL-23p19 antibodies and hence demonstrating the role of innate 
immune cells in IL-23p19 induced colitis. However, adaptive immunity also plays a 
role as IL-23 deficient (p19
-/-
) mice, but not IL-12 deficient (p35
-/-
) mice, are resistant 
to the development of intestinal inflammation when transferred with pathogenic T 
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cells (Hue et al., 2006; Kullberg et al., 2006). Interestingly, IL-23 has been implicated 
in driving both IFN- and IL-17 responses that together synergize to trigger severe 
intestinal inflammation (Kullberg et al., 2006). However, besides promoting T cells 
responses, IL-23 drives T cell dependent colitis through restraining regulatory T cell 
activity (Izcue et al., 2008). Intestinal inflammation appears to be negatively regulated 
by regulatory T cells (Treg) as blockage of IL-10R or TGF- resulted in a more severe 
colitis (Izcue et al., 2008). Indeed, Foxp3
+
 cells were almost completely absent in the 
mesenteric lymph node (MLN) and lamina propria lymphocytes (LPL) in TGF- 
deficient mice and the frequency of Foxp3
+
 CD4 T cells in the gut was enhanced in 
IL-23 deficient mice. Adoptive transfer of Foxp3 sufficient wildtype cells induced 
colitis in IL-23 sufficient Rag1
-/-




 mice, whereas Foxp3
-/- 
CD4 T 







(Izcue et al., 2008). Hence, IL-23 appears to be a critical switch in intestinal 
inflammation as its production triggers the onset of inflammatory responses through 
innate and adaptive mechanisms and simultaneously restraining regulatory T cell 
suppressive activity. 
 
1.3.6 Roles of IL-12 and IL-23 in innate immunity 
 
Innate immunity constitutes the first line of defense against infectious agents. Innate 
immune cells upon encounter with microbial stimuli produces inflammatory mediators 
resulting in the initiation of inflammation, vasodilation and enhancing recruitment of 
inflammatory cells. These processes facilitate the development of adaptive immune 
response to the infection. IL-12 and IL-23 are among the cytokines rapidly produced 
by dendritic cells and macrophages upon stimulation by microbial components. 
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Although IL-12 and IL-23 are mainly studied in terms of their effect on T cells, they 
also have effects on innate immune cells.  
 
The functions of IL-12 have been mainly studied in lymphocytes and besides its role 
in the development of TH1 response, IL-12 plays an important role in innate immunity 
though the enhancement of NK cell function during parasitic, intracellular bacterial 
and viral infection (Gazzinelli et al., 1993; Hunter et al., 1994; Orange and Biron, 
1996; Tripp et al., 1994). IL-12 increases the generation of lymphokine activated killer 
(LAK) cells and also augments the cytotoxic activity of NK cells by inducing the 
transcription of genes encoding cytotoxic granules-associated molecules, such as 
perforin and granzymes, and by upregulating the expression of adhesion molecules 
(Kobayashi et al., 1989; Perussia et al., 1992). Furthermore, production of cytokines, 
such as granulocyte-macrophage colony-stimulatory factor, TNF- and in particular, 
IFN-, is enhanced in the presence of IL-12 (Chan et al., 1991; Kobayashi et al., 1989; 
Kubin et al., 1994).  Although IFN- by T cells and NK cells are both regulated by IL-
12, the induction of IFN- production in T cells and NK cell occurs via two different 
pathways. IFN- production by T cells is induced through activation of TCRs, CD3, 
phorbol diesters or ionomycin, and is sensitive to cyclosporine A, while NK cells is 
through IL-12, IL-18 or ligands for CD28, and is resistant to cyclosporin A (Kubin et 
al., 1994; Yang et al., 1999).  
 
Early research of IL-23 function has been mainly focused on the TH17 lineage, 
however, there is increasing evidence of IL-23 in directly activating the innate 
immune system. Systemic administration of DC-activating antibody, anti-CD40, 
resulted in a systemic wasting disease and intestinal inflammatory response in RAG-
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deficient mice and were therefore B- and T- cells independent (Uhlig et al., 2006). 
Neutralization of IL-12 resulted in the reversal of systemic wasting and inhibition of 
elevated serum levels of proinflammatory cytokines. On the contrary, neutralization of 
IL-23 resulted in the reduction of intestinal immunopathology and reduced intestinal 
expression of proinflammatory cytokines. These results suggested a specific role for 
IL-23 in local mucosal inflammation while IL-12 mediates a systemic innate 
inflammatory response. Interestingly, anti-CD40 administration induced intestinal 
expression of IL-17 mRNA in an IL-23p19 dependent manner in the absence of T 
cells. Hence, IL-23 can also act on non-T cell populations to induce expression of IL-
17A (Uhlig et al., 2006). Concurrent with the findings, IL-23 has been shown to be 
crucial for Helicobacter hepaticus induced intestinal inflammation via both innate and 
T cell dependent mechanism (Kullberg et al., 2006; Hue et al., 2006). Helicobacter 
hepaticus infection of RAG deficient mice resulted in a systemic activation of innate 
inflammatory response and intestinal inflammation that is ameliorated with the IL-23 
blockage.  
 
The identification of a possible innate role of IL-23 in the etiology of various 
inflammatory diseases generated immense interest in the identification of innate 
immune cells involved. Given the importance of IL-23 in intestinal pathology, study 
into murine colitis model identified the role of innate lymphoid cells with IL-23 
dependent innate intestinal pathology. On top of the classical lymphoid tissue inducer 
(LTi)-like cells, which are present in the intestines and produce IL-22 and IL-17 on 
stimulation with IL-23, a novel subset of IL-23 dependent, IL-17 expressing innate 














ROR-t+ and expressed LTi-related genes such as those encoding lymphotoxin (LT)- 
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and LT-, TRANCE and CXCR5.  However, unlike LTi-like cells, the subset of 




 and also expressed SCA-1 (Buonocore et al., 
2010). The depletion of Thy1 cells decreased severity of colitis in both H. hepaticus 
and anti-CD40 induced model of colitis in Rag
-/-
 mice (Buonocore et al., 2010). 
Hence, this suggests a crucial role of IL-23 dependent Thy
+
 innate lymphoid cells in 
innate intestinal pathology. In humans, innate lymphoid cells (ILCs) are also divided 
into two populations depending on their expression of NK marker CD56 (Crellin et 
al., 2010; Geremia et al., 2011). Both populations share the expression of NKp44, 
NKp46, CD161, c-kit and RORC. Analysis of IL-23-responsive ILCs in the control 
and inflamed human intestines demonstrated that IL17A and IL17F is restricted to 
CD56
-
 ILCs, whereas IL-23 induces IL-22 and IL-26 production by the CD56
+
 ILC 
subset (Geremia et al., 2011). However, CD56
-
 but not IL-23 responsive CD56
+
 ILC 
has been shown to be enhanced in intestines of Crohn’s disease. Hence, a direct role of 
IL-23 on the pathogenesis of human inflammatory bowel disease via innate lymphoid 
cells remains to be elucidated.  
 
Besides innate lymphoid cells, a subset of  T cells are also IL-23R+ and respond 





  T cells and promotes the secretion of IL-17, IL-21 and IL-22. In an 
experimental autoimmune encepthalitis model, the proportion of IL-23R
+
  T cells in 
the brain was increased during the peak of the disease. Interestingly, when CD3
+
 T 
cells depleted of  T cells were transferred into IL-23R deficient host immunized 
with MOG peptide/CFA, there was a reduction in percentage of Treg cells. 
Furthermore, supernatant from IL-23 activated  T cells abrogates the TGF- driven 
induction of Foxp3 in conventional T cells. Hence these evidences suggest a role of  
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T cell in overcoming the tolerogenic effects of Tregs cells via an IL-23 dependent 
mechanism. Other studies on IL-17 producing  T cells have also demonstrated their 
ability to enhance the generation of pathogenic TH17 CD4 T cells (Do et al., 2011; 
Sutton et al., 2009) and activating  T cells by reversal of Treg suppression in an IL-
23 dependent mechanism (Petermann et al., 2010).  
 
1.4 Transcriptional regulation of IL-12 and IL-23 production 
 
1.4.1 Regulation of IL-12p40 promoter 
 
The promoter of the gene encoding IL-12p40 has been most extensively studied while 
lesser is known for gene encoding IL-p12p35 and IL-23p19. An analysis of 
nucleosome positioning, chromatin remodeling and transcriptional factor binding for 
gene encoding mouse p40 has shown that the p40 gene promoter is normally 
configured in a nucleosome array (Weinmann et al., 2001). After activation with the 
microbial stimuli, LPS, nucleosome 1 is selectively remodeled such that it allows 
accessibility to transcription factor C/EBP (CCAAT/enhancer-binding protein). 
However, the remodeling of nucleosome is insufficient for transcription of gene 
encoding p40 as the p40 promoter contains several other elements that function 
synergistically to induce transcription of p40 (Becker et al., 2001). 
 
One of the first transcription factors associated with the regulation of IL-12p40 gene 
transcription was NF-. Through a series of experiments involving truncation and 





) inducible with the treatment of LPS and IFN- has been 
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identified (Murphy et al., 1995). Binding of NF- complexes containing p50 and    
c-Rel to the NF- element is crucial for p40 transcription (Sanjabi et al., 2000). 
Furthermore, a downstream C/EBP site has been shown to cooperate with REL 
proteins that bind to the NF- site, and over expression of C/EBP was found to be 
sufficient for p40 promoter activity (Becker et al., 2001; Plevy et al., 1997). However 
the role of C/EBP on IL-12p40 transcription remains controversial as C/EBP 
deficient mice were reported to produce enhanced levels of IL-12p40 suggesting a 
regulatory role of C/EBP on p40 transcription (Gorgoni et al., 2002). An ETS 
consensus element upstream of NF- site has also been identified and may bind to 
two members of the ETS family of transcription factors, ETS2 and PU.1. These two 
transcription factors in turn form a large supramolecular complex with c-Rel and 
several members of the interferon (IFN) regulatory factor (IRF) family, including 
IRF1, IRF2 and IRF8. IRF1 and IRF8 have been shown to positively regulate p40 
transcription while IRF2 is a negative regulatory factor (Gri et al., 1998; Ma et al., 
1997; Salkowski et al., 1999; Wang et al., 2000). Lastly, p40 promoter has also been 





) upon LPS stimulation (Zhu et al., 2001a). 
 
Besides transcriptional activators, binding of transcriptional repressor GA12-binding 
protein (GAP12) to the repressor site, GA12, in unstimulated cells inhibits the 
transcription of IL-12p40. The suppression of IL-12p40 by GAP12 was further 
demonstrated with IL-4 and prostaglandin-E2 treatment which enhances GAP12 with 
a corresponding decrease in IL-12p40 production (Becker et al., 2001). Hence, 
transcription of p40 promoter is governed by the balance of both transcriptional 
activators and repressors. 
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1.4.2 Regulation of IL-12p35 promoter 
 
The analysis of IL-12p35 promoter was complicated not only by its ubiquitous 
expression, but also by its low level of expression. Hence, much lesser is known 
regarding the regulation of IL-12p35 promoter. Similar to IL-12p40, an inducible 
remodeling of nucleosome spanning -310 and -160 of IL-12p35 promoter region is 
observed on stimulation with LPS/IFN-. The NF- family of transcription factors is 
also implicated in the induction of p35 transcription and the binding of p50/c-Rel 
complex to the murine p35 promoter region -122/-93 is crucial for the induction of 
p35 promoter (Kollet and Petro, 2006; Liu et al., 2003; Saccani et al., 2003). Besides, 
NF-B, 3 members of the IRF family, IRF1, IRF3 and IRF8, are also involved in the 
regulation of the p35 promoter. These transcription factors exhibit enhanced nuclear 
localization on a variety of stimuli and furthermore, IRF1, IRF3 and IRF8 deficient 
mice all exhibit a defect in the induction of IL-12p35 transcription (Goriely et al., 
2006; Liu et al., 2004; Salkowski et al., 1999). 
 
1.4.3 Regulation of IL-23p19 promoter 
 
With the identification of IL-23p19, it is of interest to determine the transcriptional 
regulation of IL-23p19 and identify pathways that differentially govern the expression 
of IL-12p35 and IL-23p19 since both cytokine chains compete for the same IL-12p40 
subunit. Initial studies identified the role of NF- transcription factors, c-Rel and 
Rel-A, for the induction of IL-23p19 promoter (Carmody et al., 2007; Mise-Omata et 
al., 2007). Although both IL-12p35 and IL-23p19 are governed by NF-B 
transcription factors, the NF-B response appears to be differentially regulated by 
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protein phosphatase 2A (Chang et al., 2010). The production of IL-23 but not IL-12 
was negatively regulated by protein phosphatase 2A through the suppression of IKK-
. This results in enhanced accumulation of inhibitor of  (I) and the 
suppression on NF- responses. Besides NF-B, IL-23p19 promoter is regulated by 
IRFs and an interferon stimulated response element (ISRE) has been identified 
(Sheikh et al., 2010). However, only IRF1, but not IRF2 and IRF8, was shown to be 
able to interact with the ISRE. Experiments with IRF1 deficient mice demonstrated an 
enhanced production of IL-23 hence suggesting a regulatory role of IRF1 on IL-23p19 
transcription instead. Furthermore, under conditions of ER stress and TLR stimulation, 
IL-23p19, but not IL-12p40 and IL-12p35, transcription was enhanced by the 
induction of transcription factor C/EBP homology protein (CHOP) (Goodall et al., 
2010).  Hence, although IL-12p40, IL-12p35 and IL-23p19 share similar transcription 





1.5 Post-transcriptional control of cytokine production 
 
Post-transcriptional regulation of cytokine levels serves as a critical mechanism to 
dampen the expression of cytokines and inflammatory mediators so as to avoid the 
pathological effects of excessive inflammation. Although the level of cytokine 
production is ultimately determined by both transcriptional and post-transcriptional 
events, post-transcriptional regulation enables the fine-tuning of inflammatory 
responses that cannot be achieved at the level of transcription. Transcription provides 
the ‘on’ mechanism but the levels of cytokine production would also depend on the 
half-life of mRNA after the cessation of transcription. If the mRNA has a long half-
life, transcriptional arrest would not immediately stop the production of cytokines. On 
the contrary, negative feedback mechanisms that inhibit translation or enhance mRNA 
decay enables a rapid decline in cytokine production (Anderson, 2008; Stoecklin and 
Anderson, 2006).  
 
1.5.1 Post-transcriptional control of cytokines via the AU-rich elements  
 
Clusters of adenine and uridine-rich elements (AREs) are found in the 3’ untranslated 
regions (UTRs) of many short lived cytokine mRNA. AREs were discovered by their 
characteristic nucleotide pattern and a high degree of sequence conservation across 
mammalian species (Caput et al., 1986). Their role in mRNA metabolism was first 
demonstrated when the insertion of GM-CSF ARE region into the 3’ UTR of a stable 
house-keeping gene, -goblin, resulted in its rapid decay (Shaw and Kamen, 1986). 
Conversely, the deletion of the ARE from the 3’UTR of IL-3 and TNF- enhances 
mRNA expression by stabilizing the mRNA (Kontoyiannis et al., 1999; Stoecklin et 
al., 1994). Besides its role in ARE-mediated mRNA decay (AMD), ARE is also 
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involved in the translational regulation of mRNA production (Anderson, 2008; 
Stoecklin and Anderson, 2006). 
 
AREs are typically AU-rich sequences that contain copies of AUUUA pentamer 
and/or nonamer and are classified according to their deadenylation kinetics (Chen and 
Shyu, 1995; Chen et al., 1995). The most typical Class II AREs of cytokine mRNA 
(E.g., GM-CSF, IL-3 and TNF-) contain a cluster of 4-7 partially overlapping 
AUUUA pentamers and they trigger a very rapid, asynchronous shortening of poly-A 
tail prior to decay of mRNA body (Chen and Shyu, 1995). Whereas Class I AREs (eg, 
c-myc, c-fos) have fewer and more scattered AUUUA pentamers while Class III 
AREs (E.g., c-jun) lack the AUUUA motif. Both Class I and Class III AREs are 
associated with a less rapid, synchronous shortening of the poly-A tail (Chen and 
Shyu, 1995). The minimal sequence that can induce mRNA degradation is an 
UUAUUUAUU nonamer (Lagnado et al., 1994; Zubiaga et al., 1995) which is also 
the minimal binding site of the ARE-binding protein, tristetraprolin (TTP) (Blackshear 
et al., 2003; Worthington et al., 2002). However, a typical ARE sequence spans across 
50-100 nucleotides and is unique between different mRNA genes, thus empowering 
the immune cells with the ability to fine-tune the immune response through a 
coordinated regulation of translation and mRNA stability (Anderson, 2008; Stoecklin 
and Anderson, 2006). 
 
1.5.2 ARE-binding proteins 
 
ARE recruits ARE-binding proteins (ARE-BP) that can positively or negatively 
regulate mRNA translation and mRNA stability. Binding of these proteins to ARE 
regions can occur via several protein domains; the RNA recognition motif (found in 
54 
 
TIA-1, TIAR, HuR, AUF1 and AUF2), the zinc finger domain (found in TTP, BRF1 
and BRF2) and the K-homology domain (found in FXR1P and KSRP) (Anderson, 
2008). However, these binding proteins can results in diverse outcomes ranging from; 
translational inhibition by TIA-1, TIAR (Piecyk et al., 2000), FXR1P (Garnon et al., 
2005) and CUGBP2 (Mukhopadhyay et al., 2003); mRNA decay by TTP (Carballo et 
al., 1998), BRF1, BRF2 (Stoecklin et al., 2002) and KSRP (Chou et al., 2006; Gherzi 
et al., 2004); inhibition of decay by HuR (Fan and Steitz, 1998; Peng et al., 1998); 
while AUF1 can either promotes or inhibits decay (Laroia et al., 1999; Lu et al., 
2006a; Lu et al., 2006b; Sarkar et al., 2003). However, the AREs are often subjected 
to regulation by multiple ARE-BPs and the resultant outcome would then be 
determined by whether it is a cooperative or competitive binding to the ARE. For 
example, in myeloid cells from transgenic mice engineered for inducible expression of 
HuR, HuR and TIA-1 cooperatively inhibited translation of TNF- and IL-1 as HuR 
induced translational silencing effect is abrogated in mice lacking TIA-1 (Katsanou et 
al., 2005). On the contrary, TIA-1 and TTP compete for binding to the ARE. When 
TTP is transiently expressed into COS-7 cells, TTP displaces TIA-1 from the TNF- 
ARE (Anderson. 2008). This result suggests that the induction of TTP in activated 
immune cells may similarly displace endogenous TIA-1 from the TNF- ARE. 
Hence, TTP not only functions as an inducer of mRNA decay but is also critical in 
relieving mRNA from translational silencing. 
 
1.5.3 The central role of ARE-binding proteins in ARE-mRNA degradation 
 
Degradation of mRNA in the cytoplasm is first initiated by the removal of the Poly-A 
tail and subsequently, mRNA decay can occur in the 3’→5’ or the 5’→3’ direction. 
3’→5’ exonucleases act directly on the 3’ end while the 5’ end requires the removal of 
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7-methyl guanosine cap by the complex Dcp1/Dcp2 in a process known as 
‘decapping’.  mRNA is then degraded by a 5’→3’ exonuclease, Xrn1 (Cougot et al., 
2004; Fillman and Lykke-Andersen, 2005; Parker and Song, 2004). The 5’ mRNA 
degradation machinery, i.e. Dcp1/Dcp2 and Xrn1 which form a larger complex with 
Lsm1-7 proteins, are concentrated in small cytoplasmic foci termed processing bodies 
(Cougot et al., 2004; van Dijk et al., 2002). Processing bodies are believed to be the 
sites mediating 5’→3’ RNA degradation in the cytoplasm. On the other hand, 3’→5’ 
mRNA degradation is mediated by the exosome ,which is a multimeric protein 
complex mediating 3’→5’ exonuclease activity.  
 
AREs have been implicated in promoting mRNA degradation through deadenylation, 
5’ decapping and facilitates the subsequent degradation of mRNA body (Gao et al., 
2001; Shyu et al., 1991; Xu et al., 1997). In vitro studies on mRNA decay have 
demonstrated the involvement of ARE in exosome mediated degradation. However, 
mammalian exosome does not recognize ARE-containing RNAs on its own. Instead, 
recognition of ARE requires ARE-binding proteins that can interact with ARE and 
recruit it to the exosomes (Chen et al., 2001). Various binding proteins such as KSRP, 
AUF1 and TTP, have been suggested to interact with exosomal components to 
mediate mRNA decay. A direct role of TTP in deadenylation of mRNA via the 
recruitment of CAF1 deadenylase has recently been identified (Marchese et al., 2010). 
On the other hand, ARE also facilitates the decapping of RNA in vitro (Gao et al., 
2001). TTP/BRF1 have been shown to interact with the decapping/Xrn1 complex. 
Thus this suggests that ARE-binding proteins, such as TTP/BRF1, are central to the 
initiation of mRNA degradation by targeting mRNA to both decay pathways.   
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Interestingly, TTP also interacts with two proteins of the RNA-induced silencing 
complex (RISC), Argonaute 2 and 4, which enables microRNA miR16 to base-pair 
with ARE. Argonaute proteins also colocalize at the processing bodies and mRNA 
targeting by miRNA become concentrated in these structures (Liu et al., 2005). Hence, 
this novel findings suggest a dual function of ARE; to recruit ARE binding proteins as 










  Figure 1.2 Mechanism of Tristetraprolin mediated ARE-mRNA decay. 
The zinc finger protein, TTP/BRF1 binds with high affinity to the ARE, inducing degradation 
of mRNA by interacting with deadenylases, exosome, processing bodies and RISC. 
1) mRNA degradation is initiated by deadenylation by deadenylases (i.e. CAF1 deadenylase) 
2) 3’→5’ mRNA degradation is mediated by exosome which is a complex of exonucleases & 
helicases 
3) At the 5’ end, mRNA is decapped by Dcp1/2 and this is followed by Xrn1-mediated 5’→3’ 
degradation. Dcp1/2 and Xrn1 are components of a larger complex consisting of Lsm1-7 and are 
concentrated in the processing bodies. 
4) RNA-induced silencing complex (RISC) & miRNA 16 are required for ARE-mRNA 
degradation.                    


















1) Deadenylation  





1.5.4 Tristetraprolin and its regulation through covalent modifications 
 
Tristetraprolin (TTP) (also known as Nup475, TIS11 or Zfp36) is a prototypical 
member of zinc finger proteins containing two highly conserved CCCH (Cys-Cys-
Cys-His) zinc fingers and three tetraprolin (PPPP) motifs (DuBois et al., 1990; 
Gomperts et al., 1990; Lai et al., 1990; Varnum et al., 1991). TTP deficiency leads to 
an inflammatory condition characterized by medullary and extramedullary myeloid 
hyperplasia associated with cachexia, erosive arthritis, dermatitis, conjunctivitis, 
glomerular mesangial thickening and high titers of auto antibodies (Taylor et al., 
1996). This phenomenon was resulted from excessive production of tumor necrosis 
factor  (TNF-) as treatment of young TTP-deficient mice with antibodies to TNF-
prevented the development of all aspects of the phenotype. Bone marrow chimeras 
generated with transfer of TTP
-/-
 bone marrow into WT mice also resulted in a 
phenotype similar to TTP-deficient mice. Hence, this suggests the involvement of 
hematopoietic progenitors in the development of this syndrome. Indeed, supernatants 
from TTP-deficient macrophages from peritoneal cavity of TTP-deficient mice 
demonstrated elevated levels of TNF-(Carballo et al., 1997.  
 
TTP is involved in the regulation of mRNA decay though the binding to 3’ UTR of 
mRNA via both zinc fingers as the mutation of a single cysteine residue in either zinc 
fingers to arginine severely attenuated the binding of TTP to TNF- ARE (Lai et al., 
1999). However, the zinc fingers alone were insufficient to mediate degradation as 
truncation of either the carboxyl or amino ends of TTP caused a loss in TTP function 
(Rigby et al., 2005). Both ends of TTP zinc finger contain a cluster of phosphorylation 
sites and a number of studies have implicated the involvement of p38 MAPK/MK-2 
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pathway in the regulation of TTP activity (Carballo et al., 2001; Zhu et al., 2001b). 
Serine 52 and serine 178 on TTP have been identified as the sites of phosphorylation 
by MK2 and phosphorylation of serine 178, in particular, enables the recruitment of 
adaptor protein, 14-3-3 (Chrestensen et al., 2004; Johnson et al., 2002; Stoecklin et al., 
2004). Binding of 14-3-3 to TTP prevents the association of TTP with stress granules 
and this inhibits TTP mediated mRNA decay (Stoecklin et al., 2004). Furthermore, 
TTP/14-3-3 complex formation protects TTP from dephosphorylation by protein 
phosphatase 2A and hence, TTP remains in a hyperphosphorylated inactive state (Sun 
et al., 2007).  
 
A direct role of MK-2 on TTP function has been demonstrated as bone-marrow 
derived macrophages from TTP and MK-2 double knockout mice demonstrate 
comparable levels of TNF- production as compared to TTP knockout mice. This 
suggests that the regulation of TNF- by TTP is genetically downstream of MK2. 
Furthermore, MK-2 is essential for the stabilization of TTP mRNA and 
phosphorylation by MK-2 further leads to an increased in TTP protein stability despite 
a decrease in ability of TTP to bind to ARE (Hitti et al., 2006). Hence, while MK-2 
enables the stabilization of TNF- mRNA through inhibition of TTP-binding to TNF-
-ARE, MK-2 also allows the accumulation of TTP which will subsequently 
negatively regulate TNF- mRNA levels once TTP are dephosphorylated. In another 
study, MK-2 has also been demonstrated to be crucial in the inhibition of CAF1 





1.6 Aims of this thesis 
 
Despite the importance of IL-12 and IL-23 in protective immunity, excessive 
production of IL-12 and IL-23 can be a nuisance as it leads to immunopathology. 
Hence, it is crucial to elucidate the factors that regulate the production of IL-12 and 
IL-23. To achieve this, the effect of various microbial stimuli on IL-12 and IL-23 
production will first investigated and the time course of IL-12 and IL-23 production 
will be studied in GM-CSF-derived BMDCs. 
 
Initial results revealed a rapid kinetic of IL-23p19 mRNA degradation and it seems 
that IL-23p19 is regulated at the level of mRNA degradation. One possible candidate 
is Tristetraprolin (TTP) which has been shown to negatively regulate TNF- 
production by inducing mRNA degradation (Taylor et al., 1996; Lai et al., 1999). The 
importance of regulating cytokine levels through mRNA degradation is evident in 
TTP
-/-
 mice which developed an inflammatory condition characterized by myeloid 
hyperplasia associated with cachexia, erosive arthritis, dermatitis, conjunctivitis, 
glomerular mesangial thickening and high titres of auto antibodies (Taylor et al., 
1996).  
 
Hence, this study sought to investigate the role of TTP in the regulation of IL-12p40, 
IL-12p35 and IL-23p19 mRNA degradation in bone marrow derived dendritic cells 
(BMDCs). Furthermore, as IL-12 and IL-23 production by dendritic cells are crucial 
for the development of TH1 and TH17 cells respectively, the role of TTP in regulating 
the TH1/TH17 polarizing potential of BMDCs will be investigated.      
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1.7 Specific aims 
 
1. To investigate the effects of various microbial stimuli on IL-12 and IL-23 
production and the time course of IL-12 and IL-23 production upon microbial 
stimulation. 
2. To investigate the role of Tristetraprolin (TTP) on mRNA stability of IL-23p19. 
3. To investigate the role of IL-23p19 3’UTR regions in TTP-mediated IL-23p19 
mRNA degradation. 
4. To investigate the role of TTP on mRNA stability of IL-12p40 and IL-12p35.  





1. IL-12 and IL-23 production require different microbial and T cell stimulation. 
2. The rapid kinetics of IL-23p19 mRNA degradation occur through a 
Tristetraprolin-dependent mechanism via the ARE-rich region 
3. Tristetraprolin mediates the degradation of other cytokine genes 






Chapter 2: Material and Methods 
 
 
2.1 Preparation of buffers and culture media 
 
2.1.1 Phosphate-buffered saline (PBS) 
 
PBS was obtained from 1
st
 base (Singapore) as a 10x stock (137 mM NaCl, 2.7 mM 
KCl and 10 mM phosphate buffer). The 10x was diluted with water to obtain the 1x 
working solution 
 
2.1.2 MACS/FACS buffer 
 
1. MACS/FACS buffer consisted of 1 x PBS with 2 % FCS with 5 mM EDTA, pH 
7.2-7.4 at 4
o
C and made under sterile conditions. 
2. Sterile filtered 10x PBS was added to 9 parts of sterile deionised water. 
3. Sterile filtered 0.5 M EDTA was added to 1 x PBS solution to final 
concentration of 5 mM EDTA. 
4. The pH of this solution was adjusted to 7.2- 7.4 with HCl.  
5. The solution was autoclaved with the cap loosely but firmly screwed to the 
bottle to minimize evaporation at this stage. 
6. The solution was allowed to cool to r.t. before adding FCS to a final 
concentration of 2 % v/v. 
7. Buffer was chilled to 4oC, distributed into 50ml aliquots and used for either cell 
separation with MACS, FACS or preparation of cells for flow cytometry. 
62 
 
2.1.3 Complete medium for cell culture 
 
All cells in this study were cultured in complete medium. This was prepared from 
RPMI-1640 with L-Glutamine (Gibco) with the addition of the following: 
a) 10 % v/v FCS, heat inactivated for 30 mins at 55
o
C 
b) 1 % v/v Non-essential amino acid (100 x from stock) 
c) 1 mM Sodium pyruvate (100 x from 100 mM stock) 
d) 5μM β-Mercaptoethanol (2 860 000 x from 14.3 M stock) 
e) 100 IU/ml Penicillin and 0.1mg/ml Streptomycin (100 x from 10 000 IU/ml 
Penicillin and 10mg/ml Streptomycin stock) 
 
2.1.4 Optiprep density centrifugation media for splenic DC isolation 
 
1. Optiprep was provided as a 60 % w/v solution with a density of 1.32 g/ml. This 
was diluted using Optiprep diluent to 10.88 % w/v (5.5 x dilution with Optiprep 
diluent) with a density of 1.062 g/ml, determined empirically to be optimal for 
splenic DC yield. The required density was calculated using the % w/v to density 
(g/ml) linear relationship represented by the formula:     
 
y = 0.0052 x + 1.0054; where y = density, x = % w/v. 
 
2. Optiprep diluent consisted of 0.8% (w/v) NaCl , 5 mM EDTA, 10 mM Tricine 




2.1.5 Digestion buffer for splenic dendritic cells isolation 
 
Liberase TL (Roche) was dissolved in RPMI with 1% FCS to a final concentration of 
0.1mg/mL.  
 
2.1.6 Buffers for ELISA 
 
Blocking buffer was prepared to a final concentration of 1x PBS and 1% BSA, pH7.2 
- 7.4 and washing buffer was prepared to a final concentration of 1xPBS with 0.05% 
Tween, pH7.2 - 7.4. 
 
2.1.7 Buffers for SDS-PAGE and Western Blot  
 
10 x Tris-glycine SDS buffer was from 1
st
 Base (Singapore) 
Transfer buffer was prepared to a final concentration of 25 mM Tris-HCl, pH8.0, 192 
mM glycine and 10% methanol. 
Washing buffer was prepared to a final concentration of 1 x PBS with 0.5% Tween. 
 
2.2 Cell isolation  
 
2.2.1 Generation of GM-CSF-derived bone marrow dendritic cell (BMDCs) 
 
1. Tibia and femur of mice were excised with surrounding tissue removed and 
exposing the bones 
2. The ends of tibia and femur were cut and bone marrow was flushed from each of 
the shafts using RPMI1 (RPMI with 1% FCS) 




4. Cells were pelleted by centrifugation at 300g for 7 mins 
5. Red blood cell lysis was carried out using red blood cell lysis buffer (150mM 
NH4Cl, 10mM KHCO3 and 0.1mM EDTA) for 1 min.  
6. Cells were centrifugated at 300g for 7 mins and washes were repeated with 
RPMI1 for another 2 times. 
7. Bone marrow cells were cultured at a concentration of 1 x 106 cells/ml in 
complete RPMI with 10% FCS with 20ng/mL of mouse recombinant GM-CSF 
from peprotech (New Jersey, USA) in a 12 well plate with 2ml per well. 
8. At Day 2 and Day 4, 75% of the media was removed and replenished with fresh 
media containing 20ng/mL of GM-CSF 
9. On day 6 (harvest), the plate was gently tapped to dislodge DC aggregates. Media 
was aspirated completely and the wells were washed once along the walls with 
warm RPMI1.  
10. Centrifugation was carried out at 300g for 7 mins 
11. Cell pellet was washed twice with RPMI1 by centrifugation at 300g for 7 mins 
12. After the final wash, cell pellet was resuspended with complete RPMI and ready 




2.2.2 Isolation of splenic dendritic cells 
 
1. Spleens were perfused and digested with liberase (1.5-2mL of liberase/ spleen); at 
37°C for 30 mins. 
2. A single cell suspension was obtained by pressing spleen through a 70m mesh 
using 1mL syringe head. Cells were pelleted by centrifugation at 350g for 5 mins.  
3. Cells were washed with 5mL of MACS buffer followed by centrifugation at 350g 
for 5 mins. 
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4. Cell pellet was then resuspended in Optiprep (2mL/spleen) and transferred into a 
15mL falcon tube. 2mL of FCS was layered onto the Optiprep layer. 
5. Centrifugation at 1700g for 10 mins was carried out with brakes and acceleration 
set off. 
6. Cells accumulating at the interface were harvested by transferring the cells to a 
new 15mL falcon tube. Centrifugation was carried out at 350g for 5 mins at 4°C. 
7. Supernatant was discarded and cells were washed with MACS buffer. Expected 
cell yield at this stage will be from 10-20 million cells accumulating at the 
interface per spleen. 
8. After washing, supernatant was discarded to obtain a dry cell pellet. To this cell 
pellet, CD11c microbeads (Miltenyi Biotec, GmbH), at a volume of 10µL per 10 
million cells, were added. 
9. Mixture was incubated at 4°C for 8-10 mins 
10. After incubation, cells were washed by adding 2mL of MACS buffer and 
centrifugated at 350g for 5 mins at 4°C. 
11. MACS column was prepared by inserting a LS column (Miltenyi Biotec, GmbH) 
into magnetic stand. Column was pre-wet with 1mL of MACS buffer.  
12. Supernatant was discarded and cell pellet was resuspended with 1mL of MACS 
buffer. Cell clumps were avoided by pipetting several times. 
13. Cells were loaded onto column and allowed to flow through. 3mL of MACS 
buffer was added to wash column when reservoir was dry. Washing of column 
was repeated at least thrice. 
14. Cells were harvested by removing column from magnetic stand. 2mL of MACS 
buffer or culture media (depending on experimental purpose) was added and cells 
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were forced out of the column using a plunger. Cells were washed by 
centrifugation at 350g for 5 mins at 4°C. 
15. Cells were resuspended with appropriate media. Expected cell yield from wild-
type mice spleen is 2-4 million. Cell purity is routinely >93%. 
 
2.2.3 Isolation of splenic CD4 or CD8 T cells 
 
1) A single cell suspension was obtained by passing the spleen through a 70m 
nylon mesh into a 50ml falcon tube using 1ml syringe head. MACs buffer was 
added intermittently. 
2)  Centrifugation was carried out at 350g for 5 mins at 4°C 
3) 5mL of ficoll was added into a 15mL falcon tube and pre-warmed to r.t. 
4) Supernatant from cell pellet was discarded and 2-3mL of fresh MACS buffer was 
added.  
5) 3mL of cell suspension was added onto ficoll carefully. For cell suspensions from 
more than 2 spleens, a separate tube of ficoll was used. 
6) Cells were centrifugated at 600g for 20 mins at r.t. Brakes and acceleration were 
set off (set to 0) 
7) Cells accumulating at the interface were harvested by transferring the cells to a 
new 15mL falcon tube. MACS buffer was added to the harvested cells for 
washing. Centrifugation at 350g for 5 mins at 4°C was carried out. 
8) Supernatant was discarded and cells were washed once more with MACS buffer. 
Expected cell yield at this stage will be from 60-80 million cells accumulating at 
the interface per spleen. 
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9) After washing, supernatant was discarded and a dry cell pellet was obtained. To 
this cell pellet, CD4 or CD8 microbeads (Miltenyi Biotec, GmbH) were added at 
a volume of 4µL per 10 million cells. 
10) Cell pellet was disrupted by pipetting several times. 
11) Mixture was incubated at 4°C for 25-30 mins. Cell suspension was agitated every 
5-10 mins during incubation. 
12) After incubation, cells were washed by adding 2mL of MACS buffer. 
Centrifugation was carried out at 350g for 5mins at 4°C. 
13) MACS column was prepared by inserting a LS column into magnetic stand 
(Miltenyi Biotec, GmbH) and pre-wet with 0.5mL of MACS buffer.  
14) Supernatant was discarded and cells were resuspended with 0.5mL of MACS 
buffer. Cell clumps were avoided by pipetting several times. 
15) Cells were loaded onto the column and allowed to flow through. 0.5mL of MACS 
buffer was added to wash column when reservoir was dry. Washing should be 
done at least thrice. 
16) Cells were harvested by removing column from magnetic stand, addition of 2-
3mL of MACS buffer or complete RPMI and cells were forced out of the column 
using a plunger. Centrifugation was carried out at 350g for 5mins at 4°C. 
17) Cells were resuspended with appropriate media, and an aliquot was obtained for 
cell counting. Expected cell yield from is 6-8million. Cell purity should be >90%. 
 
2.2.4 Stimulation of dendritic cells with microbial components and cytokines 
 
Dendritic cells were stimulated with various microbial components such as LPS, poly-
IC, flagellin, gardiquimod, PAM3CSK, CpG and zymosan. LPS, flagellin, 
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gardiquimod and PAM3CSK were purchased with InvivoGen (California, USA). 
Poly-IC and zymosan were purchased from Sigma Aldrich (St Louis, MO) and CpG 
were synthesized by AITbiotech (Singapore). IFN- was purchased from peprotech 
(New Jersey, USA). MegaCD40L was purchased from Axxora (California, USA). 
Purified agonistic anti-mouse CD40 antibody (Clone 3/23) was purchased from BD 
Pharmingen. 
 
2.2.5 Coculture of dendritic cells and T cells  
 
For study of cytokine production, BMDCs were cocultured with CD4 or CD8 T cells 
at a concentration of 0.33 x 10
6
/mL for BMDCs and 1 x 10
6
/mL for T cells in 96 well 
round bottom plates and incubated at 37°C and 5% CO2 overnight (Ratio of BMDC: T 
cells at 1:3). Supernatants were harvested for ELISA for IL-12 and IL-23 production. 
For polarization of naïve CD4 T cells, BMDCs were cocultured with naïve CD4 T 
cells at a concentration of 0.1 x 10
6
/mL for BMDCs and 1 x 10
6
/mL for naïve CD4 T 
cells in a 96 well round bottom plate pre-coated with anti-CD3 (2g/mL in PBS for 90 
mins). Cells were incubated at 37°C and 5% CO2 for 4 days (Ratio of BMDC: T cells 
at 1:10).  
 
2.3 Fluorescent activated cells sorting (FACS) analysis 
 
2.3.1 Surface staining of cells  
 
1. Cells were transferred into FACS tubes; > 0.2x106 cells per tube and cells were 
pelleted by centrifugation at 350g, 4°C for 5 mins. 
2. Supernatants were discarded by inversion of the FACS tubes.  
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3. Cells were washed by adding 2ml of FACS buffer into tube and centrifugation 
was carried out at 350g, 4°C for 5mins. 
4. Supernatants were discarded by inversion of the tubes and tubes were blotted dry. 
Washing was repeated once more. 
5. To cell pellet, 1 L of Fc Block per 1 million cells (0.5ug per 106 cells) was 
added and cells were incubated for 5 mins at 4°C. 
6. Desired antibody combination and appropriate isotype controls were added 
directly to cell pellet. FACS tubes were gently raked to mix the antibodies. 
7. FACS tubes were incubated in the dark at 4°C for 20-30 mins. 
8. After incubation, cells were washed by adding 2mL of FACS buffer. 
9. Cells were pelleted by centrifugation at 350g, 4°C for 5 mins. 
10. Supernatants were discarded by inversion of the tubes and the tubes were blotted 
dry before re-inverting. Cell pellets were disrupted by gentle raking on tube racks. 
11. Washing was repeated once more. 
12. After final wash, cells were resuspended in 0.5mL of FACS buffer. 
13. Cells were filtered through 70m gauze into new FACS tubes. 
14. Cells were analysed immediately. If analysis was done after more than 8 hours, 
cells were resuspended in 1% PFA in PBS. 
15. 7AAD was used routinely for viability assay. 1ul of 1g/mL of 7AAD was added 
to 1ml of cell suspension prior to flow cytometry analysis. Dead cells will be 
positively stained by 7AAD and subsequently gated out. 
 
2.3.2 Intracellular cytokine staining of cells  
 
1. Cells for intracellular staining were first restimulated with 10ng/ml PMA and 
400ng/ml ionomycin. Protein secretion was blocked with BD GolgiStop (BD 
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PharMingen) and BD GolgiPlug (BD PharMingen). Both GolgiPlug and 
GolgiStop were used at 1μl per 1ml of culture. 
2. After 5 hours, cells were harvested, transferred into FACS tubes and washed by 
adding PBS and centrifugation at 350g, 5 mins at 4
o
C. Washing was repeated 
once. 
3. Supernatant was discarded and cells were suspended in 500uL of PBS with 0.5uL 
of LIVE/DEAD fixable violet dead cell stain (Invitrogen). Cells were incubated 
for 20 mins at 4C. 
4. Cells were washed by adding FACS buffer and centrifugation at 350g, 5 mins at 
4
o
C. Washing was repeated once. 
5. To cell pellet, 1uL of Fc Block per 106 cells (0.5ug per 106 cells) was added and 
cells were incubated for 5 mins at 4°C. 
6. Desired antibody combination and appropriate isotype controls were added 
directly to cell pellet. FACS tubes were gently raked to mix the antibodies. 
7. FACS tubes were incubated in the dark at 4°C for 20 to 30 mins. 
8. After incubation, cells were washed by adding 2mL FACS buffer. 
9. Cells were pelleted by centrifugation at 350g, 4°C for 5 mins. 
10. Supernatants were discarded by inversion of the tubes and the tubes were blotted 
dry before re-inverting. Cell pellets were disrupted by gentle raking on tube racks. 
11. Washing was repeated once more. 
12. Cells were fixed and permabilized by the addition of 1ml of fixed/ 
permeabilization buffer (BD Pharmingen) for 1 hour or overnight at 4°C .  
13. Cells were then centrifuged at 350g for 5 mins.  
14. Supernatants were discarded and cells were washed twice with 1ml of 
permeabilization/ wash buffer (BD Pharmingen). 
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15. Appropriate antibodies specific for intracellular targets or isotype controls were 
added to the tubes. The tubes were incubated for 30 min at 4°C. 
16. After incubation, cells were washed twice with 1ml of perm/wash buffer. 
17.  Cells were subsequently resuspended in FACS buffer for immediate analysis.  
 
2.3.3 Preparation of cells for sorting 
 
1. Cells for sorting were prepared and placed into sterile FACS tubes. 
2. 0.5μg per 106 cells of Fc Block (1μl of 0.5mg/ml stock per 106 cells) were added 
and incubated for 5 mins at 4
o
C. Antibodies directly conjugated to fluorophores 
were added directly to cell pellet and mixed by raking gently on tube racks.  
3. Cells were incubated in the dark at 4oC for 30 min. 
4. After incubation, cells were washed by adding 3ml MACS buffer and 
centrifugation at 350g, 4
o
C for 5 min. Supernatants were discarded and wash was 
repeated once more. 
5. Cells were raked and resuspended to 106 cells /ml, filtered through a 61μm gauze 
and sorted using a MOFLO cell sorter (Dako). 
 
2.3.4 List of antibodies used for FACS analysis and cell sorting 
 
Antibodies Company  Antibodies Company 
IA/IE PB BD Pharmingen  CD62L FITC Biolegend                    
(San Diego, CA) 
CD4 PB BD Pharmingen  CD25 PE Biolegend   
(San Diego, CA) 
CD8 FITC  BD Pharmingen  IL17A PE Biolegend   
(San Diego, CA) 
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B220 FITC BD Pharmingen  CD11c AF647 Biolegend   
(San Diego, CA) 
Siglec H BD Pharmingen    
IFN- AF647 BD Pharmingen    
CD44 APC BD Pharmingen    
 
2.4 ELISA for detection of cytokines 
 
IL-12p40, IL-12p70, IL-23, IFN-γ, TNF-α, IL-6, IL-10, IL-17 levels were detected 
using sandwich ELISA with DuoSet ELISA development kit from R&D systems 
(Minneapolis, MN) according to the manufacturer’s protocol. OptEIATM TMB reagent 
substrate set from BD (San Diego, CA) 
 
1. The appropriate capture antibody was diluted in 1 x PBS to the concentration 
recommended by the manufacturer (typically 180 fold dilutions) 
2. The diluted capture antibodies were dispensed into 96 well Maxisorp plates at 
50μl per well and incubated overnight at r.t. 
3. Capture antibody coated wells were then washed thrice with wash buffer 
4. Coated wells were blocked with 100μl blocking buffer for 1 h at r.t. 
5. Wells were washed thrice with wash buffer 
6. Pre-diluted standards and supernatants diluted with blocking buffer to 50μl were 
added to the appropriate wells and incubated for 2 h at r.t. 
7. Wells were washed thrice with wash buffer 
8. The appropriate detection antibody was diluted in blocking buffer to the 
recommended concentration (typically 180 x). 
18. Diluted detection antibodies were dispensed into wells at 50μl per well and 
incubated for 2 h at r.t. 
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19. Wells were washed thrice with wash buffer 
20. HRP was diluted 200 x with blocking buffer and dispensed into wells at 50μl per 
well and incubated for 1 h at r.t 
21. Wells were washed 3 x with wash buffer 
22.  50L of TMB substrate were added to the wells for 20-30 mins. 
23. 25L of 1M of H2SO4 were added to the wells to stop the reaction. 
24. Color intensity at 450 nm was determined using a microplate reader (Biorad, 
model 680). Levels of cytokines present were determined by reference to 
standard curves. 
 




10 x Tris-glycine SDS buffer was from 1
st
 Base (Singapore). 10% SDS-PAGE gels 
were routinely used and gels were prepared with 30% acrylamide/ 
0.8%Bisacrylamide, 1.5M Upper Tris (pH8.8), 0.5M Lower Tris (pH6.8), distilled 
water, 10% APS, TEMED. Tris base, anti-TTP and anti-GAPDH-HRP antibodies 
were obtained from Sigma-Aldrich (St Louis, MO) and anti-V5 antibodies were from 
eBioscience (California, USA). HRP conjugated anti-rabbit antibody was obtained 
from Invitrogen (California, USA). 30% acrylamide/0.8%Bisacrylamide, TEMED and 
APS were purchased from Bio-Rad (California, USA). Amersham Hyperfilm ECL 
from GE healthcare (Wisconsin, USA), Immobilon-P transfer membrane, PVDF from 
Merck Millipore (Massachusetts, USA) SuperSignal West Pico Chemiluminescent 




2.5.2 SDS-PAGE and Western Blot  
 
1. SDS-PAGE and Western Blot was performed on 10% SDS-PAGE according to 
previously described (Towbin et al., 1979).  
2. Proteins on SDS-PAGE gels were transferred onto PVDF membrane and probed 
with either anti-TTP, anti-V5 or anti-GAPDH-HRP antibodies for 2 hours at r.t.  
3. Membranes were washed three times with 1 x PBS + 0.5% Tween-20 for 15 mins. 
4. Blots incubated with anti-TTP and anti-V5 antibodies were subsequent incubated 
with secondary antibodies (anti-rabbit-HRP) for 1-2 hours at r.t.  
5. Membranes were washed three times with 1 x PBS + 0.5% Tween-20 for 15 mins. 
6. SuperSignal West Pico ECL reagent was added for 5 min.  
7. Membrane was subsequently exposed to x-ray film and developed using x-ray 
developer.    
 
2.6 Qualitative and quantitative analysis of nucleic acid 
 
2.6.1 Quantification of mRNA and DNA levels  
 
mRNA and DNA content in sample were quantified using NanoDrop ND-1000 
spectrometer (Thermoscientific, DE, USA). Concentration of mRNA and DNA were 
determined by measuring absorbance at 260nm. The ratio of absorbance at 260nm and 
280nm (A260/280) is used to assess the purity of nucleic acid. Pure mRNA will have an 
A260/280 ratio of ~2.0. Pure DNA will have an A260/280 ratio of ~1.8. 
 
2.6.2 Extraction of mRNA from cells 
 
1. mRNAs were harvested from cells using Qiagen’s Qiashredder and RNeasy Mini 
kit (Hilden, Germany) according to manufacturer’s protocol. 
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2. Cells (< 5 x 106) were lysed with 350L of Buffer RLT and loaded onto 
Qiashredder spin column for the removal of cell debris. Centrifugation was 
carried out for 1 min at full speed on a table centrifuge. Flow-through was 
collected in the collection tube. 
3. Equal volume of 70% isopropanol in DEPC-treated water (350L) was added to 
the flow-through and mixed by pipetting. Mixture was then loaded onto RNeasy 
spin column.  
4. Centrifugation was carried out for 1 min at full speed on a table centrifuge. 
5. Flow-through was discarded and RNeasy spin column was washed with 700L of 
Buffer RW1. 
6. Centrifugation was carried out for 1 min at full speed on a table centrifuge. 
7. Flow-through was discarded and RNeasy spin column was washed with 500L of 
Buffer RPE. 
8. Centrifugation was carried out for 1 min at full speed on a table centrifuge. 
9. Flow-through was discarded and RNeasy spin column was centrifuged for 1 min 
at full speed on a table centrifuge to eliminate residual amount of Buffer RPE. 
10. 50L of RNase-free water was added to the spin column membrane. 
Centrifugation was carried out at full speed on a table centrifuge. mRNA samples 
were kept at -80°C until usage. 
 
2.6.3 Reverse Transcription  
 
1. Reverse transcription was carried out using Qiagen’s Quantitect reverse 
transcription kit (Hilden, Germany) according to manufacturer’s protocol.  
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2.  Template RNA was thawed on ice and 0.5g of template RNA was added to a 
PCR tube. Template RNA was diluted in DEPC-treated water to a final volume of 
12L. 
3. 2ul of gDNA wipeout buffer was added to template RNA and the mixture was 
incubated at 42°C for 2 mins.  
4. Mixture was immediately transferred onto ice. 
5. To each tube of template RNA, 4L of RT buffer, 1L of RT primer mix and 
1L of reverse transcriptase were added and a total reaction mixture of 20L was 
obtained. If there are more than 2 tubes of template RNA, a master mix of RT 
buffer, RT primer mix and reverse transcriptase was prepared. 
6.  Mixture was incubated at 42°C for 15 min and finally at 95°C for 3 min to 
inhibit the reverse transcriptase. 
 
2.6.4 Real-time PCR 
 
1. The reaction for real-time PCR was prepared to a total volume of 25L in the 
following composition: 
12.5L of GoTaq® qPCR Master Mix (2x) (Promega, Wisconsin, USA) 
8.5L of water 
1L of cDNA template diluted in water to 100ng/L 
1.5L of 5M forward primer and 1.5L of 5M reverse primer 
 





1. 50°C for 2 min  
2. 95°C for 10 min  
3. 95°C for 15 sec 
4. 60°C for 60 sec 
5. Go back to Step 3 for another 39 cycles 
 
3. Primers used for real-time PCR: 
i. mGAPDH Forward primer: 5’ AGGCCGGTGCTGAGTATGTCG 3’  
mGAPDH Reverse primer: 5’ GCAGAAGGGGCGGAGATGAT 3’ 
ii. IL-12p35 Forward primer: 5’ ACGGGACCAAACCAGCACATT 3’ 
IL-12p35 Reverse primer: 5’ AAGGCACAGGGTCATCATCAAAGA 3’ 
iii. IL-12p40 Forward primer:  5’ TCCCCATTCCTACTTCTCCCTCAA 3’  
IL-12p40 Reverse primer: 5’ CCGCCTTTGCATTGGACTTC 3’ 
iv. IL-23p19 Forward primer: 5’ CACCAGCGGGACATATGAATCTAC 3’ 
IL-23p19 Reverse primer: 5’ CTGGCTGTTGTCCTTGAGTCCTT 3’ 
v. TNF-α Forward primer: 5’ CTGTAGCCCACGTCGTAGCAAACC 3’ 
TNF-α Reverse primer: 5’CGGCTGACGGTGTGGGTGAG 3’ 
vi. TTP Forward primer: 5’ AAGCCAATCGCCACCCCAAGTA 3’ 
TTP Reverse primer: 5’ GGAAGGCGAAAAGGAACAAGAGGA 3’ 
 
2.6.5 Isolation of genomic DNA from mouse tail  
 
1. Mice were anaesthetised and a small segment of tail is excised for genotyping.  
2. Tail lysis was carried out with 500L of Tail Lysis Buffer (100 mM NaCl, 50 
mM Tris-HCl (pH 7.9), 10 mM MgCl2, 1 mM DTT, 1% Triton X-100) with 
addition of 20L of proteinase K in a 1.5mL eppendorf tube. Lysis was carried 
out at 65°C for 3 hours 
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3.  Cell debris was pelleted by centrifugation for 10 min at 13000 rpm on 
microcentrifuge. 
4. Supernatants were transferred to a fresh tube and 1mL of cold absolute ethanol 
was added to precipitate the genomic DNA. Suspension was mixed. 
5. Centrifugation was carried out at maximum speed for 10 min. 
6. Supernatants were discarded and pellet was washed with 1mL of 70% ethanol. 
7.  Centrifugation was carried out at maximum speed for 10 min. 
8. Supernatants were discarded and tubes were left to air-dry. 
9. Pellet was dissolved in TE buffer (10 mM Tris-HCl, 1mM EDTA, pH 7.5) for 
subsequent analysis. 
 




1. The reaction for PCR was prepared to a final volume of 25L according to the 
following composition:   
a. 12.5L of GoTaq® Green Master Mix (Promega, Wisconsin, USA) 
b. 8.5L of water 
c. 1L of genomic DNA template isolated from mouse tail 
d. 1.5L of 5M forward primer and 1.5L of 5M reverse primer 
2. Primers used: Primer set A:  
a. MGTTP/5832-5856 (5’-CGAATCCCTCGGAGGACTTTGGAAC-3’) 
b. MGTTP/r6267-6247 (5’-CTGGCCAGGGAGAGCTAGGTC-3’) 
           Primer set B:  
a. MGTTP/5832-5856 (5’-CGAATCCCTCGGAGGACTTTGGAAC-3’)  




3. PCR was carried out according to the following setup: 
1. 94°C for 2 min  
2. 94°C for 30 sec  
3. Annealing at 62°C for 15 sec 
4. Extension at 72°C for 2 min 
5. Return to Step 2 for another 29 cycles 
6. Final extension at 72°C for 10 min 
7. Hold at 4°C 




Difco™ LB Broth and Bacto ™ agar are from BD (New Jersey, USA). QIAGEN 
QIAquick Gel Extraction Kit, QIAGEN HiSpeed Plasmid Maxi Kit, QIAprep Spin 
Miniprep Kit and Polyfect Transfection Reaction are from Qiagen (Hilden, Germany). 
TOPO® TA Cloning Kit and pcDNA 3.1/V5-His TOPO® TA Expression kit are from 
Invitrogen (California, USA). Tet-off Advanced and pTre-Tight vector are purchased 
from Clontech (California, USA). Ampicillin and G418 are from Sigma Aldrich (St. 
Louis, MO). EcoRI and EcoRI buffer are purchased from New England Biolabs 
(Massachusetts, USA). BamHI and Buffer E are from Promega (Wisconsin, USA). 
 
2.7.2 Preparation of LB broth and LB agar 
 
1. LB broth was prepared by dissolving 20g of Difco™ LB Broth in 1L of water. 
Solution was mixed well and autoclaved. 
2. LB agar was prepared by dissolving 20g of Difco™ LB Broth and 15g of 
Bacto ™ agar in 1L of water. Solution was mixed well and autoclaved. After 
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cooling to around 60°C, solution was poured onto plates and left to r.t. to 
solidify. 
3. Ampicillin was added to LB broth or LB agar to a final concentration of 
100g/mL. 
 
2.7.3 Purification of DNA from gel 
 
1. DNA fragment was excised from the gel using a clean, sharp scalpel. 
2. Gel slice was weighed in a clean colourless tube. 3 volumes of Buffer QG 
were added to 1 volume of gel and incubated at 50°C for 10 min or until the 
gel completely dissolved. Tube was vortexed every 2-3 min. 
3. 1 volume of isopropanol was added and mixed. 
4. Sample was loaded onto a Qiaquick column and centrifugation was carried out 
for 1 minute at maximum speed on a microcentrifuge. 
5. Flow-through was discarded and 750L of Buffer PE was added to the 
Qiaquick column for washing. Centrifugation was carried out for 1 minute at 
maximum speed. 
6. Flow-through was discarded and Qiaquick column was centrifugated once 
more to remove residual buffer. 
7. Qiaquick column was then removed from its collection tube and placed onto a 
1.5mL eppendorf tube.  
8. 50L of water was added to the membrane of Qiaquick column and 





2.7.4 Plasmid DNA purification using the QIAprep Spin Miniprep Kit (Qiagen) 
 
1. The bacteria cells were pelleted by centrifugation at 6000g for 15 min at 4°C. 
2. Bacterial pellet was resuspended in 250L of Buffer P1 and transferred to an 
eppendorf tube. 
3. 250L of Buffer P2 was added and it was mixed vigorously by inverting tube 
4-6 times. 
4. 350L of Buffer N3 was added and solution was immediately mixed 
thoroughly by inverting 4-6 times. Centrifugation was carried out at maximum 
speed in a microcentrifuge for 10 min. 
5. Supernatant containing plasmid DNA was loaded onto a QIAprep spin column 
by decanting or pipetting.  
6. Centrifugation was carried out for 30s. Flow-through was discarded. 
7. 750L of Buffer PE  was added to QIAprep spin column and centrifuged for 
30s. 
8. Flow through was discarded and centrifugation was carried out for an 
additional 1 min to remove residual wash buffer. 
9. QIAprep column was placed in a clean 1.5mL eppendorf tube and 50L of 
water was added to the center of each QIAprep spin column. The column was 
left to stand for 1 min before centrifugation for 1 min. 
 
2.7.5 Plasmid DNA purification using Qiagen HiSpeed Plasmid Maxi Kit 
 
1. Bacterial cells were harvested by centrifugation at 6000g for 15 min at 4°C. 
2. Bacterial cell pellet were resuspended in 10mL of Buffer P1. 
3. 10mL of Buffer P2 were subsequently added and mixed thoroughly by 
inverting the sealed tube 4-6 times. Tube was incubated at r.t. for 5 min. 
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4. 10mL of Buffer P3 was added and tube was mixed by inverting 4-6 times. 
5. Lysate was poured into the barrel of the QIAfilter Catridge and incubated at r.t. 
for 10 min. 
6. HiSpeed Maxi Tip was equilibrated by applying 10ml of Buffer QBT and the 
column was allowed to empty by gravity flow. 
7. The cap from the QIAfilter outlet nozzle was removed and the plunger was 
gently inserted. The cell lysate was filtered into the previously equilibrated 
HiSpeed Tip.The clear lysate was allowed to enter the resin by gravity flow. 
8. 60mL of Buffer QC was added to the HiSpeed Maxi Tip. 
9. DNA was eluted with the addition of 15mL of Buffer QF. 
10. DNA was then precipitated by addition of 10.5mL of isopropanol to the eluted 
DNA. Sample was mixed and incubated at r.t. for 5 min. 
11. During the incubation, the plunger from a 30mL syringe was removed and the 
QIAprecipitator Maxi Module was attached to the outlet nozzle.  
12. The eluate/isopropanol mixture was transferred into the 30mL syringe and the 
plunger was inserted. Eluate/isopropanol mixture was filtered through the 
QIAprecipitator using constant pressure. 
13. The QIAprecipitator was removed from the 30ml syringe and plunger was 
removed. 2mL of 70% ethanol was added to the syringe and the DNA was 
washed by inserting the plunger and pressing the ethanol through the 
QIAprecipitator using constant pressure. 
14. The QIAprecipitator was removed from the 30ml syringe and plunger was 
removed. QIAprecipitator was reattached to the 30mL syringe and plunger was 
inserted to dry the membrane by pressing air through the QIAprecipitator 
quickly and forcefully. This step was repeated a couple of times. 
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15. The nozzle of the QIAprecipitator was dried with an absorbent paper to 
prevent ethanol carryover. 
16. The plunger of a new 5mL syringe was removed and attached the 
QIAprecipitator onto the outlet nozzle of the 5mL syringe. The outlet of the 
QIAprecipitator was placed over a 1.5mL collection tube. 1mL of water was 
added to the 5mL syringe and the plunger was inserted to elute the DNA into 
the collection tube. 
17. QIAprecipitator was removed from the 5mL syringe, remove the plunger and 
the QIAprecipitator was reattached to the 5mL syringe. 
18. The eluate from step 16 was transferred to the 5mL syring to eluate for a 
second time into the same 1.5mL tube. 
 
2.7.6 Polyfect of HEK293 cell line 
 
1. HEK293 cells were seeded in a 24-well plate at a concentration of 0.25 x 
10
6
/mL in 0.5mL of complete DMEM. Cells were incubated at 37°C and 5% 
CO2 overnight. Wells were approximately 40% confluent on the day of 
transfection. 
2. DNA plasmid used for polyfect was dissolved in TE buffer (10 mM Tris-HCl, 
1mM EDTA, pH 7.5) and 0.5g of DNA plasmid was added to plain DMEM 
to a volume of 35L.  
3. 5L of Polyfect Transfection Reaction was added to the solution and solution 
was mixed by pipetting. Samples were incubated at r.t. for 5-10 min. 
4. 210L of complete DMEM was added and solution was mixed by pipetting 
and transferred to the wells plated with HEK293 cells. 
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2.7.7 Creation of a stable Tet-off Advanced HEK293 cell line  
 
1. HEK293 cells were seeded in a 6-well plate at a concentration of 0.25 x 
10
6
/mL in 2 mL of complete DMEM. Cells were incubated at 37°C and 5% 
CO2 overnight. Wells were approximately 40% confluent on the next day. 
2. HEK293 cells were transfected with 2g of Tet-off Advanced vector using 
Polyfect Transfection Reaction in a 6 well plate. 
3. HEK293 cell were selected for Tet-off Advanced vector by culturing the cells 
in complete DMEM supplemented with 600g/mL of G418. 
4. Cells were replenished with fresh media with G418 every 3 days. 
 
2.7.8 pcDNA 3.1/V5-His TOPO® TA Expression of V5-His-Tristetraprolin 
 
1. Cloning of Tristetraprolin with a V5/His-tag was carried using pcDNA 3.1/V5-
His TOPO® TA Expression kit according to manufacturer’s protocol. 
2. Gene product were first amplified using the following primers from cDNA of 
BMDCs stimulated with LPS for 2 hours: 
TTP Kozak forward: 5’ GCCACCATGGATCTCTCTGCC 3’ 
TTP Kozak reverse: 5’ CTCAGAGACAGAGATACGATTGAAGATGG 3’ 
3. PCR was carried out using Platinum PCR SuperMix HiFi (Invitrogen) 
according to manufacturer’s protocol. Briefly, a 25L PCR reaction was 
prepared with 20L of platinum PCR SuperMix, 200nM of forward and 
reverse primer and 1-200ng of cDNA. Cycling conditions were:  
1. 94°C for 2 mins 
2. 94°C for 30 sec 
3. 52°C for 30 sec 
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4. 68°C for 90 sec 
5. Return to step 2 for 34 cycles 
6. 68°C for 2 mins 
7. 4°C to hold 
4. PCR product were subjected to 1% agarose gel electrophoresis and DNA 
fragment of the appropriate size was excised and purified using QIAquick gel 
extraction kit (Qiagen) according to manufacturer’s protocol described above. 
5. 4uL of gel purified PCR product was added with 1uL of salt solution (1.2 M 
NaCl; 0.06 M MgCl2) to 1uL of pcDNA 3.1/V5-His TOPO® vector. Reaction 
was mixed gently and incubated at r.t. for 5 min.  
6. JM109 bacteria were thawed on ice and 30-50L of bacteria was added to 
pcDNA 3.1/V5-His TOPO® cloning reaction mixture. Reaction was mixed 
gently and incubated on ice for 30 min. 
7. The bacteria were then heat-shocked at 42°C for 30 sec and immediately 
placed on ice for 2 min. 
8. 250L of prewarmed S.O.C medium was added to the bacteria and incubated 
at 94°C for 30-60 min. 
9. Centrifugation was carried out to pellet the bacteria and 200L of S.O.C 
medium was removed. Pellet was resuspended in the remaining S.O.C medium 
and spread onto pre-warmed ampicillin-LB agar plates. 








2.7.9 Topo TA cloning of IL-23p19, IL-23p19Δ763, IL-23p19Δ1219 & IL-23p19Δ1284  
 
1. Cloning of pTre-IL-23p19, pTre-IL-23p19Δ763, pTre-IL-23p19Δ1219 and 
pTre-IL-23p19Δ1284 were carried out using TOPO TA Cloning® kit from 
invitrogen according to manufacturer’s protocol.  
2. Gene product were first amplified using the following primers: 
Amplification of all gene products were carried out using the same IL-23p19 
forward primer while 3’ truncation mutants were amplified with a different 
reverse primer. Gene products were amplified from cDNA of BMDCs 
stimulated with LPS for 2 hours. 
a. IL-23p19 Forward: 5’ GAAGTCGGACTACAGAGTTAGACTCAGAACC 3’ 
IL-23p19 Reverse: 5’ GCCACATAAATAAATCTTTATTGAAAAAAAAAATAC 3’ 
b. IL-23p19Δ763  Reverse: 5’ GGTAGATGTCTGGGCTGATAGATTAGTC 3’  
c.  IL-23p19Δ1219 Reverse: 5’ GGTCATAGTGGTAGTATTTGTCAGTTCG 3’  
d. IL-23p19Δ1284 Reverse: 5’ CTGTTACAAGGATAAATAATATCAAAAGTTC 3’  
3. PCR was carried out using Platinum PCR SuperMix HiFi (Invitrogen) 
according to manufacturer’s protocol. Briefly, a 25L PCR reaction was 
prepared with 20L of platinum PCR SuperMix, 200nM of forward and 
reverse primer and 1-200ng of cDNA. Cycling conditions were:  
8. 94°C for 2 mins 
9. 94°C for 30 sec 
10. 52-55°C for 30 sec 
11. 68°C for 90 sec 
12. Return to step 2 for 34 cycles 
13. 68°C for 2 mins 
14. 4°C to hold 
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4. PCR product were subjected to 1% agarose gel electrophoresis and DNA 
fragment of the appropriate size was excised and purified using QIAquick gel 
extraction kit (Qiagen) according to manufacturer’s protocol described above. 
5. 4uL of gel purified PCR product was added with 1uL of salt solution to 1uL of 
TOPO® vector. Reaction was mixed gently and incubated at r.t. for 5 min.  
6. JM109 bacteria were thawed on ice and 30-50L of bacteria was added to 
TOPO® cloning reaction mixture. Reaction was mixed gently and incubated 
on ice for 30 min. 
7. The bacteria were then heat-shocked at 42°C for 30 sec and immediately 
placed on ice for 2 min. 
8. 250L of prewarmed S.O.C medium was added to the bacteria and incubated 
at 94°C for 30-60 min. 
9. Centrifugation was carried out to pellet the bacteria and 200L of S.O.C 
medium was removed. Pellet was resuspended in the remaining S.O.C medium 
and spread onto pre-warmed ampicillin-LB agar plates. 
10. Agar plates were incubated at 37°C overnight. 
 
2.7.10 Ligation of IL-23p19, IL-23p19Δ763, IL-23p19Δ1219 and IL-23p19Δ1284 
DNA fragment into pTre-tight vector. 
 
1. Positive clones on ampicillin LB agar plates were cultured in ampicillin LB 




2. 2uL of Miniprep DNA was digested by EcoRI in EcoRI buffer for 1 hour at 
37C and subjected to 1% agarose gel electrophoresis. Bands of the 
appropriate size was excised and subjected to gel purification.  
3. pTre-tight vector (Clontech) was similarly digested with EcoRI and EcoRI was 
heat killed by heating at 80°C for 15 min. pTre-tight vector was treated with 
AP/CIP (0.5L buffer, 4uL water and 0.5L AP/CIP) at 37°C for 1 hour to 
remove 5’ phosphate group. Gel extraction was subsequently carried out. 
4. Ligation of IL-23p19, IL-23p19Δ763, IL-23p19Δ1219 and IL-23p19Δ1284 
DNA fragment to pTre-tight vector was carried out using T4 ligase from New 
England Biolabs (Ipswich, MA, USA). Reaction was prepared according to the 
following composition: 1L of vector, 4L of insert, 1.5L of T4 buffer, 8L 
of water and 0.5L of T4 ligase. Mixture was incubated at r.t. for more than 4 
hours. 
5. 50L of thawed JM109 bacteria was added to ligates and mixture was 
incubated on ice for 30 min. 
6. The bacteria were then heat-shocked at 42°C for 30 sec and immediately 
placed on ice for 2 min. 
7. 250L of prewarmed S.O.C medium was added to the bacteria and incubated 
at 94°C for 30-60 min. 
8. Centrifugation was carried out to pellet the bacteria and 200L of S.O.C 
medium was removed. Pellet was resuspended in the remaining S.O.C medium 
and spread onto pre-warmed ampicillin-LB agar plates. 
9. Agar plates were incubated at 37°C overnight. 
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10. Positive clones on ampicillin LB agar plates were cultured in ampicillin LB 
broth overnight and minipreps were carried out on individual clones of bacteria 
cells. 
11. Clones with correctly inserted DNA fragment were identified with BAMHI 
restriction enzyme cleavage in Buffer E for 1 hour at 37C and PCR 
amplification with:    
a. IL-23p19 Forward: 5’ GAAGTCGGACTACAGAGTTAGACTCAGAACC 3’ 




1. If data shown is representative of independent experiments, graph will be 
expressed as mean ± SD. 
2. If data shown is mean of independent experiments, graph will be expressed as 
mean ± SE.  
3. Values were analyzed using two-tailed unpaired Student’s t-test as data consisted 





Chapter 3: Interleukin-23 production by murine GM-CSF-derived                         





Interleukin-23 was first characterized as a factor inducing proliferation of both mouse 
and the human memory T cells (Oppmann et al., 2000). Subsequently, IL-23 has been 
shown to be crucial for both innate and adaptive immunity. Given the importance of 
IL-23 in protective immunity, identifying the cellular sources of IL-23 would help 
elucidate the regulation of functions of IL-23. Early studies identified the expression 
of IL-23 subunit, p19 and p40 mRNA and protein expression of p19p40 heterodimer 
in activated human peripheral blood derived dendritic cells and murine bone-marrow 
derived dendritic cells (Oppmann et al, 2000). Protein expression of the IL-23p19 
subunit has also been reported in virus activated human monocytes-derived 
macrophages (Pirhonen et al., 2002). The majority of studies have detected IL-23 
production in dendritic cells, and more specifically, in human peripheral blood derived 
dendritic cells and murine bone-marrow derived dendritic cells. However, less is 
known about the ability of steady-state dendritic cells to produce IL-23. Hence, we 
sought to compare the ability of murine steady-state dendritic cells of splenic origin 




Unlike IL-12, the stimuli for IL-23 production have been less extensively studied. 
There have been reports of IL-23 production by various pathogen associated 
molecular patterns (PAMPS) in both murine and human dendritic cells. In murine 
GM-CSF derived bone marrow dendritic cells, IL-23 was induced in the presence of 
Poly-IC, LPS and R848, which are agonists of Toll-like receptor 3, 4 and 7 
respectively (Waibler et al., 2007). Mycobacterium tuberculosis is also able to induce 
IL-23 production in human monocyte derived dendritic cells. Furthermore, 
combinations of ligands for nucleotide-binding oligodimerization domain (NOD2) and 
TLR-2, which mimic induction by M. tuberculosis, synergistically induces IL-23 
(Gerosa et al., 2008)). -glycan, the ligand for dectin-1, also induce IL-23 production 
in human monocyte derived dendritic cells (Gerosa et al., 2008)). Using murine GM-
CSF-derived bone marrow and splenic dendritic cells, we tested an extensive array of 






3.2.1 Generation of GM-CSF-derived BMDCs 
 
Bone marrow-derived dendritic cells were generated from mouse bone marrow 
following culture in complete RPMI supplemented with GM-CSF for 6 days. Cells 
were harvested after 6 days and isolated by positive selection using α-CD11c magnetic 
beads (Miltenyi Biotec, GmbH). Cells collected before and after positive selection 
were subjected to flow cytometric analysis for CD11c and MHC II expression (IA/IE) 
(Figure 3.1A and 3.1B). Percentages of cells expressing CD11c were summarised in 
Table 3.1. Approximately 70-80% of cells expressed CD11c after 6 days of culture 
with GM-CSF, and following positive selection via α-CD11c magnetic beads, around 
99% of the cells were positive for CD11c expression. 
 
3.2.2 Purification of splenic dendritic cells 
 
Splenic dendritic cells are obtained from the spleens of mice following digestion of 
spleen tissue using liberase, Optiprep density centrifugation and positive selection 
using α-CD11c magnetic beads (Miltenyi Biotec, GmbH). Cells isolated were 
subjected to flow cytometric analysis of CD11c, IA-IE (MHC-II) which are classical 
markers for splenic dendritic cells (Fig 3.2A). The purity of CD11c
+
 cells is 
routinely >90%. The population of CD11c
+



















 cells are 
approximately 30%, 15% and 45% respectively. (Figure 3.2B) The population of 






 and was 
routinely around 5%. (Figure 3.2C) 
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Figure 3.1. Phenotyping of bone marrow-derived dendritic cells. 
Bone marrow cells were harvested after 6 days of culture in cRPMI supplemented 
with GM-CSF. Flow cytometric analysis of bone marrow cells before (A) and after 









Table 3.1. Percentages of CD11c
+
 expressing cells before and after CD11c positive selection 
of bone-marrow cells cultured with GM-CSF for 6 days. 
Bone marrow cells were harvested on day 6 of culture with GM-CSF. Flow cytometry 
analysis of bone marrow cells were done before and after CD11c postitive selection. 
Percentages of bone marrow cells expressing CD11c before and after CD11c positive 
selection were computed in the table. 3 sets of representative experiments were 
shown.  
  
Positive selection of 




























                
  
   
 
Figure 3.2. Isolation of splenic dendritic cells. 
Splenic dendritic cells were isolated following Optiprep density centrifugation and 
positive selection using α-CD11c magnetic beads as described. Flow cytometry 
analysis of CD11c and class II (IA/IE) expression (A) were carried out. CD11c
+
 cells 
were further analyzed for CD4 and CD8 expression (B) and B220 and Siglec-H (C).  










3.2.3 Differential ability of microbial stimuli to induce IL-12 and IL-23 production 
 
Given the differential role of IL-12 and IL-23 in the protection against pathogens, we 
hypothesized that various microbial stimuli would differ in their ability to induce IL-
12 and IL-23. To investigate the stimuli required for IL-23 and IL-12 production by 
GM-CSF derived bone-marrow dendritic cells (BMDCs), we did a dose-titration of 
various microbial stimuli in the absence or presence of IFN- respectively (Fig. 3.3 
and 3.4). The microbial stimuli used were ligands for various pattern recognition 
receptors, such as PAM3CSK (PAM) for Toll-Like Receptor (TLR)-2, Polyinosinic-
polycytidylic acid (PolyIC) for TLR-3, lipopolysaccharide (LPS) for TLR-4, flagellin 
(Flag) for TLR-5, gardiquimod (Gard) for TLR-7, unmethylated CpG (CpG) for TLR-
9 and zymosan (Zym) for Dectin-1. Cell supernatants were harvested at 8 or 24 hours 
post-stimulation for detection of IL-23 and IL-12p70 respectively. The concentrations 
of microbial stimuli that induced the highest production of IL-12 or IL-23 were used 
in subsequent experiments (Fig. 3.3 and 3.4). We were unable to detect the presence 
of IL-23 production when BMDCs were stimulated with flagellin and IL-12 
production was undetectable when stimulated with PolyIC, flagellin and zymosan. 
 
For IL-23 production, various microbial stimuli alone can induce IL-23 production, 
with LPS being the most potent. Furthermore, IL-23 production was not significantly 
different in the presence of IFN- (Figure 3.5A).  On the other hand, TLR agonists or 
zymosan alone were poor inducer of IL-12p70 production. However, high levels of 
IL-12p70 production were observed in the presence of IFN-, with CpG being the 
most potent inducer (Figure 3.5B). IL-12p40, TNF- and IL-10 can be induced by 
TLR agonists or zymosan alone with CpG inducing the highest levels of IL-12p40 





Figure 3.3. Determining the dose of TLR agonists and zymosan required for the production of 
IL-23 by BMDCs. 
Various TLR agonists and zymosan were titrated for the production of IL-23. Cell 
supernatants were harvested at 8h post-stimulation and assayed via ELISA for IL-23 
production. Figures shown are representative of 2 independent experiments and error 
bars represent mean ± SD. Ligands used were agonists for TLR2- PAM3CSK (PAM); 
TLR3-Polyinosinic-polycytidylic acid (PolyIC); TLR4- Lipopolysaccharide (LPS); 
TLR5- Flagellin (Flag); TLR7- Gardiquimod (Gard); TLR9-unmethylated CpG DNA 







































































































                
      
 
Figure 3.4 Determining the dose of TLR agonists and zymosan required for the production of 
IL-12p70 by BMDCs. 
Various TLR agonists and zymosan were titrated in the presence of IFN-γ (10ng/mL) 
for IL-12p70 production. Cell supernatants were harvested at 24h post-stimulation and 
assayed via ELISA for IL-12p70 production.  Figures shown are representative of 2 
independent experiments and error bars represent mean ± SD. Ligands used were 
agonists for TLR2- PAM3CSK (PAM); TLR3-Polyinosinic-polycytidylic acid 
(PolyIC); TLR4- Lipopolysaccharide (LPS); TLR5- Flagellin (Flag); TLR7- 

























































































Fig 3.5. Differential requirements for the production of IL-12p70 and IL-23. 
GM-CSF-derived BMDCs are stimulated with various microbial stimuli. Cell 
supernatants are harvested at 8h post-stimulation and assayed via ELISA for IL-23 
production (A) and 24h post-stimulation for IL-12p70 production (B). Results are 
expressed as mean ± SD, representative of 2 independent experiments. Concentration 
of ligands used were PAM (0.5g/mL), PolyIC (100g/mL), LPS (50ng/mL), Flag 















































Figure 3.6. Production of IL-12p40, IL-10 and TNF-a by different TLR agonists. 
GM-CSF-derived BMDCs are stimulated with various microbial stimuli. Cell 
supernatants are harvested at 8h post-stimulation and assayed via ELISA for IL-10 
and TNF- and 24h post-stimulation for IL-12p40 production. Results are expressed 
as mean ± SD, representative of 2 independent experiments. Concentration of ligands 
used were PAM (0.5g/mL), PolyIC (100g/mL), LPS (50ng/mL), Flag (1g/mL), 






















































3.2.4 Production of IL-12 and IL-23 are enhanced by CD4 T cells and are dependent 
on CD40-CD40L interaction 
 
Besides the ability of various TLR agonists in inducing IL-23 production, we are 
interested in investigating the ability of CD4 and CD8 T cells in inducing IL-23. 
BMDCs were cocultured with CD4 and CD8 T cells in 96-wells round bottom plates, 
with or without anti-CD3 and in the presence or absence of LPS or CpG. Supernatants 
were harvested after 24 hours of culture and assayed for IL-12 and IL-23 production. 
Both CD4 and CD8 T cells significantly enhanced the production of IL-12 while only 
CD4 but not CD8 T cells significantly enhanced IL-23 production (Figure 3.7).  
 
Hence we went on to investigate the factors mediating the enhanced production of IL-
23 and IL-12. CD40L and IFN- has been shown to induce IL-12 production by both 
CD4 and CD8 T cells, hence we sought to investigate if CD4 T cells induce IL-23 
production via CD40L and IFN-. To investigate the role of CD40L on IL-12 and IL-
23 production, CD4 T cells were cocultured with WT or CD40 KO BMDCs on anti-
CD3-coated 96 wells plates and supernatants were harvested 24 hours later (Figure 
3.8A). CD40 KO BMDCs demonstrated significant reduction in production of both 
IL-12 and IL-23. Neutralization of IFN- was also carried out on CD4 T cell-BMDC 
coculture. Neutralization of IFN- significantly reduced the levels of IL-12p70 
production while there is no effect on IL-23 production (Figure 3.8B). To further 
confirm the effect of CD40L stimulation on IL-23 production, BMDCs were 
stimulated with LPS and increasing concentrations of agonistic anti-CD40 antibodies 
or MegaCD40L. Indeed, the production of IL-23 is enhanced with both anti-CD40 and 







Fig 3.7. Effect of CD4 and CD8 T cells coculture on IL-23 and IL-12p70 production. 
BMDCs were cocultured with CD4 and CD8 T cells in 96-well round bottom plates pre-
coated with or without anti-CD3 (2g/mL in PBS) and in the presence of LPS (50ng/mL) or 
CpG (0.2M). Supernatants were harvested after 24 hours and analysed for IL-23 (A) and IL-
12p70 (B) production via ELISA. Figures shown are representative from 4 independent 
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Figure 3.8. CD4 T cells enhances IL-12 and IL-23 production via a CD40-CD40L 
dependent mechanism. 
CD4 T cells were cocultured with WT or CD40 KO BMDCs (Figure A) and coculture with 
WT BMDCs in the presence or absence of anti-IFN-g/mL)(Figure B) on 96 wells round 
bottom plates pre-coated with anti-CD3 (2g/mL in PBS). Cocultures were stimulated with 
LPS (50ng/mL) or CpG (0.2M). Supernatants were harvested 24 hours later and analysed for 
IL-23 and IL-12p70 production. Data shown are representative of 2 independent experiments. 

































































































Figure 3.9. Effect of agonistic anti-CD40 and MegaCD40L on IL-23 production. 
GM-CSF-derived BMDCs are stimulated with LPS (50ng/mL) and various 
concentrations of anti-CD40 (3/23) or MegaCD40L. Cell supernatants are harvested at 
8h post-stimulation and assayed via ELISA for IL-23 production. Graph shown were 










































3.2.5 Differential ability of BMDCs and splenic DC to produce IL-12 and IL-23 
 
In vitro GM-CSF/IL-4 derived BMDCs are similar to inflammatory Tip-DCs in vivo 
with their ability to produce nitric oxide and cytokines such as TNF-, IL-10 and 
CCL-2. On the contrary, steady-state splenic CD11c
+
 conventional dendritic cells 
have impaired production of these cytokines (Serbina et al., 2003; Xu et al., 2007). 
Hence, we tested the ability of BMDCs and splenic DCs to produce Il-23, IL-12p70, 
TNF- and IL-10 (Figure 3.10). BMDCs produced high levels of IL-23, IL-12p70, 
TNF- and IL-10, whereas these cytokines were either not produced or produced at a 
much lower level by the splenic dendritic cells. Hence, BMDCs were used to study the 




       
 
    
Fig  3.10. Production of IL-23, TNF-a, IL-10 and IL-12p70 by splenic dendritic cells 
and BMDCs. 
Splenic DC and BMDCs were stimulated with various TLR agonists or zymosan for IL-
23, TNF- & IL-10 production and in the presence of IFN-γ for IL-12p70 production. 
Supernatants that were used for the analysis of IL-23, TNF- & IL-10 production were 
harvested at 8h and supernatants for IL-12p70 production were harvested at 24h post-
stimulation . Levels of cytokines were assayed by ELISA. Concentration of ligands used 
were PAM (0.5g/mL), PolyIC (100g/mL), LPS (50ng/mL), Flag (1g/mL), Gard 
(10g/mL), CpG (0.2M) and Zym (100g/mL). Control (untreated cells).Graph shown 















































































In our study, IL-23 production can be induced by Poly-I:C, LPS, gardiquimod, CpG 
and zymosan which are agonists of TLR-3, TLR-4, TLR 7, TLR-9 and dectin-1 
respectively. The ability of IL-23 to be induced by microbial stimuli of virus, bacteria 
and fungi origin suggests the all-encompassing nature of IL-23. Indeed, IL-23 has 
been demonstrated to be crucial for immunity against various bacteria, fungi and 
viruses.  Our study agrees with a previous study on murine dendritic cells which 
identified TLR-3, TLR-4 and TLR-7 agonists as inducers of IL-23 production 
(Waibler et al., 2007). However, in that study, CpG does not appear to be effective in 
the induction of IL-23. We have tested our source of CpG for presence of endotoxin 
and the level of endotoxin was below detection. Hence, we ruled out a possible 
contamination of CpG. However, another possible reason is the use of different CpG 
as stimuli.  
 
CpG is classified into 3 types (Type A, B and C) which differs in their stimulatory 
activities. Type A CpG contains a phosphodiester central CpG-containing palindromic 
motif and a phosphorothioate 3’ poly-G string. They are effective in inducing high 
IFN- production of plasmacytoid dendritic (pDC) but are weak inducers of TLR-9 
dependent NF-B activation. Type B CpG contain a full phosphorothioate backbone 
with one or more CpG dinucleotides. They are strong activators of B-cells but poor 
inducers of IFN- secretion. As for Type C CpG, they contain both the full 
phosphorothioate backbone and a CpG-containing palindromic motif, hence 
encompassing the ability to induce B-cell activation and IFN- secretion. The former 
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study uses a Type A CpG as opposed to the Type B CpG that we have used and hence, 
could account for the differences in observations. 
 
Following up with the report of zymosan and -glycan inducing IL-23 production in 
human monocyte derived dendritic cells (Gerosa et al., 2008), we tested the ability of 
zymosan to induce IL-23 from murine bone-marrow derived dendritic cells. Both 
zymosan and -glycan are ligands for dectin-1 receptor. However, zymosan has also 
been shown to simultaneously activate TLR-2 receptor (Brown et al., 2003; Gantner et 
al., 2003). Our data also demonstrated the ability of zymosan to induce IL-23 
production in murine bone marrow derived dendritic cells. As TLR-2 agonist 
(PAM3CSK) alone was unable to induce IL-23 production, it is likely that IL-23 
production induced by zymosan occurs via dectin-1 receptor or via both TLR-2 and 
dectin-1 receptor in a synergistic manner.   
 
On the contrary, IL-12 is preferentially induced by gardiquimod and CpG which are 
agonists for TLR-7 and TLR-9 respectively. Gardiquimod is a small synthetic 
molecule which can stimulate TLR-7, mimicking response to their natural ligands, 
ssRNA found in RNA viruses. As for CpG, they are DNA sequences with unique 
modifications that are found in bacteria and DNA viruses. The requirement of bacteria 
and viruses components for IL-12 induction suggests a preferential induction of IL-12 
during a viral or bacterial infection, and possibly, a crucial role of IL-12 in protective 
immunity against these agents. On the contrary, IL-12 is poorly induced by fungal 
components, such as zymosan. The high levels of IL-10 production induced by 
zymosan could possibly be a reason why zymosan does not stimulate Il-12 as IL-10 is 
a potent inhibitor of IL-12 production (Aste-Amezaga et al., 1998; Fiorentino et al., 
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1991). As LPS and CpG are the most potent stimuli for IL-23 and IL-12 respectively, 
these two stimuli are used for our subsequent experiments. 
 
Besides the ability of various TLR agonists and zymosan in inducing IL-23 
production, we have also investigated the ability of CD4 and CD8 T cells in inducing 
IL-23. Interestingly, CD4 but not CD8 T cells were able to enhance LPS induced IL-
23 production. Further investigation revealed the role of CD40L and CD40 interaction 
in IL-23 production. Indeed, there are several lines of evidence supporting the role of 
CD40L-CD40 interaction for IL-23 (Jasny et al., 2008). Although IFN- is reported to 
be inhibitory for IL-23 production (Sheikh et al., 2011; Sheikh et al., 2010); Qian et 
al., 2011), neutralization of IFN- has no effect on IL-23 production in our study. One 
possibility for this difference in the effect of IFN-on IL-23 production could be due 
to the slower production of IFN- by T cells as compared to IFN- supplementation at 
the start of the cell culture in previous studies (Sheikh et al., 2011; Sheikh et al., 2010; 
Qian et al., 2011). IFN- mediated suppression of IL-23 production could be occurring 
at an earlier phase and thus, it was not observed in our neutralization experiments.    
 
Dendritic cells from different cellular compartments are specialized to more 
effectively carry out their function; plasmacytoid dendritic cells produce of type-1 
interferons for viral immunity, Langerhans cells act as sentinels in the periphery, 
migrating to the lymph nodes to present antigens to T cells and CD8+ dendritic cells 
adapted for cross-presentation to CD8 T cells. Dendritic cells have been traditionally 
known to produce cytokines and furthermore, appear to be specialized for IL-12 and 
IL-23 production. However, less is known about the ability of different subsets to 
produce these cytokines. 
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Our study has shown the differential ability of splenic cDC and GM-CSF derived 
bone-marrow dendritic cells (BMDCs) to produce cytokines. BMDCs appear to be 
specialized for cytokine production as high levels of various cytokines, such as IL-23, 
IL-12p70, TNF- and IL-10, were produced. Hence, in subsequent experiments, 
BMDCs were used to study the regulation of IL-12 and IL-23. Our findings are similar 
to a previous study that has reported a differential ability of Flt-3 ligand and GM-
CSF/IL-4 generated BMDCs (Xu et al., 2007) to produce cytokines. GM-CSF/IL-4 
derived BMDCs are similar to the GM-CSF derived BMDCs used in our experiments 
while Flt-3 ligand generated BMDCs are in vitro equivalence of steady-state 
conventional dendritic cells in the spleen. High levels of cytokines, such as IL-12, IL-
10, TNF- and CCL-2, were reportedly produced by the GM-CSF/IL-4 derived 
BMDCs while Flt-3 ligand generated BMDCs produced solely IL-12 (Xu et al., 2007). 
However, the production of IL-23 production was not investigated in that study. 
 
GM-CSF receptor deficient mice have impaired development of MHC-II
+
 dendritic 
cells from inflammatory monocytes (Naik et al., 2006; Shortman and Naik, 2007). 
This implies a requirement of GM-CSF in the generation of inflammatory dendritic 
cells and hence, GM-CSF derived BMDCs have been suggested to be in vitro 
equivalents of inflammatory dendritic cells that arise during inflammation. More 
recent evidences have supported this hypothesis. Similar to Tip-DCs, GM-CSF 
derived BMDCs expresses MAC-3 and produce high levels of TNF- and NO upon 







 monocyte precursors which have been 
reported to be precursors of Tip-DC in vivo (Serbina and Pamer. 2006).   
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GM-CSF derived dendritic cells are believed to be a homogenous population. 
However, splenic dendritic cells can be further characterized into various populations 
with their CD4/CD8 expression and furthermore, splenic dendritic cells also contain a 
subpopulation of plasmacytoid dendritic cells characterized by their intermediate 
expression of MHC-II and their expression of B220 and Siglec-H. One limitation of 
the study was the limitation of cell numbers as dendritic cells constitute a small 
population in splenic cells and hence, it will be difficult to obtain sufficient cells if 
cells were further purified into CD4/CD8 populations or into plasmacytoid dendritic 
cells for this extensive study of cytokine production. Thus, the study of splenic 
dendritic cells was done on total splenic dendritic cells. 
 
Our data shows that inflammatory dendritic cells have the ability to produce high 
levels of various cytokines.  This ability of excessive cytokine production is lacking in 
the steady-state splenic dendritic cells. As excessive inflammatory responses are 
undesirable, the specialized development of inflammatory dendritic cells during 
conditions of inflammation serves as a mechanism that limits excessive production of 








Chapter 4: IL-23 production is dependent on 





Many pro-inflammatory transcripts are short-lived and are usually defined by the 
presence of an adenine/uridine element (ARE) in their 3’UTR. ARE enables 
individual mRNA to be regulated at the posttranscriptional level and targets them for 
rapid cytoplasmic degradation. While transcriptional regulation governs turning on the 
gene, post-transcriptional regulation allows the fine-tuning of inflammatory responses 
through the regulation of mRNA stability and translational initiation. This allows the 
length and the strength of inflammatory responses to be closely regulated. 
Tristetraprolin (TTP) is a critical mediator of mRNA degradation and the lack of TTP 
in TTP deficient mice resulted in an inflammatory condition characterized by myeloid 
hyperplasia associated with cachexia, erosive arthritis, dermatitis, conjunctivitis, 
glomerular mesangial thickening and high titers of auto antibodies (Taylor et al., 
2007). This results from excessive TNF- production as the mechanism that initiates 
TNF- mRNA degradation is defective. Hence, post-transcriptional control pathways 
that dampen the expression of cytokines and inflammatory mediators serve as a 
crucial mechanism to protect tissues from the pathological effects of excessive 
inflammation.  
 
Following the identification of TTP in the regulation of TNF-, a number of other 
cytokines have been shown to be similarly regulated in various different cell types.   
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IL-2 and IFN- production by T cells have been shown to be negatively regulated by 
TTP as TTP-deficient T cells exhibit enhanced production of IL-2 and IFN- 
following restimulation with anti-CD3/anti-CD28 (Ogilvie et al., 2005; Ogilvie et al., 
2009). TTP is also a negative regulator of GM-CSF production in bone-marrow 
stromal cells (Carballo et al., 2000). Interestingly, TTP not only regulates the mRNA 
stability of pro-inflammatory genes, a genome-wide analysis of mRNAs that binds to 
TTP identified IL-10 as a possible target of TTP (Stoecklin et al., 2008).  IL-10 is a 
potent inhibitor of macrophage activation that reduces the expression of many 
cytokines (Moore et al., 2001). Hence, it seems that the regulation of pro-
inflammatory and anti-inflammatory responses is coupled so as to prevent excessive 
inflammatory responses when cells are activated. 
 
Our study of IL-23 and IL-12p70 kinetics of mRNA and cytokine production has 
revealed that the mRNA of IL-23p19 subunit of IL-23 follows a rapid kinetics 
following LPS stimulation. As TNF- mRNA is also rapidly degraded post-
stimulation, we hypothesized that IL-23p19 and TNF- are similarly regulated in 
terms of mRNA stability and that Tristetraprolin (TTP) might be a factor that regulates 
the transient expression of IL-23p19. As the majority of studies were performed on 
macrophages, (Mahtani et al., 2001; Hitti et al., 2006;(Datta et al., 2008; Jalonen et al., 
2006; Schaljo et al., 2009) we are one of the first to report a role of TTP in dendritic 
cells. The involvement of p38 MAPK in the mRNA stability of IL-12p40, IL-12p35 
and IL-23p19 was investigated with a potent p38 MAPK inhibitor (SB202190). 
Finally, with TTP-deficient mice, we investigated the role of TTP in the production of 





4.2.1 IL-23p19 production follows a rapid kinetics of mRNA accumulation 
 
Bone marrow derived dendritic cells were stimulated with LPS or LPS/IFN- and cells 
were harvested at 0, 2, 4, 6, 8, hours post-stimulation. Following stimulation, IL-
23p19 mRNA was rapidly induced. The levels of mRNA peaked at the second hour 
post-stimulation and decreased to near basal levels by the 4
th
 hour. On the contrary, 
IL-12p40 and IL-12p35 mRNA induction followed a gradual kinetics that peaked at 
the 4
th
 hour post-stimulation and decreased gradually to the 8
th
 hour (Fig 4.1). 
Addition of IFN- enhanced mRNA expression of IL-12p40 and IL-12p35 while IL-
23p19 mRNA remained unchanged. 
 
Secretion of IL-23, IL-12p40 and IL-12p70 closely mirrored the kinetics of mRNA 





 hour post-stimulation and peaked after 6 hours. As for IL-12p40 and IL-





stimulation (Fig 4.2).  Addition of IFN- significantly enhanced the production of IL-









   
 
 
Figure 4.1. Kinetics of IL-12p40, IL-12p35 and IL-23p19 mRNA upon LPS/IFN- stimulation. 
BMDCs were cultured in the presence of LPS (50ng/mL), with and without the addition of 
IFN- (10ng/mL) and cells were harvested at time 0, 2, 4, 6, 8 hours post-stimulation. mRNAs 
were subsequently isolated, reverse-transcribed and the relative expression of mRNAs were 
assayed through quantitative real-time PCR. Values were normalized to GAPDH and further 
normalized to results at 0h for IL-12p40 and IL-12p35 mRNA. As levels of IL-23p19 mRNAs 
were below detection limit at 0h, expression of IL-23p19 were normalized to GAPDH and 
further normalized to results at 8h. ND: not detected. Figures shown are representative of 2 














































































Figure 4.2. Kinetics of IL-12p40, IL-12p70 and IL-23 cytokine production upon LPS or 
LPS/IFN- stimulation. 
BMDCs were cultured in the presence of LPS (50ng/mL), with and without the addition of 
IFN- (10ng/mL) and cell supernatants harvested at 0, 2, 4, 6, 8, 12, 16, 24h were assayed for 
IL-23, IL-12p40 and IL-12p70 production via ELISA. Figures shown are average of 4 





































































4.2.2 mRNA degradation of IL-23p19, IL-12p40, IL-12p35 and TNF- are dependent 
on p38 MAPK  
 
As p38 MAP kinase pathway has been implicated in the regulation of mRNA stability 
of cytokine genes (Stoecklin et al., 2004; Chrestensen et al., 2004; Stoecklin et al., 
2006), we tested the effect of a p38 MAP kinase inhibitor (SB202190) on the stability 
of IL-23p19, TNF-, IL-12p40 and IL-12p35 mRNA.  
 
For IL-23p19 and TNF-, BMDCs were stimulated with LPS for 2 hours prior to the 
addition of actinomycin D, an inhibitor of transcription. DMSO (Vehicle control) or 
SB202190 were added together with actinomycin D and cells were harvested at 0, 20, 
40 and 80 mins post-actinomycin-D addition. In the absence of SB202190, the half-
life of IL-23p19 and TNF- mRNAs were approximately 30 mins. The addition of 
SB202190 reduced the half-life of IL-23p19 and TNF- mRNAs to 15 mins. The 
levels of IL-23p19 mRNAs were significantly reduced at all time points while levels 
of TNF- mRNAs were significantly reduced at 20 and 40 mins post-actinomycin-D 
addition (Figure 4.3A).  
 
As IL-12p40 and IL-12p35 peaked at the 4
th
 hour, to investigate the mRNA 
degradation of IL-12p40 and IL-12p35, BMDCs were stimulated with CpG/IFN- for 
4 hours prior to the addition of actinomycin D. Similarly, DMSO or SB202190 were 
added. IL-12p40 and IL-12p35 have a mRNA half-life of >80 mins. The addition of 
SB202190 also significantly reduced the levels of IL-12p40 and IL-12p35 and the 
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Figure 4.3.  Degradation of IL-23p19, TNF-, IL-12p40 and IL-12p35 mRNAs are dependent 
on a p38 MAPK dependent mechanism. 
BMDCs were pretreated with LPS (50ng/mL) for 2 hours (A) or CpG (0.2M)/ IFN- 
(10ng/mL) for 4 hours (B) prior to addition of 2g/mL of actinomycin D (ActD). Cells were 
harvested at 20, 40, 60 and 80 min post-ActD addition. mRNAs were subsequently isolated, 
reverse-transcribed and the relative expression of mRNAs were assayed by quantitative real-
time PCR. Values were normalized to GAPDH and further normalized to results at 0 min 
post-ActD addition, which were set at 100%. Figures shown are mean of 3 independent 












































































































































4.2.3 LPS induces the mRNA and protein expression of Tristetraprolin (TTP) 
 
The regulation of IL-23p19 mRNA stability by p38 MAP kinase suggests a possible 
involvement of Tristetraprolin (TTP) hence, we first evaluated if TTP is present in 
bone-marrow derived dendritic cells (BMDCs). BMDCs were stimulated with LPS 
and mRNAs were harvested at different length of times. Real time PCR showed that 
TTP mRNA was induced at the first hour and rapidly decline to near basal levels by 
the second hour post-LPS stimulation (Figure 4.4A). 
 
Protein expressions of TTP were also analyzed from LPS-stimulated BMDCs. 
BMDCs were lysed at different length of time and lysates were subjected to SDS-
PAGE and Western Blot analysis. Unactivated BMDCs have low levels of TTP but 
TTP is rapidly induced at the first hour after LPS stimulation. TTP appeared as a 
diffuse band of 45-55kDa due to the presence of multiple phosphorylated forms. At 
the first hour, TTP is predominantly present in a hypophosphorylated form with a 
smaller molecular mass but as time passes, TTP becomes increasingly phosphorylated 
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Figure 4.4. Kinetics of TTP mRNA and protein expression post-LPS stimulation. 
BMDCs were stimulated with LPS (50ng/mL) and cells were harvested at 0, 1, 2, 4, 6, 8, 
hours (A).  mRNAs were subsequently isolated, reverse-transcribed and the relative 
expression of mRNAs were assayed through quantitative real-time PCR. Values were 
normalized to GAPDH and further normalized to results at 0h. Data shown is mean of 3 
independent experiments with error bars representing SE of mean. BMDCs were stimulated 
with LPS and cell lysis were performed at 0, 1, 2, 3, 4, 6, hours post-LPS stimulation (B). Cell 
lysate were subjected to SDS-PAGE and western blot analysis for the protein expression of 







































Hours post-LPS stimulation 








4.2.4 Genotyping of TTP deficient mice  
 
As we hypothesized a possible involvement of TTP in the regulation of IL-23, hence, 





were a kind gift from Dr Blackshear from The Research Triangle Park, NC, USA. As 
TTP
-/-
 mice eventually developed an inflammatory condition, they were not suitable 
for breeding. Hence, breeding was done using TTP
+/-





 mice. Tail genotyping of TTP
+/- 
offspring were routinely 
carried out and two sets of primers were used; primer set A (MGTTP/5832-5856; 
MGTTP/r6267-6247) which encodes for the full length TTP and primer set B 
(MGTTP/f5832-5856;pMC1PolA Neo) which contains a reverse primer on the 
neomycin insertion gene (Figure 4.5A).  
 
PCR and gel electrophoresis with primer set A will typically yield a 435 nucleotide 
band for endogenous TTP and a 1575 nucleotide band for TTP with a neomycin 
insertion. As each gene is represented by two alleles, PCR and gel electrophoresis of 
wild-type mice would yield only a 435 band, TTP
+/-
 mice would express both 435 and 
1575 band and TTP
-/-
 mice would express the 1575 band (Figure 4.5B). As for primer 
set B, the presence of neomycin insertion would yield a PCR fragment of 1106 




 mice but not in 
wildtype mice (Figure 4.5B). 
 
Bone marrow dendritic cells from wildtype and TTP
-/-
 mice stimulated with LPS for 2 
hours and cell lysate was subjected to Western Blot analysis for the detection of TTP 
protein expression. TTP protein expression is present in wildtype mice following LPS 
stimulation while TTP
-/-
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Figure 4.5. Genotyping of tristetraprolin deficient mice. 
TTP
-/- 
mice contains an inserted neomycin resistance gene into the protein-coding region of 
the gene encoding TTP, Zfp-35. Figure depicting the primers used for genotyping of TTP
-/-
 
mice (A). Genomic DNA was isolated from the tail of mice and subjected to PCR with primer 
set A (primers flanking the endogenous TTP) and primer set B (forward primers derived from 
endogenous TTP while reverse primer is complementary to neomycin gene) (B). WT and 
TTP
-/-
 bone-marrow cells were cultured in the presence of GM-CSF for 6 days for the 
differentiation into BMDCs. WT and TTP
-/-
 BMDCs were subsequently stimulated with LPS 
for 2 hours and the cell lysate subjected to SDS-PAGE and Western Blot analysis (C). Figures 
shown are representative of the routine genotyping and Western Blot analysis for TTP 
expression of TTP
-/-
 mice.  
#1   #2   #3                      #1   #2   #3 










Primer set A: MGTTP/5832-5856; MGTTP/r6267-6247 
Primer set B: MGTTP/f5832-5856;pMC1PolA Neo 
 
 






4.2.5 Characterization of TTP
-/-
 bone marrow derived dendritic cells 
 
Bone marrow cells of wildtype and TTP
-/-
 mice were cultured in GM-CSF for 6 days 
to generate BMDCs. Cells were subsequently subjected to positive selection using 
anti-CD11c miltenyi beads and the expression of CD11c, IA/IE and CD86 by wildtype 
and TTP
-/-
 bone marrow dendritic cells routinely carried out by flow cytometry.  
Wildtype and TTP
-/-
 BMDCs express similar levels of IA/IE (80-90%) and CD86 
(20-30%) although the expression of IA/IE and CD86 by TTP-/- BMDCs appears to 
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-/-
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Figure 4.6. CD11c, MHC-II (IA/IE) and CD86 expression on WT and TTP
-/-
 BMDCs. 
Bone marrow cells were cultured for 6 days in the presence of GM-CSF. On day 6, cells were 
harvested and subjected to positive selection with anti-CD11c magnetic beads. CD11c, MHC-
II (IA/IE) and CD86 expression of WT and TTP
-/-
 BMDCs were analysed by flow cytometry. 
Figures shown are representative of purity data from several experiments. Numbers represent 




9.85% 89.7% 15.63% 86.9% 
76.57% 22.96% 70.11% 29.41% 
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4.2.6 Tristetraprolin negatively regulates the expression of IL-23 by enhancing mRNA 
degradation of IL-23p19 
 
BMDCs from wildtype and TTP
-/-
 mice were cultured in the presence or absence of 
LPS for 8 hours and culture supernatants were harvested for ELISA. TTP
-/-
 BMDCs 
produced significantly higher amounts of IL-23 and TNF- as compared to wildtype 
BMDCs, while levels of IL-12p40 were significantly reduced in TTP
-/-
 BMDCs 
(Figure 4.7).  
 
To evaluate the effect of TTP deficiency on the mRNA levels of IL-23p19 in wildtype 
and TTP
-/-
 BMDCs, mRNAs were harvested after 2 hours of LPS stimulation. 
Realtime PCR analysis of mRNA expression was carried out for TNF-, IL-23p19 
and IL-12p40 with values were normalized to GAPDH and further normalized to 
mRNA expression in control cells.  LPS stimulation significantly increased the mRNA 
expression of IL-23p19 and TNF-in TTP-/- BMDCs while IL-12p40 mRNA was 
significantly reduced instead (Figure 4.8). 
 
As TTP has been known to negatively regulate cytokine genes through mRNA decay, 
we sought to investigate the effect of TTP deficiency on the mRNA stability of        
IL-23p19. WT and TTP
-/-
 BMDCs were stimulated with LPS for 2 hours prior to the 
addition of actinomycin-D, an inhibitor of transcription, and cells were subsequently 
harvested at 0, 30, 60, and 120 mins (Figure 4.9A). The relative mRNA expression of 
IL-23p19 in TTP
-/-
 BMDCs was significantly enhanced at all time points. 
Furthermore, the half-life of IL-23p19 in TTP
-/-
 BMDCs was > 120 mins and this was 
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considerably longer than in wildtype BMDCs which have a half-life of  50 mins 
(Figure 4.9B).  
 
mRNA of TNF- was similarly stabilized in TTP-/- BMDCs as the relative mRNA 
expression of TNF- was significantly enhanced at 30 and 60 mins. Half-life of TNF-
 in TTP-/- BMDCs was  50 mins which was increased from   25 mins in wildtype 
BMDCs (Figure 4.9B). Although both IL-23p19 and TNF- appear to be regulated by 
TTP, TNF- mRNA followed a more rapid rate of decay as TNF- mRNA has a 
shorter half-life. On the contrary, IL-12p40 mRNA was relatively stable in WT mice 
with a half-life of >120 mins and the relative mRNA expression of IL-12p40 in WT 








Figure 4.7.  TTP
-/-
 BMDCs showed enhanced IL-23 secretion post-LPS stimulation. 
WT and TTP
-/-
 BMDCs were stimulated with or without LPS (50ng/mL) for 8 hours and the 
supernatants were analyzed by ELISA for IL-23, IL-12p40 and TNF-. Figures shown are 
mean of 3-4 independent experiments with error bars representing mean ± SE. Data were 










































































 BMDCs exhibit enhanced levels of IL-23p19 and TNF- mRNA expression. 
WT and TTP
-/-
 BMDCs were treated with or without LPS (50ng/mL) for 2 hours and cells 
were harvested. mRNAs were isolated, reversed transcribed and realtime PCR was carried out. 
IL-23p19, IL-12p40 and TNF- expressions were normalized to GAPDH and further 
normalized to expressions of control cells. Graphs shown are average of 3 or 4 independent 




















































































































 BMDCs exhibit prolonged expression of IL-23p19 mRNA through enhanced 
mRNA stability. 
Schematics of the experimental setup to determine the rate of mRNA decay of IL-23p19 and 
TNF- (A).  BMDCs were stimulated with LPS (50ng/mL) for 2 hours prior to the addition of 
actinomycin D (2g/mL) and cells were harvested at 0, 30, 60, 120 mins. mRNAs were 
isolated, reverse transcribed and realtime PCR was carried out. mRNA levels of IL-23p19 and 
TNF- were normalized to GAPDH and further normalized to 0 min, which were set to 100% 
(B). Graphs shown were mean of 3 or 4 independent experiments. Error bar depicts mean ± 











































































































Post-transcriptional regulation of mRNA through mRNA degradation is crucial to 
ensure timely shutdown of inflammatory responses. Control of mRNA degradation not 
only regulates the levels of cytokine production; the duration of the responses can also 
be specifically regulated. An array of the inflammatory cytokines, such as IL-1, IL-3, 
IL-6, IL-11, IL-8, TNF-, IL-10, IFN-, and IL-2, have been shown to be regulated 
through mRNA degradation (Stoecklin and Anderson. 2006). Hence, it seems that the 
transient expression of mRNA is a hallmark of many inflammatory cytokines.  
 
Transient expression of IL-23p19 mRNA correlates with the rapid kinetics of IL-23 
secretion and hence, under normal conditions, production of bioactive IL-23 appears 
to be largely dependent on the levels of IL-23p19 mRNA but not IL-12p40 mRNA. 
Due to the nature of IL-23 and IL-12 sharing the same p40 subunit, the competition 
for p40 subunit may affect the relative levels of IL-23 and IL-12. However, this is 
unlikely as IL-12p40 appears to be produced in excess with levels of mono- or dimeric 
IL-12p40 secreted far exceeding the combined levels of IL-23 and IL-12p70 at all 
time points. Furthermore, the bulk of bioactive IL-23 is mostly secreted before the 4
th
 
hour, which is distinct from IL-12p70 where secretion occurs mainly after the 4
th
 hour. 
This temporal difference in the production of IL-23 and IL-12p70 reduces the 
likelihood of competition for the common IL-12p40 subunit. 
 
The involvement of p38 MAP kinase in regulation of mRNA stability has been well 
documented (Stoecklin and Anderson. 2006). Hence, it is possible that the mRNA 
stability of IL-23p19, IL-12p40 and IL-12p35 are all dependent on p38 MAP kinase. 
However, the half-life of IL-23p19 and TNF- mRNA decay appears to be much 
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shorter than that of IL-12p40 and IL-12p35, suggesting the possibility of differences 
in the regulation of mRNA decay of these cytokines. One possible candidate that may 
regulate the mRNA stability of IL-23p19 is Tristetraprolin (TTP) which has been 
initially shown as a key regulator of TNF- mRNA stability. Furthermore, TTP 
mediated mRNA decay occurs via a p38-MK2 kinase dependent mechanism (Carballo 
et al., 2001; Hitti et al., 2006; Zhu et al., 2001b). 
 
To test this hypothesis, we first determined whether bone-marrow derived dendritic 
cells express TTP upon LPS stimulation. TTP was rapidly induced with peak mRNA 
levels occurring after the first hour of LPS treatment and TTP was detected via SDS-
PAGE and western blot analysis in the first hour. This is in agreement with other 
studies which have also reported rapid induction of TTP upon stimulation (Hitti et al., 
2006; Mahtani et al., 2001; Zhu et al., 2001b). Indeed, TTP was first identified as a 
product of a primary response gene, Zfp36, induced upon stimulation by mitogens 
(Varnum et al., 1989; Gomperts et al., 1990; Lai et al., 1990).  
 
Western blot analysis also revealed the presence of TTP in a variety of molecular 
weights and there is an overall gain in molecular weight with time. This is likely due 
to the presence of multiple phosphorylation sites in TTP (Zhu et al., 2001b) and it has 
been shown that the treatment of LPS stimulated cells with alkaline phosphatase 
reduces TTP into a single band at 43kDa (Carballo et al., 2001).  The function of 
TTP is closely coupled to its phosphorylation status as binding of TTP to ARE is 
impaired when TTP is in a phosphorylated state (Carballo et al., 2001). Subsequently, 
both p38 and MK-2 have been identified as a crucial factor in the inactivation of TTP, 
with serine 52 and serine 178 being the two major sites of phosphorylation (Zhu et al., 
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2001b; Carballo et al., 2001; Hitti et al., 2006). With the rapid kinetics of TTP 
induction in BMDCs, it seems that TTP is positioned to regulate the rapid turnover of 
cytokine genes in BMDCs. However, TTP appears to be present in the active 
hypophosphorylated form predominantly in the first hour of LPS stimulation as TTP is 
increasingly phosphorylated with time. Hence, TTP could possibly regulate mRNA 
destabilization more rapidly at an earlier time frame when TTP is predominantly in an 




 BMDCs appears to be less matured as compared to the wildtype BMDCs 
due to their slightly lower expression of CD86 and MHC-II (Total IA/IE). However, 
this did not seem to have an effect on cytokine production as production of cytokines 
in TTP
-/-
 BMDCs was enhanced instead. Furthermore, in later experiments, wildtype 
and TTP
-/-
 BMDCs are both able to induce the proliferation of naïve CD4 T cells. 
Hence, TTP
-/-
 BMDCs still retains the functionality of BMDCs. A study on the effect 
of TTP on murine dendritic cells has also reported a lower CD40 and CD86 
expression in unstimulated TTP
-/-
 BMDCs. However, this reduction was compensated 
upon LPS stimulation as wildtype and TTP
-/-
 BMDCs expressed comparable levels of 
CD40 mRNA upon 0.5h of LPS stimulation (Bros et al., 2010).  
 
LPS was used in the study of IL-23p19 mRNA stability due to its ability to induce the 
highest level of IL-23 production. However, toll IL-1 receptors family appears to 
differ in their ability to promote the stabilization of ARE containing mRNA (Datta et 
al., 2004). While TLR4 and IL-1R1 promotes stabilization of unstable chemokine 
mRNA, TLR3 does not. Interestingly, this difference depends on the use of individual 
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TIR-containing adaptors; the ability of enhance mRNA stabilization depends on 
MyD88 and Mal whereas Trif and Tram are unable to enhance mRNA stability.  
 
The experiments using TTP
-/-
 BMDCs demonstrated increased IL-23 cytokine 
production and elevated IL-23p19 mRNA levels upon LPS stimulation. Furthermore, 
the mRNA stability of IL-23p19 was greatly enhanced in TTP
-/-
 mice. Hence, it seems 
that IL-23p19 mRNA stability is negatively regulated by TTP. While mRNA stability 
of TNF- is also enhanced in TTP-/- mice, the half-life of TNF- mRNA in TTP-/- 
mice was 50 mins which is considerably faster than the half-life of IL-23p19 in TTP-
/-
 mice. One reason is that TTP might not be the sole factor that regulates the 
degradation of TNF- as other ARE-binding proteins may also have a role. Indeed, 
KH-type splicing regulatory protein (KSRP), which also promotes ARE-directed 
mRNA degradation, has also been shown to regulate the mRNA degradation of TNF-
 ARE containing mRNA in Jurkat cells (Gherzi et al., 2004). On the other hand, TTP 
seems to be a critical factor that regulates the mRNA stability of IL-23p19 as IL-
23p19 mRNA appears to be stable in the TTP
-/-










Chapter 5:  Overexpression of Tristetraprolin in HEK293 cell line 





The 3’ untranslated regions (UTR) of many short-lived cytokines are marked by 
clusters of adenine and uridine rich elements (ARE) and these AU-rich regions have 
been implicated in the regulation of mRNA decay and translation. Tristetraprolin 
(TTP) has been one of the most well studied regulators of mRNA decay. It was first 
identified as a regulator of TNF- mRNA decay and subsequently, TTP has been 
implicated in the regulation of various cytokine and non-cytokine genes.  
 
The regulation of cytokine genes by TTP have been demonstrated to occur via an 
ARE dependent mechanism. Overexpression of TTP enhanced the degradation of -
globin mRNA that is coupled to IL-8 ARE (Winzen et al., 2007). Similarly, the 
degradation of CXCL1 mRNA is enhanced with the overexpression of TTP using a 
Tet-Off® gene expression system in HEK293 cells. The increased degradation of 
CXCL1 is reversed with the deletion of ARE regions at the 3’UTR of CXCL1 mRNA 
(Datta et al., 2008).  Similarly, the mutation of IFN- ARE regions also renders IFN- 
insensitive to TTP (Ogilvie et al., 2009). Although the role of ARE in TTP mediated 
mRNA decay is indisputable, there is considerable diversity of ARE regions across 
different mRNA genes. While TNF- ARE contains a series of UUAUUUAUU 
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nonamers and AUUUA pentamers, CXCL1 ARE regions contain mixture of AUUUA 
pentamers and overlapping pairs of pentamers, all of which appear to be crucial for the 
regulation of mRNA degradation by TTP. Hence, using a Tet-Off® Gene Expression 
system, we sought to demonstrate a role of TTP in mediating the degradation of IL-
23p19 mRNA. In addition, as IL-23p19 mRNA has a long 3’UTR with multiple ARE 
regions, we would like to elucidate if these ARE regions differ in their sensitivity 








5.2.1 Creating a HEK293 cell line stably expressing tetR-VP-16 fusion protein 
(HEK293/Tet off) and cloning of IL-23p19, IL-23p19∆1219, IL-23p19∆1284 into 
pTRETIGHT vector 
 
To determine if the mRNA decay of IL-23p19 is directly dependent on Tristetraprolin 
(TTP), Tet-off® gene expression system (Clontech) was used as previously described 
(Datta et al., 2008). Tet-off® gene expression system consists of two components; 1) 
HEK293 cell line stably expressing tetR-VP-16 fusion protein that functions as a 
doxycycline sensitive transcriptional activator and 2) gene of interest cloned into 
pTRETIGHT  vector under the control of tetracycline response element (TRE). In the 
absence of tetR-VP-16 fusion protein, the altered minimal CMV promoter (PminCMV) 
of pTRETIGHT lacked strong enhancer elements associated with normal CMV 
promoter, resulting in low basal expression of the gene. When transfected into cells 
with tetR-VP-16 fusion protein, VP-16 domain converts tetR into a transcriptional 
activator and the hybrid protein (tTA) binds to TRE promoter of pTRETIGHT and 
activates the transcription of the gene of interest (Figure 5.1). 
 
HEK293 cell line stably expressing tetR-VP-16 fusion protein (HEK293/Tet-Off) was 
generated by transfection of HEK293 cell line with 2g of pTet-off vector using 
PolyFect Transfection Reagent (Qiagen) in a 6 well plate. Positive clones were 















Figure 5.1. Schematic of gene regulation in Tet-Off gene expression system. 
tTA binds to TRE promoter of pTRETIGHT and activates the transcription in the absence of 
doxycycline. Figure from Clontech Tet-Off gene expression system user manual. 
 
 
The IL-23p19 3’ UTR contains five AUUUA pentamers and a UUAUUUAUU 
nonamer close to its 3’ end (Figure 5.2A). In order to study the role of AU-rich 
elements (ARE) in TTP mediated mRNA decay, IL-23p19 full mRNA together with 
two IL-23p19 3’UTR truncation mutants were cloned. IL-23p19 contains the 5’UTR, 
coding region and an intact 3’UTR while IL-23p19∆1284 and IL-23p19∆1219 were 
truncated at residue 1284 and 1219 respectively (Figure 5.2B). In IL-23p19∆1284, the 
region truncated consists of a UUAUUUAUU nonamer, 2 overlapping AUUUA 
pentamer and one independent AUUUA pentamer while in IL-23p19∆1219, two 




The cloning strategy of IL-23p19, IL-23p19∆1284 and IL-23p19∆1219 is summarized 
in Figure 5.3 and 5.4. Briefly, TOPO TA cloning were carried out with PCR product 
encoding IL-23p19, IL-23p19∆1284 and IL-23p19∆1219 and transformed into JM109 
competent E. coli cells. E. coli cells were plated onto ampicillin agar plates overnight 
at 37°C. Positive clones were individually cultured in LB broth supplemented with 
ampicillin overnight at 37°C and miniprep was carried out (Figure 5.3). Miniprep 
eluate was then subjected to EcoRI digest. EcoRI fragment was gel purified and 
ligated with pTRETIGHT vector pretreated with EcoRI and AP/CIP phosphatases. The 
ligates were subsequently transformed into JM109 competent E. coli cells and plated 
onto ampicillin agar plates overnight at 37°C. Positive clones were individually 
cultured in LB broth supplemented with ampicillin overnight at 37°C and miniprep 
was carried out. Positive clone was cultured in 500-1000mL of LB broth overnight at 
37°C and maxiprep was carried out to obtain the plasmid (Figure 5.4).  
 
To identify the clones with correct insertion of IL-23p19, IL-23p19∆1284 and IL-
23p19∆1219, BAMHI digest was carried out (Figure 5.5A). As all three genes have a 
BAMHI restriction site near the 3’ end of the sense strand, correctly inserted plasmid 
will yield a larger band of 1000bp, 900bp and 850bp for IL-23p19, IL-23p19∆1284 
and IL-23p19∆1219 respectively. The presence of a correct insertion was also 
confirmed with polymerase chain reaction (PCR) using pTRETIGHT forward primer 
coupled with reverse primers of IL-23p19, IL-23p19∆1284 or IL-23p19∆1219 (Figure 
5.5B).  The presence of a correct insertion will yield bands of 1700bp, 1600bp and 

































                                                                                                                                                              1219 
CUAGUCACUAAGAACUAACAGGACUACCAAUACGAACUGACAAAUACUACCACUAUGACC/UGUGACAAAGCUGCAUA 
                                                                                                                                   1284 
UUUAUUAAGUGGGAAGGGAACUUUUGAUAUUAUUUAUCCUUGUAACAG/UAUAGAUGAUGGUUAUUUAUUCUAUU 









Figure 5.2. Diagram depicting a series of IL-23p19 3’UTR deletion contructs. 
mRNA of IL-23p19 showing putative ARE regions at IL-23p19 3’UTR (A). IL-23p19 
contruct contains the full mRNA sequence while IL-23p19Δ1284 and IL-23p19Δ1219 are 
mutant contructs with deletion of putative ARE regions at residues 1284 and 1219 
respectively (B).   
ARE region 









1. Polymerase chain reaction to obtain PCR product encoding IL-23p19, IL-23p19Δ1219 and 
IL-23p19Δ1284 
 












3. Transformation of JM109 competent E.coli and plated onto Ampicillin 
agar plates overnight at 37°C 
 
4. Pick 6-10 clones and culture each clone in 5mL of LB broth/Ampicilin 
overnight at 37°C 
 
5. Miniprep of selected clone 
 
Figure 5.3. Schematic diagram showing TOPO TA cloning of IL-23p19, IL-23p19Δ1219 and 
IL-23p19Δ1284. 
Plasmid map from Invitrogen TOPO TA cloning User Manual.   
141 
 
1. Restriction digestion by EcoRI on Miniprep of plasmid encoding IL-23p19, IL-
23p19Δ1219 and IL-23p19Δ1284 
 
2. T4 ligation of EcoRI digest with pTRETIGHT vector predigested with EcoRI 








2. Transformation of JM109 competent E.coli and plated onto Ampicillin 
agar plates overnight at 37°C 
 
4. Pick 6-10 clones and culture each clone in 5mL of LB broth/Ampicillin 
overnight at 37°C 
 
5. Miniprep of selected clones and identification of insertion by BAMHI 
restriction enzyme cleavage and PCR with pTRETIGHT forward primer  
 
6. Maxiprep of selected clone 
 
Figure 5.4. Schematic diagram showing EcoRI restriction digest and ligation of IL-23p19,  
IL-23p19Δ1219 and IL-23p19Δ1284 into pTRETIGHT vector. 
Plasmid map from Clontech Tet-Off Gene expression system user manual  
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                              A) BAMHI Digest                                       B) pTRETIGHT forward/IL-23p19 reverse  
                                 
                                 
                                 
Figure 5.5. Identification of bacterial clones expressing pTRE-IL-23p19,                               
pTRE-IL-23p19Δ1284, pTRE-IL23p19Δ1219. 
Miniprep eluate was subjected to BAMHI restriction digest and pTRE vector with correct 
insertions yield a band of 1000bp, 900bp, 850bp for IL-23p19, IL-23p19Δ1284 and IL-
23p19Δ1219 respectively (A). Miniprep eluate was subjected to PCR amplification with 
pTRETIGHT forward and IL-23p19, IL-23p19Δ1284 or IL-23p19Δ1219 reverse primer. Correct 
insertions yielded bands of 1700bp, 1600bp and 1550bp for IL-23p19, IL-23p19Δ1284 and 
IL-23p19Δ1219 respectively (B). Clones with a correct insertion are circled. 
 #1     #2     #3    #4     #5     #6   #1     #2     #3    #4     #5     #6  
 #1     #2      #3    #4      #5     #6   #1     #2     #3    #4     #5     #6  












5.2.2 Cloning of V5/His-tagged Tristetraprolin 
 
To study the role of Tristetraprolin (TTP) overexpression on the decay of IL-23p19 
mRNA, coding DNA sequence (CDS) of TTP with a 5’ Kozak sequence (-GCCACC-) 
was cloned into a pcDNA3.1/V5-His-TOPO vector under the regulation of CMV 
promoter (Figure 5.6). To identify the clones with a correct insertion of 
Tristetraprolin, BAMHI restriction digest and PCR amplification with T7 forward and 
TTP reverse primer were carried out.  BAMHI restriction site was present towards the 
3’ end of TTP CDS and hence, pcDNA3.1/V5-His-TOPO vector with a correct 
insertion of TTP CDS yielded bands of 900bp and 1100bp for BAMHI restriction 
digest and PCR respectively (Figure 5.7A). 
 
HEK293 cell line does not normally express detectable levels of TTP by Western blot. 
When HEK293 cells (overnight culture of 1.25 x 10
5
 cells/well in 24 well plate) were 
transfected with 2g of plasmid encoding TTP (V5-His-TTP), a diffused band around 
50kDa was detected when western blot was carried out using anti-TTP antibody. 
Detection of western blot via anti-V5 antibody resulted in a band of the same size 
hence confirming the protein expression of V5-His-TTP in HEK293 cell line when 
transfected with plasmid encoding TTP (Figure 5.7B).   
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1. Polymerase chain reaction to obtain PCR product encoding Tristetraprolin 
 










3. Transformation of JM109 competent E.coli and plated onto Ampicillin 
agar plates overnight at 37°C 
 
4. Pick 6-10 clones and culture each clone in 5mL of LB broth/Ampicilin 
overnight at 37°C 
 
5. Miniprep and identification of insertion by BAMHI restriction enzyme 
cleavage and PCR with T7 forward primer 
 
6. Maxiprep of selected clone 
 
Figure 5.6. Schematic diagram showing TOPO-cloning of V5/His-tagged Tristetraprolin. 





                      
 
Figure B 
                        
                        
 
Figure 5.7. Cloning of V5-His-tristetraprolin (TTP) and transfection into HEK293 cell line. 
Miniprep eluate was subjected to BAMHI restriction digest and PCR amplification with T7 
forward and TTP reverse primer.  pcDNA/V5-His vector with a correct insertion yielded 
bands of 900bp and 1100bp for BAMHI restriction digest and PCR amplification 
respectively. All the clones shown contains pcDNA3.1/V5-His-TOPO vector with a correct 
insertion (A).  HEK293 cells, cultured overnight at 1.25 x 10
5
 cells/well (24 well plate), were 
transfected with 0.5g of pcDNA or V5-His-TTP overnight and cells were subsequently lysed 
and subjected to SDS-PAGE and western blot analysis for expression of TTP and V5 (B).  
50kDa 
Anti-TTP           Anti-V5 
pcDNA   HisTTP     pcDNA   HisTTP 
V5/His-TTP 
GAPDH 
1)BamHI digest                                                     2) T7 forward/TTP reverse primer  





5.2.3 Transfection of pTRE-IL-23p19 into HEK293 stably expressing Tet-off 
Advanced 
 
By using the Tet-off® gene expression system, the transcription of IL-23p19 can be 
specifically shut down in the presence of doxycycline. Hence, this enables us to 
determine if the rate of IL-23p19 mRNA decay is dependent on TTP overexpression. 
Indeed, when pTRE-IL-23p19 plasmid was expressed in HEK293/Tet-off cell line, the 
mRNA levels were sensitive to doxycycline as there was a dose dependent inhibition 
of IL-23p19 mRNA levels. IL-23p19 mRNA expression exhibited a 90% inhibition 
by  10ng/mL of doxycycline after 4 hours of treatment (Figure 5.8B).  
 
 To determine if the mRNA decay of IL-23p19 is sensitive to the action of TTP, 
HEK293/Tet-off cell line was cotransfected with pTRE-IL-23p19 and control vector 
or TTP overnight. Doxycycline was then added and cells were harvested at 0, 1, 2 
hours (Figure 5.9A). In the absence of TTP, the mRNA of IL-23p19 remained 
relatively stable, and the mRNA was slightly reduced to 92.6% after 2 hours of 
doxycycline addition. However, when IL-23p19 was cotransfected with TTP, the half-
life of IL-23p19 was markedly shortened to 1.5h and the mRNA level was 
significantly reduced to 45.9% by the 2
nd
 hour (Figure 5.9B).  
 
Since overexpression of TTP markedly increased the decay of full length IL-23p19 
mRNA, we next sought to determine the regions of the IL-23p19 3’UTR that are 
necessary for sensitivity to TTP.  Two deletion mutants of the 3’UTR were generated 
and they were truncated at 3’UTR at residue 1284 and 1219. Plasmid encoding for IL-
23p19∆1284 and IL-23p19∆1219 were separately cotransfected into HEK293/Tet-Off 
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cell line with control vector or TTP, and mRNA decay was assessed by realtime PCR 
normalized to expression at 0h. In both cases, IL-23p19∆1284 and IL-23p19∆1219 
appeared to have lost their sensitivity to TTP as the levels of IL-23p19 mRNAs are not 
significantly different at the 2
nd
 hour of doxycycline addition (Figure 5.9B). Hence, 
these findings suggest that TTP targets the 3’UTR of IL-23p19, and our study have 
also highlighted the crucial role of residues between 1284 and 1359 in mediating the 









                 
Figure 5.8. Transcription of IL-23p19 mRNA under the control of TRE promoter is sensitive 
to doxycycline when transfected into HEK293 cells stably expressing tetR-VP-16 
(HEK293/Tet-off). 
Schematic showing the time course for transfection of HEK293/Tet-off with pTRE-IL-23p19 
plasmid (0.5g) and the addition of doxycycline (A). Varying concentration of doxycycline 
(0, 0.1, 1, 10, 100, 1000 ng/mL) were added to HEK293/Tet-off cell line that were transfected 
with pTRE-IL-23p19 vector and cells were harvested after 4 hours. Total RNA was isolated, 
reverse transcribed and realtime PCR was carried out (B). Data were normalized to GAPDH 
mRNA and expressed relative to untreated cell. Graph shown reflects the mean ± SE of 3 
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Figure 5.9. Tristetraprolin enhanced the degradation of IL-23p19 mRNA via ARE region. 
0.25g of pTRE-IL-23p19, pTRE-IL-23p19Δ1284 or pTRE-IL-23p19Δ1219 were 
cotransfected into HEK293/Tet-off on a 24 well plate with either 0.25g of pcDNA or               
V5-His-TTP overnight. Doxycycline (20ng/mL) was added and cells were harvested after 0, 
1, 2 hours (A). Total mRNA harvested was reverse transcribed and subjected to real time PCR 
analysis. IL-23p19 mRNA levels were normalized to GAPDH expression and expressed 
relative to expression at 0 hour (B). Graph shown reflects the mean ± SE of 3-5 independent 






Although the regulation of Tristetraprolin mediated mRNA decay via ARE regions is 
well accepted, the diversity of the ARE sequences and the role of ARE binding 
proteins in regulating individual mRNA remain to be fully understood. In agreement 
with our earlier data using TTP
-/-
 mice, overexpression of TTP in a Tet-Off® Gene 
Expression System enhanced the breakdown of IL-23p19 mRNA. Hence, this 
confirms a direct role of TTP in regulating the mRNA stability of IL-23p19.  
 
The regulation of IL-23p19 mRNA by TTP in macrophages has recently been 
published (Qian et al., 2011). The luciferase construct coupled with the IL-23p19 
3’UTR exhibits significantly reduced luciferase activity when cells were cotransfected 
with TTP hence, this demonstrated a role of TTP in the regulation of IL-23p19 via its 
3’ UTR. In addition, region 590-621 of IL-23p19 3’UTR, which corresponds to region 
1294-1325 of the full length IL-23p19 mRNA, plays a role in the negative regulation 
of IL-23p19 mRNA as a truncation mutant exhibits significantly enhanced luciferase 
activity (Qian et al., 2011). In spite of this, authors did not fully address the role of 
TTP in mediating the mRNA decay of IL-23p19 via region 590-621.  
 
In our system, by using a Tet-Off® Gene Expression System, the addition of 
doxycycline halts the transcription of IL-23p19 mRNA, hence enabling us to study the 
mRNA decay kinetics of IL-23p19 in the absence or presence of TTP. To elucidate the 
sequence of ARE regions critical for TTP mediated mRNA decay of IL-23p19, two 
3’UTR truncation mutants were generated. Study from the deletion analysis of IL-
23p19 3’ UTR demonstrated that the region 1284-1359 of IL-23p19 mRNA is crucial 
for TTP mediated mRNA decay as truncation of this region (IL-23p19∆1284) 
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rendered IL-23p19 mRNA insensitive to TTP. Region 1284-1359 of full IL-23p19 
mRNA encompasses the region 590-621 of IL-23p19 3’UTR identified previously 
(Qian et al., 2011). Hence, our data confirms a role of TTP in mediating IL-23p19 
mRNA decay via region 1284-1359. Sequence analysis of 1284-1359 identified the 
presence of an UUAUUUAUU nonamer, a pair of overlapping AUUUA pentamers 
and an individual AUUUA pentamer. On the other hand, region 1219-1284 contains 2 
AUUUA pentamer. Hence, these results suggest that the UUAUUUAUU nonamer and 
overlapping AUUUA pentamer appears to be crucial for TTP induced IL-23p19 
mRNA decay while individual AUUUA pentamers does not appear to be essential.  
 
A number of studies have also investigated the sequences of ARE that are critical for 
sensitivity towards TTP.  While TTP binds to sites with three to four uridine residues 
flanked by at least one adenine (Brewer et al., 2004), TTP appears to have a highest 
affinity with the UUAUUUAUU nonameric sequence element. Furthermore, 
UUAUUUAUU is also the minimal sequence that can induce mRNA degradation and 
the minimal binding site of tristetraprolin (TTP) (Blackshear et al., 2003; Worthington 
et al., 2002). In the regulation of CXCL1 mRNA degradation, both the overlapping 
and isolated pentamers containing sequences exhibit sensitivity to TTP (Datta et al., 
2008). However from our data, individual AUUUA pentamers in 3’UTR of IL-23p19 
mRNA do not seem to play a role in TTP mediated mRNA decay. Hence, there seems 








Chapter 6:  Tristetraprolin negatively regulates production 





Inflammatory dendritic cells (DCs) are absent in the steady state but arise during 
inflammation (Dominguez and Ardavin, 2010). Besides being able to acquire, process 
and present antigens to naïve T cells, inflammatory DCs are specialized for cytokine 
production as compared to the steady state lymphoid tissue DCs (Xu et al., 2007). 
Inflammatory dendritic cells, through cytokines production, are crucial for immunity 
against pathogens. However, immunopathology can result if the production of 
cytokines becomes uncontrolled (Dominguez and Ardavin, 2010).   
 
The cytokines produced by inflammatory dendritic cells include IL-1, IL-6, TNF-, 
IL-10, IL-12 and IL-23. While most of the cytokines can be produced by other cell 
types, IL-12 and IL-23 are exclusively produced by macrophages and dendritic cells 
(Hunter, 2005; Trinchieri, 2003). The study of IL-12 and IL-23 is of immense interest 
due to their role in the development of TH1 and TH17 subset of CD4 T cells respectively 
(Hunter, 2005; Trincheri, 2003). Besides IL-23, IL-6 and IL-1 has been implicated in 




Given the crucial role of various cytokines produced by inflammatory dendritic cell in 
defining the eventual outcome of adaptive immune response, a number of studies have 
investigated the role of inflammatory dendritic cells, monocytes and macrophages in 
the polarization of CD4 T cells using CCR2 deficient mice. Deficiency in CCR2 that 
resulted in an impaired recruitment of inflammatory monocytes, macrophages or 
dendritic cells to sites of inflammation led to a defect in IFN- production and 
impaired TH1 immunity against intracellular bacterial infection (Peters et al., 2000). 
Similarly, during pulmonary Cryptococcus neoformans infection, CCR2 deficient 
mice demonstrated prolonged pulmonary infection and an increased development of 
pulmonary TH2 responses such as eosinophilia, IL-4 and IL-5 production and high 
serum IgE (Traynor et al., 2000). This highlights the critical role of CCR2-dependent 
recruitment of inflammatory cells in promoting TH1 development over TH2. The 
specific requirement of monocyte derived dendritic cells developed at sites of 
infection was later shown to be critical for protective TH1 immunity against 
Leishmania (Leon et al., 2007). 
 
On the contrary, inflammatory dendritic cells have never been directly implicated in 
the development of TH17 cells although activated GM-CSF-derived BMDCs in the 
presence of TGF- have the capacity to induce the development of TH17 subset of 
helper T cells (Veldhoen et al., 2006). In spite of this, inflammatory dendritic cells or 
inflammatory monocytes/macrophages have been suggested to inhibit the 
development of TH17 cells as CCR2 deficiency resulted in enhanced TH17 response and 




We have demonstrated the ability of TTP to negatively regulate the production of IL-
23 through enhanced mRNA degradation. As IL-23 is a critical cytokine required for 
the maintainence and function of TH17 cells, we would like to investigate the effects of 
TTP deficiency on the polarization of naïve CD4 T cells. Besides, IL-23 and IL-12 
produced by BMDCs also affect the polarization of naïve CD4 T cells. Hence, we also 
looked into the effects of TTP deficiency on IL-12 production and dissected the 
consequences of IL-12 and IL-23 overproduction in the polarization of naïve CD4 T 





6.2.1 Tristetraprolin negatively regulates the expression of IL-12p70 through 
enhancing mRNA degradation of IL-12p35 
 
BMDCs from wildtype and TTP
-/-
 mice were cultured in the presence or absence of 
LPS and IFN- for 24 hours and culture supernatants were harvested for ELISA.    
TTP
-/-
 BMDCs produced significantly higher amounts of IL-12p70 as compared to 
wildtype BMDCs, while the level of IL-12p40 produced was significantly reduced in 
TTP
-/-
 BMDCs (Figure 6.1).  
 
As TTP negatively regulates cytokine genes through mRNA decay, we investigated 
the effect of TTP deficiency on the mRNA stability of IL-12p40 and IL-12p35. WT 
and TTP
-/-
 BMDCs were stimulated with LPS/IFN- for 4 hours prior to the addition 
of actinomycin-D, an inhibitor of transcription, and cells were subsequently harvested 
at 0, 60, 120, and 240 mins (Figure 6.2A). The relative mRNA expression of IL-12p35 
in TTP
-/-
 BMDCs was significantly enhanced at all time-points. Furthermore, the half-
life of IL-12p35 in TTP
-/-
 BMDCs was > 240 mins and this was considerably longer 
than in the wildtype BMDCs which had a half-life of  80 mins (Figure 6.2B). On the 
contrary, IL-12p40 mRNA was relatively stable in WT mice with a half-life of >240 
mins and the relative mRNA expression of IL-12p40 in WT and TTP
-/-
 BMDCs were 
not significantly different at all time-points (Figure 6.2B).  
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BMDCs showed enhanced IL-12p70 secretion when stimulated with 
LPS/IFN-. 
BMDCs were subjected to LPS (50ng/mL)/IFN- (10ng/mL) stimulation for 24 hours and 
supernatant were subjected to ELISA for the detection of IL-12p70 and IL-12p40 production. 
Figure shown are mean of 4 independent experiments in triplicates with error bars 






























































    
 
Figure 6.2. TTP KO BMDCs exhibited prolonged expression of IL-12p35, but not           
IL-12p40, mRNA through enhanced mRNA stability. 
Schematics of the experimental setup to determine the rate of mRNA decay of IL-12p40 and 
IL-12p35 (A).  BMDCs were stimulated with LPS/IFN- for 4 hours prior to the addition of 
2g/mL of actinomycin D and subsequently, mRNAs were isolated at 0, 60, 120, 240 mins. 
mRNAs were reverse transcribed and realtime PCR was carried out. mRNA levels of IL-
12p40 and IL-12p35 were normalized to GAPDH and further normalized to results at 0 min 
(B). Graphs shown were mean of 4 independent experiments. Error bar depicts mean ± SE. 











































































6.2.2 Tristetraprolin negatively regulates both TH1 and TH17 promoting cytokines 
 
As we have shown that tristetraprolin (TTP) negatively regulates IL-12 and IL-23, we 
proceeded to investigate if other cytokines involved in polarization of naïve CD4 T 
cells are regulated by TTP. WT and TTP
-/-
 BMDCs were cultured in the presence or 
absence of LPS for 8 hours and culture supernatants were harvested for ELISA. TTP
-/-
 
mice produced significantly higher amounts of IL-6 but not IL-1 as compared to 
wildtype BMDCs (Figure 6.3). 
 
 




 BMDCs produced enhanced levels of cytokines crucial for development of 
TH17 subset of CD4 T cells. 
BMDCs were stimulated with LPS (50ng/mL) for 8 hours and supernatant were subjected to 
ELISA for the detection of IL-6 and IL-1 production. Figures shown are mean of 4 
independent experiments in triplicates with error bars representing mean ± SE. Data were 







































6.2.3 Tristetraprolin KO BMDCs demonstrated enhanced polarization of naïve CD4 T 
cells to IFN- producing TH1 cells while inhibiting TH17 polarization  
 
Given the ability of TTP
-/-
 BMDCs to produce enhanced levels of both TH1 and TH17 
inducing cytokines, we were keen to investigate the effects of enhanced IL-12, IL-23 
and IL-6 production on the polarization of naïve CD4 T cells. Naïve CD4 T cells were 








 population from mouse 
lymph nodes and spleens (Figure 6.4). Sorted naïve CD4 T cells were subsequently 
cocultured with WT or TTP
-/-
 BMDCs at a ratio of 10:1 on anti-CD3 coated 96-well 
plates with 50ng/mL of LPS and in the absence or presence of 2ng/mL of TGF-. 
After 4 days of coculture, cells were restimulated with PMA/Ionomycin in the 
presence of GolgiPlug and GolgiStop.  During FACS analysis, cells were gated on the 
singlet population as well as on viable cells that were negative for the LIVE/DEAD 
violet fixable dead cell stain (Figure 6.5).  
 
Coculture with WT BMDCs in the presence of LPS induced the development of both 
IFN- and IL-17-producing CD4 T cells. On the contrary, coculture with TTP-/- 
BMDCs strongly enhanced the percentages of IFN- producing CD4 T cells but the 
percentages of IL-17 producing CD4 T cells were reduced (Figure 6.6). TTP
-/-
 
BMDCs induced a significantly higher proportion of IFN- producing CD4 T cells as 
compared to the wildtype BMDCs (Figure 6.6).  
 
The addition of TGF- and anti-IL-12p40/anti-IFN- were the conditions used to 
enhance the population of TH17 cells in a LPS-stimulated BMDCs and naïve CD4 T 
cells coculture (Veldheon et al., 2006). Therefore, to study the TH17 inducing potential 
of TTP
-/-
 BMDCs, TGF- and anti-IL-12p40/anti-IFN- (10g/mL each) were added. 
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Addition of TGF- and anti-IL-12p40/anti-IFN- enhanced the generation of IL-17 
producing cells by both WT and TTP
-/-
 BMDCs. Although TTP
-/-
 BMDCs appear to 
have a reduced ability to induce the development of IL-17 producing cells, this 





























 naïve CD4 T cells. 
FACs diagrams showing population of naïve CD4 T cells pre-sorting (A) and post-


































 naïve CD4 T cells were cocultured with WT or TTP
-/-
 
BMDCs on anti-CD3 coated 96 wells round bottom plates in a ratio of 10:1. After 4 days of 
cocultures, cells were restimulated with PMA/Ionomycin in the presence of GolgiPlug and 
GolgiStop. Intracellular staining for IL-17 and IFN- were carried out. During FACS analysis, 
cells were gated on the singlet population (R1) and total viable cells that were negative for 
LIVE/DEAD violet stain (R2). R3 is gated on cells that are IL-17
+
 while R4 is gated on cells 







                                 
 














 naïve CD4 T cells were cocultured with WT or TTP
-/-
 
BMDCs on anti-CD3 coated 96 wells round bottom plates in a ratio of 10:1. Cocultures were 
treated with LPS (50ng/mL) in the absence or presence of TGF-(2ng/mL). Cells treated with 
LPS/TGF- were also treated with anti-IL-12p40 (10g/mL) and anti-IFN-10g/mL). After 
4 days of cocultures, cells were restimulated with PMA/Ionomycin in the presence of 
GolgiPlug and GolgiStop. Intracellular staining for IL-17 and IFN- were carried out. FACs 
plots shown are representative of 3 independent experiments. Numbers represent percentages 
of IL-17A
+




















        
   
Figure 6.7. TTP
-/-









 naïve CD4 T cells were cocultured with WT or TTP
-/-
 
BMDCs on anti-CD3 coated 96 wells round bottom plates in a ratio of 10:1. Cocultures were 
treated with LPS (50ng/mL) in the absence or presence of TGF-(2ng/mL) Cells treated 
with LPS/TGF- were also treated with anti-IL-12p40 (10g/mL) and anti-IFN-
10g/mL)After 4 days of cocultures, cells were restimulated with PMA/Ionomycin in the 
presence of GolgiPlug and GolgiStop. Intracellular staining for IL-17 and IFN- were carried 
out and percentages of IFN- and IL17 producing cells obtained. Graphs shown are 
representative of 3 independent experiments with error bars representing mean ±  SD. Data 





























































6.2.4 Enhanced production of IL-12p70 from Tristetraprolin deficient BMDCs 
resulted in enhanced TH1 polarization  
 





 BMDCs were cocultured with naïve CD4 T cells and LPS in 
the presence of blocking antibodies to IL-12p40, IL-23p19, IL-1 and IL-6R. 
Addition of anti-IL-12p40 but not anti-IL-23p19 antibodies resulted in a reduction in 
the ability of TTP
-/-
 BMDCs to induce polarization of IFN- producing cells (Figure 
6.8). The suppression on IFN- producing cells by addition of anti-IL-12p40 was 
significant (Figure 6.9).  On the contrary, treatment of anti-IL-23p19 and anti-IL-6R 
antibodies appeared to enhance the population of IFN- producing cells while anti-    
IL-1 antibodies did not affect the population of IFN- producing cells (Figure 6.8).  
 
Due to the absence of IL-12p70-specific neutralizing antibody, anti-IL-12p40, which 
neutralizes both IL-12p70 and IL-23, was used. In spite of this, the ability of anti-IL-
12p40 but not anti-IL-23p19 to suppress the TH1 polarization capacity of TTP
-/-
 
BMDCs suggest a dominant role of IL-12. To further confirm the role of IL-12 and 
not IL-23 in TTP
-/-
 BMDC induced TH1 polarization, IL-12 and IL-23 were added to 
TTP
-/-
 BMDC/LPS/naïve CD4 T cell cocultures treated with anti-IL-12p40 antibodies. 
Addition of IL-12 to cocultures resulted in a significant dose-dependent enhancement 
of IFN- producing CD4 T cells. On the contrary, supplementation of IL-23 does not 
significantly enhance the population of IFN- producing cells (Figure 6.10 and 6.11). 
Hence, the enhanced production of IL-12 by TTP
-/-
 BMDCs appear to negate the TH17 
polarizing effects of increased IL-6 and IL-23 production, resulting in the greater TH1 
polarizing ability of TTP
-/-
 BMDCs.            
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Figure 6.8. Enhanced development of IFN-producing CD4 T cells by TTP-/- BMDCs results 
from enhanced production of IL-12p70 but not IL-23, IL-1 or IL-6. 
Sorted naïve CD4 T cells were cocultured with TTP
-/-
 BMDCs and LPS (50ng/mL) for 4 days 
in the presence of isotype, -IL-12p40 (10g/mL), -IL-23p19 (10g/mL), -IL-
1(10g/mL) or -IL-6R (20g/mL) antibodiesAt day 4, cells were restimulated with 
PMA/Ionomycin in the presence of GolgiPlug and GolgiStop. Intracellular staining for IL-17 
and IFN- were carried out. FACs plot shown are representative of 3 independent 
experiments.  Numbers represent percentages of IL-17A
+





















Figure 6.9. Enhanced development of IFN-producing CD4 T cells by TTP-/- BMDCs results 
from enhanced production of IL-12p70 but not IL-23, IL-1 or IL-6. 
Sorted naïve CD4 T cells were cocultured with TTP
-/-
 BMDCs and LPS for 4 days in the 
presence of isotype, -IL-12p40 (10g/mL), -IL-23p19 (10g/mL), -IL-1(10g/mL) or 
-IL-6R (20g/mL) antibodiesAt day 4, cells were restimulated with PMA/Ionomycin in the 
presence of GolgiPlug and GolgiStop. Intracellular staining for IL-17 and IFN- were carried 
out. Graphs shown are percentages of IFN- producing cells, representative of 3 independent 
experiments with error bars representing mean ±  SD. Data were analyzed via the Student’s t-






































        
 
                                
 
Figure 6.10. Supplementation of IL-12 but not IL-23 reversed -IL-12p40 suppression of TH1 
development. 
Naïve CD4 T cells and TTP
-/-
 BMDCs were cocultured with LPS (50ng/mL) and anti-IL-12p40 
(10g/mL)Cocultures were supplemented with 10ng/ml or 100ng/ml of IL-12 or IL-23.At day 4, 
cells were restimulated with PMA/Ionomycin in the presence of GolgiPlug and GolgiStop. 
Intracellular staining for IL-17 and IFN- were carried out. Figures shown are representative of 3 
independent experiments. Numbers represent percentages of IL-17A
+












-IL-12p40 +10ng/mL IL-12p70 -IL-12p40 +100ng/mL IL-12p70 
IFN- APC 
IL-17 PE 
-IL-12p40 +10ng/mL IL-23 -IL-12p40 +100ng/mL IL-23 
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Figure 6.11. Supplementation of IL-12 but not IL-23 reversed -IL-12p40 suppression 
of TH1 development. 
Naïve CD4 T cells and TTP
-/-
 BMDCs were cocultured with LPS (50ng/mL) and anti-IL-12p40 
(10g/mL)Cocultures were supplemented with 10ng/ml or 100ng/ml of IL-12 or IL-23.At 
day 4, cells were restimulated with PMA/Ionomycin in the presence of GolgiPlug and 
GolgiStop. Intracellular staining for IL-17 and IFN- was carried out. Graphs shown are 
percentages of IFN- producing cells, representative of 3 independent experiments with error 





































































We have earlier demonstrated a role of tristetraprolin (TTP) in the negative regulation 
of IL-23 production. As IL-23 has been implicated in the development of TH17 subset 
of helper T cells, we are interested in investigating the effects of TTP on the 
polarization of naïve CD4 T cells.  As polarization of naïve CD4 T cells occurs under 
the influence of multiple cytokines, we first investigated if various TH1 and TH17 
polarizing cytokines, such as IL-12p70, IL-1 and IL-6, were regulated by TTP.  Our 
results demonstrated the ability of TTP to inhibit production of both IL-6 and IL-
12p70 but not IL-1 and IL-12p40. In the case of IL-12p40, cytokine production was 
higher in TTP sufficient WT BMDCs as compared to TTP deficient BMDCs. One 
possibility is the depletion of IL-12p40 subunit in TTP deficient BMDCs due to the 
enhanced production of IL-12p70 and IL-23, as IL-12p40 is coupled to IL-12p35 and 
IL-23p19 respectively. However, this also suggested the role of TTP in the regulation 
of IL-12p70 production through IL-12p35 and not IL-12p40. Indeed, in the absence of 
TTP, IL-12p35 mRNA stability was enhanced while IL-12p40 mRNA was stable at all 
time points and remained unaffected in the absence of TTP.  
 
The role of inflammatory cytokines produced by BMDCs in the generation of IFN- 
and IL-17-producing T cells has been previously demonstrated (Veldhoen et al., 
2006). Furthermore, a number of studies have described the role of CCR2-dependent 
inflammatory monocyte, macrophages and/or dendritic cells in protective TH1 
immunity against bacterial, fungal and parasitic infections (Peters et al., 2000; Traynor 
et al., 2000; Leon et al., 2007). Given the role of TTP in the regulation of various TH1 
and TH17 inducing cytokines in BMDCs, we hypothesized a possible involvement of 
TTP in the regulation of CD4 T cell differentiation. Interestingly, despite the enhanced 
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production of both TH1 and TH17 inducing cytokines, TTP deficient mice showed 
enhanced development of IFN- producing TH1 cells. Hence, the expression of TTP in 
BMDCs seems to be crucial in limiting the TH1 response.  
 
As both IL-12 and IFN- have been shown to inhibit TH17 polarization (Harrington et 
al., 2005; Park et al., 2005), in order to study the TH17 polarising ability of TTP 
deficient BMDCs, we subjected the naïve CD4 T cells and BMDCs to conditions that 
favor TH17 development; through the addition of antibodies against IL-12 and IFN-. 
Under such conditions, the proportion of IL-17 producing cells were greatly enhanced. 
However, the proportion of IL-17 producing cells induced by WT and TTP deficient 
BMDCs were not significantly different. Thus, expression of TTP in BMDCs does not 
have an effect on TH17 cells development.  
 
To elucidate the cytokines critical for the preferential induction of TH1 polarization by 
TTP deficient mice, cocultures of naïve CD4 T cells and LPS stimulated/TTP 
deficient BMDCs were treated with various neutralizing antibodies. Neutralization of 
IL-12p40 but not IL-23p19, IL-1 and IL-6 suppressed the proportion of IFN- 
producing cells induced by TTP deficient BMDCs. The differential effects of anti-IL-
12p40 and anti-IL-23p19 suggested a role for IL-12p70 overexpression in the 
induction of enhanced TH1 responses in TTP deficient mice. The role of IL-12p70 in 
enhancement of TH1 responses was further confirmed with the supplementation of 
cocultures with recombinant IL-12p70. Hence, overexpression of IL-12p70 in TTP 
deficient BMDCs seems to be a key cytokine that governs the eventual fate of naïve 
CD4 T cells.  
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 The various pathways of T helper cell polarization do not occur independently of 
each other, instead, there are mechanisms that cross-regulate these pathways. IL-12 
and IFN- have been well characterised as inducers of the TH1 cell subset. 
Furthermore, IL-12 and IFN- reinforce TH1 development by simultaneouly promoting 
the development of TH1 and inhibiting the development of TH2 and TH17 subsets. 
Similarly, IL-4 required for TH2 development also inhibits the development of TH1 
cells.  
 
Our experiments have also demonstrated the dependency of TH1 development on IL-
12p70 production and more importantly, TTP being as a crucial regulator of TH1 
responses through the suppression of IL-12 production by BMDCs. Although TTP can 
also negatively regulate IL-23 and IL-6 production, IL-12 appears to have a dominant 
effect as seen from the enhanced IL-12-dependent TH1 responses with TTP deficient 
BMDCs, when IL-12, IL-23 and IL-6 are all overexpressed. Inspite of this, IL-23 and 
IL-6 production appears to suppress TH1 response as neutralization of IL-23 and IL-6 










7.1 Summary of findings  
 
Although both IL-12 and IL-23 are produced by dendritic cells, they have different 
roles in the polarization of CD4 T cells and are implicated in a number of allergic and 
inflammatory diseases. Hence, it is important to elucidate the signals that govern their 
production. IL-12 and IL-23 are differentially induced by various Toll-like receptor 
agonists, with LPS (TLR-4) being the most potent stimulus for IL-23 while CpG 
(TLR-9) is most efficient at inducing IL-12p70. Furthermore, the production of IL-23 
and IL-12 are both enhanced by activated CD4 and/or CD8 T cells. In spite of this, the 
enhancement of IL-12 production is dependent on both IFN- and CD40L stimulation 
while the increased IL-23 production is dependent on CD40L but not IFN-.  
 
As both IL-12 and IL-23 share a common IL-12p40 subunit, competition for IL-12p40 
subunit could possibly limit the production of IL-12 and IL-23. Interestingly, there are 
temporal differences in IL-23p19 and IL-12p35 induction. IL-23p19 mRNA was 
induced more rapidly, with mRNA peaking at the second hour post-stimulation and 
decreasing to baseline by the fourth hour. In contrast, IL-12p40 and IL-12p35 mRNA 
peaked at the fourth hour post-stimulation and decreased gradually. Hence, this 
temporal difference in production of IL-23p19 and IL-12p35 cytokine chains could 
possibly reduce the competition for IL-12p40 at any given time. In addition, IL-12p40 
is also produced in excess, thus further reducing the likelihood of competition.  
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 Differences in kinetics of IL-23p19 and IL-12p35 mRNA induction and degradation 
also suggest a differential regulation of IL-23p19, IL-12p40 and IL-12p35 through 
mRNA degradation. One possible target that could mediate the rapid degradation of 
IL-23p19 mRNA is tristetraprolin (TTP) as it was known to regulate the mRNA 
degradation of TNF- which has a rapid kinetics of mRNA degradation similar to that 
of IL-23p19.  
 
As TTP is inhibited through phosphorylation by p38 MAPK, to test if IL-23p19 
mRNA degradation is mediated by TTP, we investigated the effects of p38 MAPK 
inhibitor (SB202190) on mRNA stability of TNF-, IL-23p19, IL-12p40 and IL-
12p35. We had initially hypothesized the regulation of IL-23p19, but not IL-12p40 
and IL-12p35, mRNA degradation by a TTP-dependent mechanism and hence it was 
surprising that IL-12p40 and IL-12p35 mRNA degradation were also enhanced when 
p38 MAPK is inhibited. This raises the possibility that IL-23p19, IL-12p40 and IL-
12p35 mRNAs are all regulated by TTP. 
 
We first investigated the effects of TTP on IL-23p19 mRNA through the usage of 
BMDCs generated from TTP
-/-
 mice, as well as the overexpression of TTP in a Tet-
Off® Gene Expression system. TTP
-/-
 BMDCs demonstrated enhanced production of 
IL-23 and this resulted from enhanced mRNA stability as observed from the increased 
half-life of IL23p19. In addition, overexpression of TTP in HEK293/Tet-off cell line 
increased the degradation of IL-23p19 mRNA. However, TTP-mediated mRNA 
degradation was lost when region Δ1284-Δ1359 of IL-23p19 mRNA was truncated. 
Thus, besides confirming the role of TTP in mediating mRNA degradation of IL-
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23p19, we have demonstrated the involvement of region Δ1284-Δ1359 of IL-23p19 
3’UTR in TTP-dependent mRNA decay. 
 
Besides IL-23, TTP also negatively regulates the production of IL-12p70 and IL-6 in 
BMDCs. As the dendritic cell forms a crucial link between innate and adaptive 
immunity, the ability of TTP to negatively regulate CD4 T cell polarizing cytokines 
suggests a role for TTP in determining the eventual fate of CD4 T cells. Indeed, 
coculture of naïve CD4 T cells with WT and TTP
-/-
 BMDCs revealed a role of TTP in 
negatively regulating TH1 responses as the proportion of IFN- producing cells is 
enhanced when TTP
-/-
 BMDCs were cocultured with naïve CD4 T cells. This 
enhancement of TH1 responses is resulted from increased IL-12p70 production by 
TTP
-/-
 BMDCs. Hence, our study has revealed the importance of TTP as a negative 
regulator of inflammatory dendritic cell function. TTP acts as a negative regulator 
through the suppression of excessive IL-12, IL-23, TNF- and IL-6 production and 
inhibition the TH1 polarizing potential of BMDCs. 
 
7.2 Limitations of current studies 
 
7.2.1 GM-CSF-derived BMDCs as an in vitro equivalent of inflammatory dendritic 
cells and their role in the polarization of naïve CD4 T cells 
 
As dendritic cells are a minor population in vivo, isolation of sufficient numbers of 
dendritic cells is a challenge. In addition, dendritic cells that arise during inflammation 
are not present under steady-state conditions. Hence, in order to study this important 
subset of dendritic cells, our study uses GM-CSF derived BMDCs as they are believed 
to be in vitro equivalent of inflammatory dendritic cells in vivo. Generation of 
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BMDCs by culturing with GM-CSF was initially described by (Inaba et al., 1992). 
Subsequently, it was widely accepted as a model for the study of dendritic cells in 
both human and murine systems (Shortman and Naik et al., 2007). Indeed, a role of 
GM-CSF in the generation of inflammatory dendritic cells is evident as mice deficient 
in GM-CSF receptor have impaired ability to develop MHC-II
+
 dendritic cells during 
a vigorous inflammatory response (Naik et al., 2006).  Furthermore, GM-CSF-derived 
BMDCs are similar to in vivo inflammatory dendritic cells in their ability to produce 
cytokines and migrate to sites of inflammation (Xu et al., 2007).  
 
GM-CSF derived BMDCs are selectively trafficked to sites of inflammation when 
adoptively transferred into the mice (Xu et al., 2007). This coincides with the 
development and localization of inflammatory dendritic cells at the site of 
inflammation. However, inflammatory dendritic cells can also migrate to the draining 
lymph node where they encounter naïve CD4 T cells (Ersland et al., 2010). Recent 
studies have demonstrated the ability of inflammatory DCs to be as effective as 




 T cells (Cheong et al., 2010). 
Hence, inflammatory dendritic cells can encounter and mediate the polarization of 
CD4 T cells at both the site of inflammation and at the lymph nodes. 
 
 
7.2.2 Usage of HEK293 cell line 
 
Dendritic cells are resistant to various methods of transfection and nucleofection as 
our various attempts to transfect plasmid or siRNA into dendritic cells have failed. 
Although there are dendritic cell lines, they are aberrant and are not easily transfected. 
Hence, Tet-off
®
 gene expression system in HEK293 cell line was used in our study as 
it has been widely employed in studies that investigated the role of TTP in the 
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regulation of cytokines mRNA (Datta et al., 2008; Ogilvie et al., 2009). This system 
allows us to study a direct role of TTP on mRNA stability and furthermore, elucidate 
the contribution of mRNA regions crucial for TTP mediated mRNA degradation.  
 
 
7.3 Targeting IL-12 and IL-23 in chronic diseases 
 
While IL-12 and IL-23 are essential for protective immunity against a number of 
pathogens, excessive inflammatory responses may lead to immunopathology that is 
undesirable. The immunopathological effects of IL-12 and IL-23 are exemplified in a 
variety of autoimmune diseases and IL-12 and IL-23 have also been shown to 
exacerbate allergen-induced airway inflammation.  
 
7.3.1 Targeting IL-12 and IL-23 in inflammatory and autoimmune diseases 
 
Levels of IL-23 are elevated in chronic inflammatory diseases such as multiple 
sclerosis, Crohn’s disease, psoriasis, ulcerative colitis, and rheumatoid arthritis (Fujino 
et al., 2003; Lee et al., 2004; Lock et al., 2002; Schmidt et al., 2005). Polymorphisms 
of IL-12, IL-23 and their receptor genes are associated with psoriasis, Crohn’s disease, 
ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosis and 
rheumatoid arthritis. Hence, it does seem that experimental evidence from mouse 
models of autoimmunity have relevance in humans and that IL-12 and IL-23 are 
viable targets for treatment of the various inflammatory conditions.  
 
There have been a number of clinical trials involving the administration of IL-12p40-
specific human monoclonal antibody for various inflammatory conditions. In a Phase 
2 clinical trial for active Crohn’s disease, treatment with IL-12p40 antibodies was 
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associated with reduced clinical disease, improved histology of mucosal tissues and 
decreased production of cytokines by mononuclear cells that were isolated from the 
lamina propria (Mannon et al., 2004). Neutralization of IL-12 and IL-23 appear to 
have therapeutic benefits for Crohn’s disease patients. On the contrary, treatment with 
IL-12p40-specific antibodies for multiple sclerosis and psoriasis were less desirable. 
In both instances, although treatment resulted in reduced disease severity, the 
therapeutic effects observed were either less than with current therapies or resulted in 
side effects as patients were immunocompromised (Gordon et al., 2012; Vollmer et 
al., 2011).  
 
7.3.2 Targeting IL-12 and IL-23 in asthma? 
 
While the role of IL-23 in immunopathology of autoimmune diseases is established, 
the role of IL-12 and IL-23 in asthma is controversial. IL-12 induces the polarization 
of CD4 T cells to the IFN- producing TH1 subset of CD4 T cells while suppressing 
the generation of the TH2 subset that produces IL-4, IL-5 and IL-13. As TH2 subset of 
CD4 T cells is believed to drive the etiology of asthma, the ability of IL-12 to inhibit 
TH2 responses suggests a regulatory role of IL-12 on allergic asthma. Indeed, various 
lines of evidence suggested a protective role of IL-12 during asthma sensitization 
(Keane-Myers et al., 1998; Sur et al., 1996; Zhao et al., 2000).  In spite of this, IL-12 
contributes to full blown allergen-induced airway inflammation through enhanced 
recruitment of CD4 T cells and eosinophils, enhanced TH2 cytokines. IL-12 mediated 





IL-23 involvement in asthma was first described by Wakashin et al (2008) when 
neutralization of IL-23 resulted in decreased eosinophilia and TH2 cytokines in the 
airways. Furthermore, overexpression of IL-23 in the lung enhanced the development 
of allergic airway inflammation (Wakashin et al., 2008). A number of other studies 
have also supported a pathological role of IL-23 in allergic airway inflammation and 
the effects of IL-23 appear to be mediated via both TH17 dependent and independent 
mechanisms (Codolo et al., 2008; Lajoie et al., 2010; Peng et al., 2010). A more recent 
study has suggested otherwise as IL-23 and TH17 production appears to have a 
protective role in asthma through TLR-6 stimulation (Moreira et al., 2011).  
 
As treatment of asthma usually begins after the onset of asthmatic responses, 
management of asthma involves the targeting of manifested symptoms. While there 
have been a number of studies involving the targeting of TH2 cytokines, such as IL-4, 
IL-5 and IL-13 (Borish et al., 2001; Flood-Page et al., 2007; Hart et al., 2002; Kips et 
al., 2003; Singh et al., 2010), there has been a lack of studies regarding the targeting of 
IL-12 and IL-23 in asthma. Given the pathological effects of IL-12 and IL-23 on full 
blown asthma, neutralization of IL-12 and IL-23 seems to offer a possible new target 
for the reduction of allergic airway inflammation. 
 
7.4 Tristetraprolin as a possible target for immunotherapy 
 
7.4.1 Tristetraprolin as a global regulator of cytokine production 
 
Tristetraprolin (TTP) mediates the degradation of mRNA containing AU-rich 
elements (ARE) in the 3’UTR. Mice deficient in TTP developed an inflammatory 
condition characterized by myeloid hyperplasia associated with cachexia, erosive 
180 
 
arthritis, dermatitis, conjunctivitis, glomerular mesangial thickening and high titres of 
auto antibodies. This results from excessive TNF- production as the mechanism that 
initiates TNF- mRNA degradation is defective Taylor et al, 1996. Subsequently, 
mRNA decay of IL-10, IL-2, IFN-, GM-CSF, CXCL1 and recently, IL-6 and IL-23, 
were shown to be regulated by TTP (Ogilvie et al., 2005; Ogilvie et al., 2009; Carballo 
et al., 2000; Stoecklin et al., 2008; Datta et al., 2008;(Tudor et al., 2009); Qian et al., 
2011;(Zhao et al., 2011). Furthermore, our study has also identified a role for TTP in 
the regulation of IL-12p70 through IL-12p35 subunit. Given the role of TTP in the 
limiting excessive production of cytokines, tristetraprolin may be a potential target for 
the control of various inflammatory conditions.  
 
7.4.2 Tristetraprolin as a negative regulator of TH1 development 
 
Factors that regulate polarization of naïve CD4 T cells to various CD4 T helper cells 
subsets are of immense interest as TH1, TH2 and TH17 subsets are important for both 
immunity against pathogens and immunopathology resulting in chronic airway 
inflammation and autoimmune diseases. Cytokines produced by dendritic cells are 
critical in influencing the eventual fate of CD4 T cells; IL-12 is required for TH1 
development while IL-6, IL-23, TNF- and IL-1 are implicated in the development 
of TH17 (Trinchieri. G, 2003; Veldhoen et al., 2006). Given the role of TTP in the 
regulation of IL-12, IL-23, IL-6 and TNF- produced by dendritic cells, we 
hypothesized a possible involvement of TTP in regulating CD4 T cells responses. This 
is in the light of studies using TTP
-/-
 mice which developed inflammatory conditions 
coupled with high titres of auto antibodies as these observations suggest a role of TTP 
in the regulation adaptive immunity.  
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Despite the ability of TTP to inhibit the production of IL-12, IL-23, IL-6 and TNF- 
in WT BMDCs, TTP selectively suppressed the polarization of TH1 CD4 T cells while 
the development of TH17 subset was not affected. One possible reason for the lack of 
effect on TH17 polarization is the enhanced IL-12 production and the resultant 
enhancement of TH1 polarization. Both IL-12 and IFN- produced, by TTP
-/-
 BMDCs 
and TH1 cells respectively, can suppress TH17 polarization and hence the enhancement 
of TH17 polarization could be negated (Murphy et al., 2003; Harrington et al., 2005; 
Park et al., 2005). The role of TTP in selectively suppressing TH1 responses in vitro 
will need to be further confirmed with in vivo experimental models.  
 
7.4.3 Targeting tristetraprolin for immunotherapy 
 
Post-transcriptional regulation that dampens the expression of cytokine genes and 
inflammatory mediators serve as a mechanism to prevent excessive inflammatory 
responses. Tristetraprolin (TTP) participates in this process and hence serves as a 
potential target for the development of anti-inflammatory therapeutics. As TTP 
enhances mRNA degradation and reduce cytokine production, enhancement of TTP 
mediated degradation could possibly reduce inflammatory responses. One possibility 
is the inhibition of p38-MK2 pathway that phosphorylates and inhibits the action of 
TTP. Indeed, drugs that target p38 or MK2 inhibits the production of TNF-, IL-6 and 
IL-1 (Johansen et al., 2006; Schett et al., 2008). In mouse models, inhibitors of p38-
MK2 pathways prevent the development of inflammatory arthritis (Hegen et al., 2006) 
and these drugs are currently investigated for treatment of patients with inflammatory 




7.5 Future studies  
 
7.5.1 Effect of TTP deficiency on asthma 
 
As IL-12 and IL-23 play a role in the pathology of allergic airway inflammation, we 
would like to investigate whether the effects mediated by IL-12 and IL-23 are 
dependent on tristetraprolin. This can be investigated through adoptive transfer of TTP 
deficient BMDCs via the intratrachael route to mice during the sensitization or 
challenge phase of OVA induced asthma mice model. The involvement of TTP in the 
pathology of asthma can be assessed through the measurement of bronchial airway 
hyper-responsiveness, lung damage and the amount of infiltrating leukocytes. 
Subsequently, the contribution of IL-12 and IL-23 can be elucidated through blocking 
antibodies to IL-12p40 and IL-23p19.  
 
7.5.2 Effect of TTP deficiency on protection against influenza 
 
While excessive production of cytokines is detrimental, cytokines are important for 
mediating protection against infectious diseases. Hence, we would like to investigate 
whether TTP limits the development of effective immunity or may limit excessive 
inflammatory responses. This can be investigated through adoptive transfer of TTP 
deficient BMDCs via the intratrachael route to mice prior to an influenza infection. 
Role of TTP in protection against influenza infection can be determined through the 
measurement of the lung viral titer as well as the weight loss or survival of the mice. 
Furthermore, the involvement of TTP in possible lung damage can be assessed 
through lung histology and the measurement of lung damage through determining the 
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levels of BAL albumin. Subsequently, the contribution of IL-12 and IL-23 can be 
elucidated through blocking antibodies to IL-12p40 and IL-23p19.  
 
Elucidating the contribution of TTP as well as IL-12 and IL-23 in the ethiology of 
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